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Abstract 
Migraine - with or without aura - is an enervating primary headache disorder that 
represents a heavy economic and social burden. The health-related quality of life of 
migraineurs is poor. The aim of this research was to investigate the health-related quality of 
life of migraine without aura sufferers.  
As the thesis was approached from a biopsychosocial perspective, potential 
determinants were chosen for investigation from the molecular, individual, interpersonal and 
wider societal levels. The research was executed in two phases: Phase 1 data (N = 341) were 
gathered using a survey of health-related quality of life (Short Form 6), temperament (the 
Tridimensional Personality Questionnaire), catastrophizing as a pain coping strategy (the 
four-item Pain Coping Scale) and the amount of perceived social support (the six-item Social 
Support Questionnaire). For phase 2, participants were requested to provide blood specimens 
for ELISA serum quantification of glutamate (n = 66) and gene expression analysis of the 
main glutamate transporter gene SLC1A2 on real-time reverse-transcription polymerase chain 
reaction (n = 20).  
Of the 341 adult residents of Gauteng Province, South Africa that participated in the 
survey, 94 (28%) met the criteria for migraine without aura and a further 60 (18%) suffer 
from possible migraine without aura, using the International Classification of Headache 
Diagnosis (2nd edition) criteria. This indicates that migraine without aura is a significant 
burden for South Africa.  
Health-related quality of life was significantly poorer for migraineurs versus those 
without migraine (p < .001), and is in fact comparable to that of liver transplant, cardiac 
bypass and elderly populations. This raises concerns about the severe burden of the disease on 
the mental and physical well-being of South African sufferers. 
Investigation of the predictors of health-related quality of life yielded two significant 
variables when controlling for sex, head and neck injury and language - Harm Avoidance and 
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Catastrophizing. The regression model accounts for 29% of the variance in health-related 
quality of life. A reciprocal relationship likely exists between Harm Avoidance and 
Catastrophizing, in which a harm avoidant migraineur interprets the headache pain as a 
catastrophic event to be avoided – even at high cost to the self.  
Though there have been calls for more biopsychosocial studies of migraine, this thesis 
did not find added understanding of health-related quality of life through the combination of 
biological and psychosocial data. The implication is that the role of glutamate in migraine 
without aura still requires further investigation. Further study is also required with regard to 
which biological factors may influence the sufferer’s quality of life.  
The thesis indicates a key role for psychological intervention in aiding migraineurs to 
live a life of quality. The inclusion of interventions for the psychological aspects of migraine 
may yield improved outcomes for patients. However, Gauteng residents suffering from MO 
are potentially unaware of their diagnosis and therefore of potential management for their 
disorder. Awareness around migraine needs to be the first step in limiting this disorder’s 
devastating impact on individuals, their relationships and their potential to contribute 
meaningfully to society. 
 
Key terms: health-related quality of life, biopsychosocial, glutamate, migraine 
without aura, pain coping, SLC1A2, temperament 
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Chapter 1:  Introduction to the Study 
This chapter introduces the thesis by providing the rationale and motivation for the 
research, while engaging in critical debate about the significance of such research within 
international and local contexts.  The objectives of the thesis are laid out with reference to the 
aims and research questions in order to provide a clear map of how the work was conducted. 
The chapter concludes with an outline of the thesis chapters to help guide the reader through 
the work. 
1.1 Health-Related Quality of Life in a Biopsychosocial Framework 
The focus of this research was on health-related quality of life (HRQOL) in migraine 
without aura (MO). Specifically, a biopsychosocial framework was used to investigate the 
interactions between temperament, glutamate neurotransmission, pain coping, social support 
and, ultimately, how they may influence the MO sufferer’s HRQOL.  
The HRQOL concept is composed of physical, psychological and social components 
(Ferrans, 2005) that can be related to the biological and psychosocial contexts in which an 
individual exists (Kuehn & McClainm, 1994). As such, HRQOL embodies Engel’s (Engel, 
1980) notions that an individual can be best understood in the context of the multiple systems 
in which she exists and that these systems are not isolated.  
As a subjective construct HRQOL offers a unique opportunity for individuals to 
provide health representatives with their personal views of how their actual and ideal health 
compare (Cella, 1994). Such incorporation of the individual’s (or patient’s) view is also a 
central principle in the biopsychosocial framework (Engel, 1977; 1980).  
The broad field of pain research has benefitted greatly from biopsychosocial 
approaches to research (Gatchel, Peng, Peters, Fuchs, & Turk, 2007; Lumley et al., 2011), but 
it was only more recently that researchers began to call for more inclusion of a 
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biopsychosocial perspective specifically in headache research (Martin, 2007). Studies of how 
psychosocial difficulties contribute to migraine HRQOL are not common (Leonardi, Raggi, 
Bussone, & D’Amico, 2010; Raggi et al., 2012). Studies making use of a biopsychosocial 
perspective to guide our understanding of HRQOL in migraine are therefore also uncommon. 
The relative novelty of the study approach aside, in making use of the biopsychosocial 
perspective in exploring HRQOL in MO, this research has the potential to invite partnership 
between healthcare providers and MO sufferers in their systems as they tackle the challenges 
of this disorder (Borrell-Carrió, Suchman, & Epstein, 2004).  
This thesis draws from knowledge and techniques not traditionally associated with 
psychological studies in South Africa, including genetics and physiology. Within the South 
African context (or any other developing context, perhaps), interdisciplinary research is still 
establishing itself as a valuable force in the knowledge economy (National Research 
Foundation, 2014).  
Some of the difficulties in publishing interdisciplinary research has been presented by 
(Gajovic, 2015) and some of the practicalities of PhD-level interdisciplinary research is 
addressed by Sharp (2016). However, neither of these articles deals with the realities of a 
developing world context. Winberg, Barnes, Ncube, and Tshinu (2011) discuss the 
experiences of South African students conducting interdisciplinary research, though their 
work focuses on issues of the struggle for definition of the research. The structural challenges 
of such interdisciplinary work for South African PhD candidates are not addressed in these 
articles, though. These include matters of part-time registration being the only viable option 
for an estimated 80% of PhD candidates in South Africa (Dell, 2010) and the challenges of 
securing postgraduate supervision for interdisciplinary work Winberg et al. (2011). This 
thesis makes a significant contribution to South African research that will hopefully 
encourage other researchers to embark on interdisciplinary projects in the face of these 
challenges. 
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1.2 Problem Statement 
Headaches are a major health concern around the globe (Stovner et al., 2007). The 
World Health Organisation estimates that 47% of adults (18-65 years of age) suffered a 
headache at least once in 2011 (World Health Organization, 2012). Although headaches are 
associated with substantial social and economic cost (Stovner et al., 2007; Wieser, Walliser, 
Womastek, & Kress, 2012), they are thought to be underdiagnosed and undertreated 
worldwide (World Health Organization, 2012). Migraine has become a “forgotten epidemic” 
(Diener, Steiner, & Tepper, 2006, p.433). Given the high prevalence and the burden of 
headaches, questions arise about how people may still experience a life of quality in spite of a 
headache; how they cope with the pain; and the factors that contribute positively and 
negatively to HRQOL of headache sufferers.  
There are several subtypes of headache with divergent symptoms and aetiologies.  The 
focus of this research has been narrowed to migraine without aura (MO), which is described 
in more detail in Chapter 2. Migraine is typified by severe pain (Villalón & Olesen, 2009; 
Wendt, Cady, Singer, & Peters, 2006) and  is considered to be a chronic disorder with 
episodic manifestations (Aydemir, Ozkara, Unsal, & Canbeyli, 2011). The condition is 
diagnosed as chronic when headaches occur for 15 or more days of the month for a minimum 
of three months (Galletti, Cupini, Corbelli, Calabresi, & Sarchielli, 2009; Pompili et al., 
2010). A more in-depth discussion of migraine is undertaken in the next chapter.  
 Though migraine may not decrease life expectancy (Magnusson & Becker, 2003), it 
has a profound impact on HRQOL (Bera, Goyal, Khandelwal, & Sood, 2014; Brna, Gordon, 
& Dooley, 2006; D’Amico, Grazzi, Usai, Leonardi, & Raggi, 2013; D’Amico, Leonardi, 
Grazzi, Curone, & Raggi, 2015; Dalhof & Dimenas, 1995; de Velasco & Gonzalez, 2003) and 
the importance of understanding what contributes to and detracts from HRQOL in MO is 
clear when one considers the poor reported health outcomes of migraineurs. For example, 
Aydemir et al.'s (2011) study using the Short-Form 36 (SF-36) questionnaire showed that 
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HRQOL is lower amongst migraine sufferers in comparison to healthy subjects and even to 
people diagnosed with epilepsy. Similarly, migraine patients have shown lower mean global 
scores on the Health Utilities Index (HUI) in comparison to patients visiting a rheumatoid 
arthritis clinic; and scores equal to those of a cross section of Type 2 diabetes patients (Brown 
et al., 2008). According to Dalhof and Dimenas (1995), poor HRQOL in migraineurs extends 
even into the periods between migraine attacks. Migraine is also the most frequently reported 
primary headache disorder amongst headache sufferers seeking treatment (Villalón & Olesen, 
2009; Wendt, Cady, Singer, & Peters, 2006), with MO being the more frequently reported of 
the two migraine subtypes (Villalón & Olesen, 2009).  
However, migraine is not simply an individual burden - it affects not only the sufferer, 
but has clear implications for the wider systems in which an individual is situated. The 
relatively few peer-reviewed articles that deal with the matter of interpersonal effects of 
migraine indicate that family relationships suffer under the strain of a partner / parent in pain: 
In a study of 350 migraine sufferers in the United States, Smith found that migraine sufferers 
felt that their headaches had significantly negative effects on family life and were a source of 
conflict, unhappiness and instability (Smith, 1998). In some cases migraine sufferers were 
perceived as not providing adequate care for their children as they often had to make alternate 
care arrangements or cancel outings because of their headaches. Migraine affected the 
frequency or quality of the sexual relationships between partners in 24% of the sample and in 
5% of the cases, migraine was seen as a direct cause of divorce or separation of partners.  In a 
later study of 100 partners of migraine sufferers in both the United Kingdom and the United 
States, partners indicated that the migraine sufferer would be a better partner were it not for 
the headaches (Lipton et al., 2003). The migraineurs concurred, indicating that their 
headaches interfered with their social and family life commitments and prevented them from 
planning ahead for fear of a migraine attack. Migraine sufferers also felt that their migraine 
made it more likely that they would argue with their children and their partners.  
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In the workplace migraine affects the quality of work. A study of labour cost in 
migraine sufferers in the United States (N = 648) showed that 50% of migraine sufferers 
missed an average of two days per month due to headaches and that even when they were at 
work their productivity was severely diminished when a headache struck (Osterhaus, 
Gutterman, & Plachetka, 1992).  In a multinational study of 2670 migraine sufferers, it was 
estimated that productivity is diminished by 46% when sufferers work with a migraine and 
had to be away from work for 19.5 days a year because of their headaches (Gerth, Carides, 
Dasbach, Visser, & Santanello, 2001).  
The socio-economic burden of migraine has also become clear in recent years. The 
peak incidence of migraine occurs between 25 and 44 years of age (Jette, Patten, & Williams, 
2008), when economic and psychosocial productivity should be high (Brown et al., 2005). 
Migraine is associated with high costs in terms of treatment and lost productivity in European, 
North American and Asian populations (Lantéri-Minet et al., 2003; Lipton & Bigal, 2005; 
Rasmussen, Jensen, Schroll, & Olesen, 1995; Unger, 2006; Wang, 2003). In the United States 
these costs are estimated to be $17 billion per annum (Norton, Asmundson, Norton, & Craig, 
1999).  The Eurolight Project calculates costs for migraine to be €111 billion per annum in 
Europe (accounting for 64% of the cost burden of all headaches examined) (Linde, 2006). 
Migraine is one of the diseases for which the cumulative indirect lifetime societal cost 
exceeds direct costs for medical care (Gurwitz & Diamond, 2007), making it a serious 
liability to society.  
The severe liability created by migraine is compounded by a lack of cure. The 
management of the disorder can therefore benefit from critical examination of the aspects of 
the headache which impact the sufferers and the means by which they cope and function  
(Magnusson & Becker, 2003) - essentially, an improved understanding of predictors of their 
HRQOL.  
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1.3 Motivation for the Study 
With these poor outcomes in mind, HRQOL research in migraine becomes 
foregrounded as a theoretically significant means of moving from diagnosis to improved care 
and intervention in headaches. Unfortunately, there is currently a gap in South African 
literature regarding a number of aspects of migraine – including HRQOL. Some peer-
reviewed prevalence statistics are available for Benin, Nigeria, Ethiopia, Tanzania and 
Zimbabwe (Adoukonou, Houinato, & Kankouan, 2009; Houinato et al., 2010; Leonardi, 
Steiner, Scher, & Lipton, 2005; Mengistu & Alemayehu, 2013; Osuntokun et al., 1992), but 
South Africa has not been closely examined and information regarding the number of 
migraine cases, demographics of migraine sufferers, impact of the pain, and so forth, has not 
been collated for this country. However, a South African headache expert, Elliot Shevel, has 
been quoted as saying that South African prevalence is unlikely to differ from the global 10% 
estimate (Green, 2015). Only two studies could be identified that examine migraine 
prevalence in South Africa. Both studies explored the occurrence of migraine amongst South 
African hazardous drinkers. The prevalence of the disorder was very high in both studies (14-
30%), but given the restricted sample population, it would be premature to extrapolate these 
findings to the general population (Mertens et al., 2010; Pengpid, Peltzer, & Van der Heever, 
2011).   
Without comprehensive peer-reviewed data on even the most basic questions about 
migraine in South Africa, it is difficult to imagine a clear and precise strategy toward 
understanding the disease and improving interventions. Information regarding the general 
characteristics of migraine sufferers and their HRQOL is needed to bridge the gap between 
bench and bedside. There is therefore a strong need for systematic, inter-disciplinary 
approaches to migraine research in South Africa and indeed, on the majority of the African 
continent. In order to start addressing the gap in the literature, this study began with an 
exploration of the demographics, HRQOL and psychological functioning of MO sufferers 
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living in the Gauteng Province, South Africa. The focus of the work shifted from a general 
overview of MO to concentrate on factors that may help us understand the level of HRQOL in 
MO.   
The distinction between the two major subtypes of migraine with aura (MA) and MO 
was emphasized in this study because of the considerable differences in prevalence, 
prodromal and attack features as well as clinical data, which indicate that MA and MO are 
separate disorders or, at the very least, disorders on two different ends of a spectrum 
(Christensen, Le, Kirchmann, & Olesen, 2012; Ludvigsson, Hesdorffer, Olafsson, 
Kjartansson, & Hauser, 2006; Russell, Rasmussen, Fenger, & Olesen, 1996; Russell, Ulrich, 
Gervil, & Olesen, 2002). The choice to investigate MO instead of MA was based on the 
following: MO is more frequently reported than MA (Villalón & Olesen, 2009). This research 
could therefore assist in managing treatment for the majority of migraineurs. Using such a 
focused approach could also aid in the understanding of biological markers and psychosocial 
assets and liabilities in MO, which is important for the planning of interventions for MO 
sufferers and others affected by the disorder. For example, variations in neurotransmission 
that are associated with significant differences in HRQOL may be useful in understanding 
differences in coping and temperament in MO. Understanding the neurotransmitter, 
temperament and coping interaction may hold particular significance for isolating 
psychological assets for specific pain management interventions (Esposito et al., 2013; 
Friedman, 1968) or understanding processes such as the transformation of migraine to chronic 
daily headache through the development of medication overuse headache (Matsumoto et al., 
2007). Moreover, the symptom of aura in MA would have introduced a further confounding 
variable; the heterogeneity of those aura experiences complicating the study further. It was 
assumed that the prioritised focus on MO over MA would decrease the likelihood of within-
group heterogeneity, thereby increasing the research manageability, while allowing for in-
depth examination of the impact of MO pain on the migraineur’ s HRQOL.  
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1.4 Aims, Objectives and Research Questions  
In this thesis it was the possibility that the MO individual’s HRQOL can be predicted 
by certain biopsychosocial factors was explored. These factors were: Temperament, 
neurotransmission profile, coping mechanisms that the individual employs to deal with the 
pain of MO headache and levels of perceived social support.  Temperament is the automatic 
emotional response to situations (Boz et al., 2004). It is key to the processes of emotional 
reactivity and regulation (Henderson & Wachs, 2007), hence, it is a determinant of the 
significance one attaches to events, emotional reactions and habits (Boz et al., 2004). It is 
therefore not surprising that temperament has been associated with aspects of cognition and 
emotion, including coping (Gentzler, Kerns, & Keener, 2009; Marais & Stuart, 2006) and 
perceived social support (Kitamura, Kijima, Watanabe, Takezaki, & Tanaka, 1999). In 
addition, specific temperament dimensions have been significantly associated with various 
headache disorders, including migraine (Boz et al., 2004; Mongini, Fassino, et al., 2005; 
Sánchez-Román et al., 2007). The research approached temperament from the perspective of 
Cloninger’s Psychobiological Theory of Personality, which holds that neurotransmitters 
underpin temperament (Celikel et al., 2009; Gillespie, Cloninger, Heath, & Martin, 2003). 
The neurotransmitter, glutamate, while thought to play a role in temperament (Matsumoto et 
al., 2007), has also been significantly associated with MO (Christensen et al., 2012; Ligthart 
et al., 2011).Thus, HRQOL determinants put forward in this research were derived from 
molecular, individual and interpersonal levels, with inclusion of wider society factors 
(lifestyle habits) in the analysis.  
There are two disclaimers that should be highlighted, though: Although this research 
does not investigate such factors, it is acknowledged that environmental factors do influence 
both neurotransmission and temperament - the emerging research in the field of epigenetics 
(e.g. Wills, Sandy, & Yaeger, 2000) is testament to the influence of the environment and life 
events on the biological self (Slavich & Cole, 2013). However, exploration of MO and its 
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associated HRQOL has been limited in this thesis to allow improved manageability. The 
feedback from the environment and how this may alter temperament at behavioural and 
genomic levels were therefore considered outside the scope of this investigation. Furthermore, 
the question of MO aetiology is not investigated since an understanding of what causes MO 
was not the focus of this research. Rather, the emphasis of the work is on how the subjective 
experience of HRQOL in MO is constructed through a combination of biological and 
psychosocial events.  
The aims of the study were to: 
1. Compare the HRQOL of MO sufferers and participants not suffering from MO  
2. Explore the association between temperament and pain coping in MO 
3. Examine how neurotransmission, temperament, pain coping, perceived social 
support and lifestyle factors contribute to the HRQOL experienced in MO 
1.5 Comparing health-related quality of life  
In order to compare the HRQOL of Gauteng migraineurs and their non-migraine-
suffering counterparts, HRQOL data were collected through self-report on the Short Form 6 
(SF-6). Diagnosis of MO was made using the revised International Classification of Headache 
Disorders (Headache Classification Committee of the International Headache Society, 2005b) 
criteria.1 The research question addressed was: In what way does the HRQOL of MO 
sufferers differ from HRQOL of those without MO? Background information suggests that 
HRQOL of migraine sufferers is poorer than that of healthy cohorts and even sufferers of 
disorders such as diabetes (Aydemir, Ozkara, et al., 2011; Brown et al., 2008). However, no 
peer-reviewed data on HRQOL for MO sufferers could be located for South Africa. 
                                                 
1 The ICHD-III criteria were released in 2013 and were still in beta version at the time that this data 
were collected. This research was therefore based on the previous criteria, published as the ICHD-II. 
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1.6 Exploring temperament and pain coping in migraine without aura 
The objective was to measure the levels of the four temperament characteristics set out 
in Cloninger’s Psychobiological Theory of Personality (using the Temperament Personality 
Questionnaire or TPQ) and the pain coping strategy of catastrophizing (on the Pain 
Catastrophizing Scale or PCS)  amongst MO sufferers and NM. Finally, the relationship 
between Catastrophizing and the temperament categories was explored. Temperament has 
been indicated as an important aspect in pain coping strategies (Compas, Connor-Smith, & 
Jaser, 2004; Hachaturova, 2010; Rueda & Rothbart, 2009). The research question addressed 
was: What is the relationship between the harm avoidance (HA) temperament category and 
catastrophizing in MO? The work of Mongini and colleagues (Mongini, Fassino, et al., 2005) 
shows a significant relationship between the HA category of temperament and migraine. In 
addition, catastrophizing is highly prevalent amongst migraine sufferers as a strategy for 
coping with pain (Chiros & O’Brien, 2011; Raggi et al., 2012).  
1.7 Testing for determinants of health-related quality of life 
The objective was to determine the serum concentration of glutamate (on enzyme-
linked immunosorbent assay or ELISA) and the relative expression levels of the main 
neurotransporter for glutamate (the solute-carrier family 1 glial high affinity glutamate 
transporter 2, SLC1A2, which is also known as the excitatory amino acid transporter, EAAT-
2 on quantitative polymerase chain reaction or qPCR) and the level of perceived social 
support (on the Social Support Questionnaire, SSQ6). The relationships between HRQOL, 
neurotransmission of glutamate and the levels of HA, catastrophizing and perceived social 
support amongst MO subjects were then explored using correlation and regression. The 
research question addressed was: To what extents do temperament, neurotransmission profile, 
coping strategy and perceived social support explain the variance in HRQOL in MO? A 
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number of relationships between these variables are highlighted in the literature. These 
relationships are discussed in detail in Chapter 4.   
1.8 Outline of Chapters 
The infographic (Figure 1.1) below outlines the contents of each of the chapters. 
Reviews of the literature on migraine and HRQOL are found in Chapters 2 and 4, while 
Chapter 3 provides an overview of the Biopsychosocial Model that is used to guide the 
approach to this research. The discussion of the method is realized over two chapters 
(Chapters 5 and 6). The results of the research are also presented over two chapters (Chapters 
7 and 8), while the discussion and conclusion of the thesis are found in Chapter 9. 
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Figure  1-1: Infographic showing the outline of the chapters in this thesis 
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1.9 Conclusion of Chapter 1 
As a chronic pain disorder, migraine has a profoundly negative impact on the HRQOL 
of sufferers and for many migraineurs this HRQOL does not improve significantly even when 
the headache abates. In examining the more frequently occurring form of migraine, MO, this 
thesis aims to provide an improved understanding of which factors may augment or detract 
from HRQOL in MO. This research will contribute to our understanding of HRQOL in MO. 
This may further improvements in pain management for all migraine sufferers. The thesis has 
been approached from a biopsychosocial perspective. Thus potential determinants of MO 
HRQOL have been examined from the molecular, individual, interpersonal and wider societal 
levels. The concepts examined in relation to MO HRQOL in the thesis are neurotransmission, 
temperament, pain coping and perceived social support, with lifestyle factors receiving less 
emphasis in the literature, but being considered in the analysis.    
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Chapter 2:  Migraine 
I once had a pain in my head, 
It started when I was in bed; 
But it is my curse it later got worse, 
And now I wish I were dead 
(National Headache Foundation, 2006) 
 
An understanding of how migraine without aura (MO) is conceptualised is a necessary 
step toward hypothesising which factors influence the health-related quality of life (HRQOL) 
of people suffering from these headaches. The diagnostic classification of the disorder and its 
historical context are two important focal points in this regard. This chapter therefore begins 
with a brief account of the efforts to establish diagnostic criteria for migraine, along with a 
critical discussion of the modern diagnostic criteria, which highlights the tension between 
evidence-based practice and the dominant diagnostic discourse. The case definition of MO is 
then provided for this research, based on this discussion. 
The chapter then turns to a description of the significant findings on the possible cause 
of migraine. This discussion on the aetiology of MO is used as an arc into a more detailed 
discussion of the biological markers and psychosocial indicators of migraine. The chapter 
concludes with an argument for the integration of biological and psychosocial data in 
migraine research and the potential benefits thereof. 
2.1 The migraine diagnostic criteria 
Headaches are regarded as ancient phenomena, and are even referred to in 
Mesopotamian poems written as early as 3 000 BC (Pearce, 1986; Takano & Nedergaard, 
2009; Unger, 2006). The history of migraine begins as an adjunct to this story of general 
headache. Once the early researchers began to distinguish the distinctive symptoms of nausea, 
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aura and photophobia, however, the foundation was laid for a separate headache diagnosis, 
which eventually evolved into the current criteria for migraine. Unfortunately, the diagnosis 
of migraine has never been a simple practice and consequently, the operationalisation of the 
criteria in research remains complex (Schürks, Buring, & Kurth, 2009).  
2.2 Diagnostic committees. 
Though Hippocrates and Celsus (30 AD) are often credited with the discovery of 
migraine, it was Aretaeus that provided the first comprehensive description of our modern 
conceptualisation of migraine and referred to it as ‘heterocrania’ (Lane & Davies, 2006; 
Pearce, 2013). Galen used the term ‘hemicrania’, from which the word ‘migraine’ would 
finally evolve (Eadie, 2003; Unger, 2006). In 16th century England the term ‘megrim’ was 
used (following a number of transformations of Galen’s ‘hemicrania’) to describe a form of 
headache that was associated with nausea and visual disturbance, while in Germany it was 
called ‘migräne’ and in France ‘migraine’ (Lane & Davies, 2006). Though there was overlap 
in observations and practices across countries, there does not appear to have been a 
collaborative effort to define or determine the causes and most effective treatments for 
migraine till the 20th century. 
In fact, it was not until 1962 that an effort was made to create a headache classification 
system that could be used across nations. The National Institutes of Health (NIH) attempted a 
headache classification system in that year (McGeeney, 2009). This Ad Hoc Committee on 
Classification of Headache created 15 headache classes based on the associated pain 
mechanisms. Though it relied on experimental and clinical data, the committee described the 
system as “far from complete” (Ad Hoc Committee on Classification of Headache, 1962, p. 
179). Migraine was included in the first class of headache, which was referred to as Vascular 
headache of Migraine Type. The class included five subcategories: Classic migraine, common 
migraine (now known as MO), cluster headache, hemiplegic and ophthalmologic migraine 
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and lower-half migraine. A full description of the subcategories can be found in the 1962 
publication.  
In the 1980s members of the scientific community from various countries collaborated 
over a three-year period to refine headache classification and diagnostic criteria. This 
International Headache Society (IHS) consisted of a main committee, 12 subcommittees and 
interested parties (International Headache Society, 2004). Since then, the classifications of 
headaches and decisions about their diagnostic criteria have become the domain of the IHS. 
The committee agreed that the classification criteria for headaches were to be evidence-based 
as far as possible and that it would prioritise specificity over sensitivity (Headache 
Classification Committee of the International Headache Society, 2005a).   
The IHS publishes updated headache diagnostic criteria as the International 
Classification of Headache Disorders (ICHD).The first edition of the ICHD was published in 
1988 under the title ‘Classification and diagnostic criteria for headache disorders, cranial 
neuralgias and facial pain’. The second edition appeared in 2004 and the third in 2013 (Boes 
& Capobianco, 2005; Headache Classification Committee of the International Headache 
Society, 1988, 2013; Silberstein et al., 2005).  
There are three major divisions of the ICHD classification system: (1) Primary 
headaches, (2) secondary headaches and (3) cranial neuralgias, central and primary facial pain 
and other headaches. Primary headaches are those that originate in the brain. While secondary 
headaches are attributed to a disorder that causes headaches - such as neck trauma - primary 
headaches are not (Headache Classification Committee of the International Headache Society, 
2005a).  Headaches are organised hierarchically, starting with the major form of the headache 
and culminating in the sub-forms.  
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2.2.1 The International Classification of Headache Disorders and migraine. 
Migraine is classified as a primary headache and there are six sub-forms of the 
disorder in the ICHD –II (Headache Classification Subcommittee of the International 
Headache Society, 2004). Figure  2-1 shows the various subcategories of migraine as 
described in the ICHD-II. MO is the first sub-form listed.  
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Figure  2-1:  Diagnostic subcategories for migraine, according to the International Classification of Headache Disorders – II (Headache 
Classification Subcommittee of the International Headache Society, 2004)
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The focus of this study is on MO, therefore the ICHD criteria for MO are shown in 
Table  2-1. The criteria for MA have been included for comparison purposes only.  
 
Table  2-1 
International Headache Society criteria for migraine with and without aura (Classification Subcommittee of 
the International Headache Society, 2005) 
 
Migraine without aura 
A. At least 5 attacks fulfilling 
criteria B-D  
B. Headache attacks lasting 4-72 hours 
(untreated or unsuccessfully treated)  
C. Headache has at least two of the following 
characteristics:  
unilateral location 
pulsating quality 
moderate or severe pain intensity  
aggravation by or causing avoidance of routine 
physical activity (e.g. walking or climbing stairs) 
D. During headache at least one 
of the following:  
nausea and/or vomiting 
photophobia and phonophobia 
E. Not attributed to another disorder 
 
Migraine with aura  
A. At least 2 attacks fulfilling 
criterion B  
B. Migraine aura fulfilling criteria B and C 
for one of the sub-forms 1.2.1-1.2.6*  
C. Not attributed to another disorder  
Note: History and physical and neurological examinations do not suggest any of the disorders listed in groups 5-12, or history and/or 
physical and/or neurological examinations do suggest such disorder but it is ruled out by appropriate investigations, or such disorder is 
present but attacks do not occur for the first time in close temporal relation to the disorder.  
*Sub-forms 1.2.1-1.2.6 (also illustrated in Figure 2-1): 
 1.2.1 Typical aura with migraine headache G43.10    
1.2.2 Typical aura with non-migraine headache G43.10    
1.2.3 Typical aura without headache G43.104    
1.2.4 Familial hemiplegic migraine (FHM) G43.105    
1.2.5 Sporadic hemiplegic migraine G43.105    
1.2.6 Basilar-type migraine G43.103    
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The ICHD-II criteria for probable migraine (previously known as migrainous disorder) 
simply states that attacks fulfil all but one of criteria A-D (Classification Subcommittee of the 
International Headache Society, 2005) . This diagnosis allows for the possibility that a 
participant does not suffer from every single criterion for migraine. Such cases have also been 
included in this study. 
2.2.2 Controversy in diagnosis and the case definition for this study. 
The diagnosis of migraine is not without controversy. One disagreement centres on the 
reliability and validity of the ICHD criteria. Some of the harshest critics of the ICHD call the 
criteria “arbitrary” (Davies, 2011, p. 34) and feel that they lack biological and clinical 
validity. For Shevel and Shevel (2014), the controversy is summed up in the statement by the 
IHS chair, Jes Olesen in a 1994 paper in which he admits that the ICHD criteria were crafted 
through opinion and were not evidence-based (Shevel & Shevel, 2014). 
A further dispute involves the power of the IHS to stipulate how headache is 
researched. By declaring that no journals should publish studies that do not use ICHD criteria, 
the IHS has placed the scientific community in a double bind (Shevel & Shevel, 2014)  that 
“undermines advancement in our understanding of headache” (Spierings, 2001, p. 918). 
Spierings (2001) goes on to propose that the earlier NIH Ad Hoc Committee criteria were in 
some ways more advanced as the committee that created them left room for modification and 
admitted shortcomings. Shevel and Shevel (2014) have pointed out that the Headache 
Subcommittee has removed reference to some of the studies that indicate that decisions have 
not been taken based on evidence. Reference even to Olesen’s paper has also been removed 
from the ICHD-III. 
Shevel and Shevel (2014) are adamant that there is simply no research data to confirm 
even the number or duration of attacks chosen as criteria for the ICHD. Furthermore, Shevel 
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and Shevel point out that the studies that have been used to determine the criteria are 
inherently biased in their use of the ICHD criteria to determine prevalence. This tautology in 
diagnostic research is difficult to overcome when conflicting evidence is blocked from peer 
reviewed publication. 
There is also disagreement  as to which criteria are compulsory in diagnosis (Schürks 
et al., 2009). Notwithstanding that ICHD criteria are generally accepted as the gold standard 
when combined with physician diagnosis, there is acknowledgement that the latter is not 
possible in large population-based studies and it has therefore become acceptable to use self-
reports (Schürks et al., 2009).  
A further difficulty – certainly in population-based studies – is the use of laboratory 
tests to rule out other headache disorders in keeping with criterion E (not attributed to another 
disorder. This requires that the headaches could not be better accounted for by any of the 
causes in headache groups 5-12, i.e. it does not appear to be the result of trauma, vascular 
disease, intracranial pathology, substances, central nervous system infection, disorder of 
homeostasis such as hypoxia and is not psychiatric, cervicogenic, eye, ear, nose, throat, sinus, 
mouth or teeth-related). Even for the average patient attending a general practitioner practice 
and the well-funded researcher, this can become an incredibly time consuming and expensive 
exercise. Considering the opposition of some researchers and practitioners to the entire ICHD 
criteria, the value of these laboratory tests has also been questioned (Schürks et al., 2009).  
Striking a balance between thoroughness and over-testing is challenging and both can 
have important outcomes for migraine epidemiology: Too few examinations may raise the 
question of whether one is really diagnosing migraine when other disorders have not been 
ruled out with complete histories, physical, neurological and even laboratory examinations 
(criterion “Not attributed to another disorder” requires that the headaches could not be better 
accounted for by stipulated conditions). Migraine diagnoses then run the risk of being viewed 
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as wastepaper basket diagnoses. However, if one runs too many tests, there is the risk of 
introducing highly irrelevant data and unethically subjecting patients to unwarranted testing. 
For the purposes of this research, epidemiological research convention has been 
followed and the researcher has not relied on laboratory tests to rule out all other headache 
causes, but has rather made use of self-reporting.  The case definition for MO for this thesis 
includes two types of participants – those that meet the ICHD-II criteria for MO (at least 5 
attacks fulfilling criteria B-D of the ICHD-II criteria for MO) and those with probable 
migraine (attacks fulfilling all but one of criteria A-D of the ICHD-II criteria for MO). In 
order to satisfy the diagnostic criteria that require other headache forms to be ruled out, 
participants also could not have a self-reported history of aura or a terminal or degenerative 
nerve disease.   
The possibility of medication overuse headache was not examined and therefore these 
participants were not excluded from the study. Furthermore, the exact relationship of 
traumatic brain injury, neck injury, seizure disorders, cancer and infections to the headache 
could not be established without further specialist investigation. Therefore, the occurrence of 
these disorders are described in the results but not used as exclusions. 
The study exclusions were regarded as a reasonable attempt at ruling out headaches 
caused by the disorders stipulated in the ICHD-II. However, it is possible that some disorders 
were not ruled out. For example, glaucoma without nerve damage could not be excluded 
without ophthalmological examination. It was also assumed that participants under the 
influence of at least some (high levels of) substances would have excluded themselves from 
the study as they would not likely have been able to sustain attention for the prolonged period 
required to complete the extensive questionnaire.  
This case definition reflects some of the complexity of the current debates around 
migraine diagnosis. For further insight into the disorder, attention now turns to the debates on 
its causes. 
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2.3 Theories of causality 
One element that adds to the complication around migraine diagnosis is the continued 
enigma of migraine’s aetiology. While some forms of MA are clearly genetic in origin, MO’s 
aetiology has proven particularly tricky to uncover (Longoni & Ferrarese, 2006). Although 
the study of migraine from biological, social and psychological perspectives has led to a 
better understanding of the impact of the disease, there is still no single unifying explanation 
for its aetiology (Coppola, Pierelli, & Schoenen, 2009; Davies, 2011; Deshmukh, 2006). What 
follows is an account of the most significant theories on the aetiology of migraine to date, 
with the information organised chronologically. 
2.3.1 Early theories. 
Some of the early common treatments of migraine and other headache symptoms 
included trepanation and binding of idols (perhaps because pressure on the site was noted to 
bring pain relief) (Koehler & Boes, 2010; Unger, 2006).  More invasive treatment techniques 
included cauterisation and the insertion of garlic into an incision (Koehler & Boes, 2010).  
Binding and trepanation persisted as popular treatments for migraine into the 
Hippocratic period, when techniques expanded to reflect the dominant medical discourse of 
the time: The likes of Hippocrates, Galen and Aretaeus held firmly to the belief that a 
derangement of humors was responsible for the headaches. Consequently, patients were 
treated using various bloodletting techniques or through the withdrawal of other body fluids 
using cupping or blistering (Koehler & Boes, 2010; Pearce, 1986, 2013). Galen attributed 
migraine to an excess of bile (choler), which irritated one side of the brain (Eadie, 2003; 
Unger, 2006). Pills were therefore administered to aid liver functions (Unger, 2006). 
Migraine cases continued to feature in the works of various Byzantine-era physicians 
such as Oribasius (320–400 AD), Aetius Amidenus (520–575 AD) and Aeginata (625-690) 
(Androutsos, Dimos-Dimitrios Mitsikostas et al., 2009). Meanwhile, religious theories for the 
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cause of migraine generally portrayed them as a punishment that could be concluded through 
the performance of good deeds (Unger, 2006). This era also saw the introduction of the use of 
magnets, lifestyle interventions such as diet and exercise, as well as the early use of electrical 
treatments (Koehler & Boes, 2010). 
 In the 7th century Paulus Aeginata (7th century) of Greece described several triggers 
of migraine, namely noise, light, smells and drinking alcohol (Pearce, 1986). Ibn Sina or 
Avicenna (973–1037) also acknowledged that particular smells triggered headaches and 
proposed the use of African ginger as a treatment (Abokrysha, 2009). According to 
Abokrysha (2009), Avicenna was also the first to propose a neurovascular theory of migraine 
pathophysiology. However, it is worth noting that Galen had already proposed that arterial 
pulsation was the cause of the throbbing pain of the headache (Eadie, 2003; Unger, 2006). 
Caelius Aurelianus (400 AD) of Algeria used the term ‘crotophon’ to denote this throbbing or 
pounding pain of a migraine, which, according to Aurelianus, co-occurred with vertigo, 
burning eyes, nausea or emesis (Pearce, 1986). 
2.3.2 Neurovascular and neurogenic theories. 
In light of Avicenna’s neurovascular  theory of migraine, physicians such as 
Maimonides (1135–1204 AD) proposed that bloodletting be applied to the pulsating arteries 
that were thought to be the cause of the headaches (Koehler & Boes, 2010). In the Medieval 
period, European researchers also married mystical and clinical beliefs to explain migraine 
(Elliot, 1932) through a combination of the hypotheses of Islamic and Christian medical 
writers (Eadie, 2012). For centuries, mystical beliefs persisted alongside Galen’s theories, and 
it was not till the 1700’s that this began to change. 
Sympathetic nervous system origins. 
In 1778, Tissot published his conclusions on the origins of migraine in Traité des nerfs 
et de leur maladies following 20 years of research (Eadie, 2003). It was in the same year that 
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John Fothergill published his less extensive observations on the subject (Eadie, 2003; Pearce, 
1986), though Fothergill designated it “sick head-ach” (Eadie, 2003, p. 414). Tissot attributed 
the origin of migraine to a disturbance of the stomach of dietary or emotional cause (Eadie, 
2003). This theory placed migraine in the category of a sympathetic disorder, stipulating that 
this headache arose from the stimulation of the sympathetic system via the gut (Eadie, 2003; 
Latham, 1872).  
Nearly a century later, in 1873, Liveing  espoused a further neurogenic theory of 
migraine (Latham, 1872; Liveing, 1872). Liveing’s position was that migraine was caused by 
a nerve storm and, though he did not reject the hypotheses that the sympathetic nervous 
system and neurovasculature played roles in migraine, he was unconvinced of their centrality 
in the headache’s aetiology (Liveing, 1872; Pearce, 1986). On the other hand, Latham drew 
the conclusion that it was sympathetic hyperactivity that led to decreased cerebral blood flow, 
which caused aura, followed by sympathetic exhaustion and vasodilation that caused the 
headache (Eadie, 2005; Latham, 1872).  
Latham’s conjecture that aura and headache pain are caused by two distinct, yet 
related processes, is an important one. At present there is evidence that, while vascular 
changes in migraine are related to the mechanism behind aura, they are in fact not the primary 
cause of headache pain (Davies, 2011). This area of research was significantly advanced by 
the works of Leão and Wolff, which are described later in this chapter. 
Around the late 19th century, Woakes proposed the use of ergotamine in migraine 
treatment (Koehler & Isler, 2002). Woakes and at least three other prominent researchers of 
the time, Romberg, Symonds and Anderson, attributed migraine to neuralgia of the trigeminal 
nerve branches  (Eadie, 2005). However, the proposed involvement of the trigeminal nerve in 
migraine pathogenesis was usurped by sympathetically-related hypotheses: du Bois-Reymond 
surmised that hyperactivity of the cervical sympathetic system caused cranial vasoconstriction 
(Pearce, 1986); Moller suspected sympathetic paralysis resulting in vasodilation (Eadie, 
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2005). These two divergent views were consolidated by Wilks and Moebius in the 1890’s, 
with Wilks reworking the gastric hypothesis to suggest that this dysfunction resulted in 
paresis of the brain blood vessels (Eadie, 2005). Unfortunately, Wilks did not provide clear 
descriptions of the mechanism connecting the gut and the brain, but Eadie (Eadie, 2005) 
posited that Wilks would have connected the two via the autonomic nervous system. On the 
other hand, Moebius’s conjecture was that some initial alteration in brain functioning caused 
increased cervical sympathetic tone, which led to a change in cranial blood flow (Eadie, 2005; 
Latham, 1872). In 1900 Deyl specified compression of the trigeminal nerve as the root of 
migraine pain (Unger, 2006), thus adding to the neurological theories of the headache. 
Wolff’s contribution. 
The 20th century saw the emergence of more detailed explanations of how pathological 
neurological processes lead to neurovascular abnormalities in migraine. One of the most 
important discoveries was that of Wolff and Graham, who, in 1938, demonstrated the efficacy 
of ergotamine in constricting blood vessels and effectively ending a migraine (Baron & 
Tepper, 2010; Unger, 2006). Wolff’s work was vital in showing that the pain emanated not 
from the insensate neurons but from the highly sensitive neurovasculature (Unger, 2006) by 
demonstrating that stimulation of the blood vessels of the meninges and the cerebrum resulted 
in severe headaches, but stimulating the brain parenchyma did not (Parsons & Strijbos, 2003). 
Subsequently, Wolff’s work ascribed aura to intracranial spasm of the cerebral arteries and 
headache pain to extracranial vasodilation leading to activation of nociceptors (Shevel, 2011). 
Shevel (2011) points out that, while Wolff’s surmise about the origins of aura was disproved 
by Oelsen’s Copenhagen Group, the theory that extracranial vasodilation causes headache 
pain has not been discredited.  It was in 1948 when Wolff’s first edition of Headache and 
Other Head Pain was published (Weatherall, 2012). The text is now in its eighth edition and 
is regarded as the definitive text in the field (Geweke, 2006). 
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Cortical spreading depression and oligaemia. 
The history of migraine in the Middle ages is replete with the accounts of Hildegard of 
Bingen, a nun that described her experience of aura in great detail (Alexander, 2014). 
Hildegard’s symptoms have been diagnosed retrospectively as MA and her depictions of her 
symptoms have provided insight into the subjective experience of aura and headache pain 
(Foxhall, 2014). 
Our current understanding of the mechanism behind aura is attributed to the works of 
Leão, who documented cortical spreading depression (CSD) in the 1940’s. In 1941 Lashley 
analysed his own visual auras and hypothesised that they were caused by excitation of the 
visual cortex, followed by reduced neuronal excitability (Wolthausen, Sternberg, Gerloff, & 
May, 2009). A few years later, Leão sought a clearer understanding of the electro-
encephalogram results seen in experimental epilepsy through his experiments on rabbits,  
(Leão, 1944). One of his findings was that tetanizing current caused an enduring period of 
depressed spontaneous electrical brain activity. In migraine, CSD describes the slow 
propagating wave of neuronal burst activity, which is followed by depression of activity - 
both spontaneous and evoked (Charles & Brennan, 2009; James, Smith, Boniface, Huang, & 
Leslie, 2001; Schwedt & Dodick, 2009).  
Leão’s rabbits showed how the depression spread slowly from the point of origin all 
across the cortex and led to inhibited somatosensory and optic responses (Leão, 1944). The 
researcher posited a similarity between CSD and epileptic activity – phenomena he described 
in rabbits, cats and pigeons (Charles & Brennan, 2009). It was only in the 1950’s that the 
similarity was noted between  CSD and migraine (Milner, 1958).  
Leao (1944) also posited that CSD neuronal activity predicts changes in cerebral blood 
flow. Specifically, he suspected that a vasodilator was released, resulting in a pattern of 
marked vasodilation co-occurring in the region of the depression. This vasodilation of the 
meningeal and cortical blood vessels has been described as a powerful endogenous activator 
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of meningeal nociceptors via inflammatory pathways (Theoharides, Donelan, Kandere-
grzybowska, & Konstantinidou, 2005).  Thus, migraine pain (the headache) was deduced to 
be vascular in origin. However, this conclusion has been weakened somewhat by 
neuroimaging findings, which suggest that hyperaemia in aura is followed by oligaemia, 
which continues into the pain phase, therefore indicating that vasodilation cannot account for 
the pain (Davies, 2011).  When CSD occurs, regional cerebral blood flow (rCBF) actually 
increases only during the depolarisation phase and then decreases once neuronal activity 
diminishes (Wolthausen et al., 2009). Thus, while neuro-imaging has confirmed 
neurovascular involvement in migraine, it has also indicated that vascular changes are not the 
primary cause of the migraine pain (Davies, Macfarlane, McBeth, Morriss, & Dickens, 2009).  
This conclusion remains controversial in terms of MO, though, as regional cerebral 
blood flow (rCBF) changes are not consistently related to CSD in MO (Headache 
Classification Committee of the International Headache Society, 2013). There is, in fact, still  
uncertainty as to whether CSD is a general feature of all migraine or specific to MA 
(Headache Classification Committee of the International Headache Society, 2013).  
Rather than elaborating on the physiological mechanisms of CSD, the focus is placed 
on the discussion of how the concept has become an important focal point for the distinction 
between MO and MA. Descriptions of the mechanism of CSD can be found in Busija, Bari, 
Domoki, Horiguchi, and Shimizu (2008) and Charles and Brennan (2009). 
In a review of recent brain imaging findings, Davies (2011) discusses how findings 
from SPECT, DTI and PET studies have led to a more in-depth understanding of CSD, the 
distinction between and, ultimately, the question of how CSD relates to each of the two 
migraine subtypes. It is generally agreed that CSD is the primary cause of migraine aura 
(Charles & Brennan, 2009), but not a prerequisite for migraine (Wolthausen et al., 2009). On 
the other hand, there may even be some form of silent CSD that occurs in deep structures and 
is not recorded by surface EEG (Davies, 2011; Wolthausen et al., 2009).  
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While many concur with Schoenen (2006) that imaging has given us more insight into 
the origins of migraine, research with the technique has also raised a few questions. One of 
these questions pertains to our assumption that MO and MA are merely variations of the same 
disorder. This issue was first raised in Chapter 1 in relation to the choice of MO as opposed to 
migraine in general or MA as the population for this study. In Chapter 1 it was highlighted 
that MA and MO differ vastly in their characteristics (Christensen, Le, Kirchmann, & Olesen, 
2012; Ludvigsson, Hesdorffer, Olafsson, Kjartansson, & Hauser, 2006; Russell, Rasmussen, 
Fenger, & Olesen, 1996; Russell et al., 2002). As noted by Schoenen (2006):  
Striking features of results obtained with neurophysiological investigations in 
migraine are their heterogeneity and variability. This should not come as a surprise, 
however, if one keeps in mind that the migrainous diathesis is a functional one, 
modulated by various internal and external factors and markedly heterogeneous from a 
genetic point of view. Most likely, the future of neurophysiologic testing in migraine 
is therefore to contribute to a better phenotyping of subgroups of patients for genetic 
and therapeutic studies and possibly to the identification of dynamic functional 
changes that modulate the disorder and may chronicise it. (p. S79) 
When taking this observation to its extreme, the continued placement of MA and MO under 
the same umbrella requires further consideration. A population-based case control study 
conducted amongst Icelandic children diagnosed with migraine (n =94) showed that children 
with MA had a 3.7-fold increased risk for developing epilepsy when  compared to controls, 
whereas this risk was not apparent in the children with MO (Ludvigsson et al., 2006). For the 
authors, this result is suggestive of two different disease processes and therefore two different 
disorders. This is hardly a new notion, though, and a similar observation was made in a study 
of 484 adult migraineurs in Denmark (Russell, Rasmussen, Fenger, & Olesen, 1996). In that 
study, the authors investigated premonitory symptoms, precipitating factors, hormones, 
symptomatology and demographic variables in MO (n = 342) and MA (n = 156) sufferers. 
 30 
 
Results indicated a distinct clinical presentation for each headache type characterised by clear 
differences in the age of onset, sensitivity to female hormones and bright light. This, in 
conjunction with the different neuroimaging results for MA and MO present a convincing 
argument for the two as separate entities.  
Sterile inflammation. 
Sterile inflammation refers to the inflammatory response arising in the absence of 
microorganisms. Though it contributes to the body’s efforts to clear debris and promote 
repair, it may also arise from ischaemia-reperfusion, autoimmunity or the presence of sterile 
foreign particles. In some cases, this inflammatory response becomes uncontrolled, resulting 
in inflammation-derived injury and even further inflammation (Menezes, Mansur, McDonald, 
Kubes, & Teixeira, 2011). Possibly the most detailed description of sterile inflammation 
comes from Miskowitz’s neurovascular theory of migraine (Coelho et al., 2007). 
Miskowitz explains that both extrinsic (occurring outside the central nervous system) 
and intrinsic (within the central nervous system) nerves are stimulated in migraine. This 
process is depicted in Figure  2.1-1: Extrinsic nerves include the peripheral nerves arising from 
the superior cervical (SCG), sphenopalatine (SPG), otic (OG) or trigeminal (TG) ganglia. 
Intrinsic nerves originate in the parenchyma and microvasculature. Large cerebral vessels, 
pial vessels, large venous sinuses and the dura mater are surrounded by fibres of the TG. 
These blood vessels are innervated by noradrenergic (NA), serotonergic (5-HT), cholinergic 
(Ach), glutamate (Glu) or gamma amino butyric acid (GABA) afferents from subcortical 
neurons of the thalamus, locus coeruleus (LC), raphe nucleus (RN), basal forebrain, or the 
local cortical interneurons. Stimulation of these afferents causes vasoactivation (Hamel, 
2006). Both MA and MO show similar subsequent processes of pro-inﬂammatory secretion, 
oxidative stress, leukocyte activation, inﬂammation and dilation of intracranial and 
extracranial arteries on the side of the headache. Inflammation is mediated by Substance P 
(SP), calcitonin gene-related peptide (CGRP), neurokinin A (NKA), neuropeptide Y (NPY), 
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Somatostatin (SOM) and endothelin-3. This repeated process can cause damage to the blood 
vessels. Tachykinins change vascular permeability and CGRP causes vasodilation in what is 
known as the axon reflex flare. This vasodilation activates intracranial nociceptors (Hamel, 
2006), leading to the pain experienced in the headache. 
 
 
Figure  2-2.  Regulation of vascular tone via the intracranial perivascular nerve (Hamel, 
2006, p. 1060) 
Central and peripheral sensitisation. 
The modulation of pain is a complex process with numerous potential sites for 
disruption and dysfunctional pain experience. Both central and peripheral sites have been 
identified as being involved in causing migraine pain (Aguggia, 2012) through processes of 
allodynia and hyperalgaesia. 
Allodynia is the evolution of a pain response in the presence of a non-noxious 
stimulus (Granziera et al., 2014). Hyperalgaesia is seen when stimuli that previously produced 
minimal pain responses begin to cause increased pain (Chapman, Tuckett, & Song, 2008; 
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Sarchielli, Di Filippo, Nardi, & Calabresi, 2007). Both allodynia and hyperalgaesia are 
features of migraine that result from abnormal cortical excitability (Granziera et al., 2014). 
According to Granziera et al. (2014), thalamic neurons receiving afferents from the cranial 
meninges and extracephalic skin are sensitized in migraineurs, resulting in the reported whole 
body allodynia and hyperalgaesia. In addition, the posterior thalamus integrates nociceptive 
signals from the dura mater and retinal photosensitivity, providing a possible reason for the 
increase in pain perception in bright light (Granziera et al., 2014). 
The observation that migraine often becomes a chronic and even daily occurrence for 
many sufferers (Galletti et al., 2009) has led to investigation of possible enhanced nociception 
in such patients. Reduced functioning of pain control pathways, which compounds the pain 
arising from the inflammatory process has been posited (Goadsby, Ferrari, Csanyi, Olesen, & 
Mills, 2009; Hamed, 2009; Hamel, 2006).  
The concept of cortical hyperexcitability in migraine relates to a lack of habituation to 
evoked stimuli over various modalities, although it is not clear if this deficient habituation is 
caused by increased sensitivity or decreased inhibition. A neuron is considered to be 
hyperexcitable when it responds to subliminal stimulus or produces response of increased 
amplitude to supraliminal stimulus (Coppola et al., 2009). What is clear is that migraine 
sufferers have a low threshold for the attack and often do not recover from this inter-ictally. 
This suspected subclinical central impairment has given rise to the term “the migrainous 
brain”. Alteration of mitochondrial energy metabolism, ion transporter dysfunction and 
altered neurotransmitter levels have been considered possible causes of the low threshold 
(Coppola et al., 2009). 
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2.4 Determinants of migraine  
While the exact cause of migraine still eludes us, researchers have, nevertheless, 
managed to amass a significant body of work on correlates of migraine. The following 
sections deal with the proposed biological and psychosocial markers of migraine in general 
and MO in particular.   
2.4.1 Identified biomarkers. 
No single biological substrate has yet proven viable and feasible as an accurate means 
of diagnosing migraine. Without a biomarker for migraine diagnosis, practitioners have to 
rely on subjective criteria (Colson, Lea, Quinlan, MacMillan, & Griffiths, 2005), which can 
be unreliable and lead to protracted diagnosis processes. The neurological alterations in 
migraine are both centrally and autonomically located and separating MA and MO or even 
describing an overall pathophysiology for all migraine types has been complicated.  
Markers are mainly tested through samples from blood and CSF, but 
electrophysiology and neuro-imaging techniques are also widely used. Proposed biomarkers 
for MO include genes related to catecholamine metabolism (COMT), lipoprotein transport 
(LDL-R) and Human Leukocyte Antigen (HLA-DRB1) (Loder, Harrington, Cutrer, Sandor, 
& De Vries, 2006; Montagna, 2008; Nagata et al., 2009).  
2.4.2 Genetic determinants of migraine without aura. 
To date, no fewer than ten genes have been studied in relation to migraine. The 
clearest genetic outcomes are seen in studies of familial hemiplegic migraine (FHM). The 
conclusion is that FHM has a Mendelian pattern of autosomal dominant heritability (Nagata et 
al., 2009). The following genes have previously been studied in FHM patients: genes 
associated with channelopathies (P/Q neural calcium channel, Na+/K+ ATPase and voltage-
gated sodium channel); neurotransmitter genes (5-HTSERT, 5-HT2A, dopamine receptor 2 or 
DRD2 and dopamine betahydroxylase) and genes that code for a host of other proteins 
 34 
 
including low density lipoprotein (LDL) and  LDL receptors, Factor V R/Q 506, protein S, 
angiotensin converting enzyme, methylene-tetra-hydrofolate reductase, progesterone 
receptors, K+ channel KCNN3 and human leukocyte antigen (HLA-DRB1) (Montagna, 2008; 
Nagata, Hattori, et al., 2009; Norton et al., 1999; Schurks et al., 2009; Stewart, Simon, 
Shechter, & Lipton, 1995; Striessnig, 2005). However, the genetic study of the more common 
non-familial migraine has yielded less conclusive outcomes, leaving a great scope for further 
research (Montagna, 2008).  
The genetic study of the more commonly occurring non-familial type of migraine – 
including MO - has yielded less conclusive outcomes (Rainero et al., 2006). There is evidence 
that first-degree relatives of MO probands have 1.9 times the risk of developing MO and 1.4 
times the risk of developing MA, whereas ﬁrst-degree relatives of MA probands have nearly 
four times the risk of developing MA and no increased risk of developing MO (Montagna, 
2008). Meanwhile, some studies show moderate effect sizes in voltage-gated channel gene-
MO interactions (Nyholt et al., 2008). Recently, a body of evidence has begun to grow around 
the involvement of glutamate in migraine. 
2.4.3 Glutamate in migraine. 
Given the prominent role of glutamate transport in pain hypersensitivity (Mathew, 
2001; Sarchielli, Di Filippo, Nardi, & Calabresi, 2007) it is not surprising that glutamate has 
been tied to migraine. Both pre-clinical and clinical observations have led to a fairly clear 
indication of glutamate involvement in migraine, although researchers have not been able to 
pinpoint its exact role (Ramadan, 2003; Vikelis, 2007).  
The argument for glutamate involvement in migraine is evinced by studies showing 
that glutamate antagonists have had some success in migraine treatment (Andreou & 
Goadsby, 2011; Lampl, Buzath, Klinger, & Neumann, 1999). Additionally, elevated 
glutamate levels have been noted in both MA and MO (Alam, Coombes, Waring, Williams, & 
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Steventon, 1998; Cananzi, D’Andrea, Perini, Zamberlan, 1995), with a fair indication that 
glutamate levels are higher in MA than MO inter-ictally, with levels climbing higher during 
attacks (Ferrari, Odink, Bos, Malessy, & Bruyn, 1990). While glutamate is implicated in CSD 
(Eikermann-Haerter, Kudo, & Moskowitz, 2007), it is also a known stimulant of the 
trigeminal nucleus caudalis (illustrated in cats by Storer and Goadsby cited in Chasman et al., 
2011), which ties the neurotransmitter to central sensitization. The evidence suggests that, 
while the neurotransmitter may be involved in both types of headache, it may play varying 
roles in the pain.  
The elevated levels of glutamate in migraine have been further investigated at the 
cellular level and linked to impaired uptake into platelets (Cananzi, D’Andrea, Perini, 
Zamberlan, et al., 1995; Vaccaro et al., 2007). Vaccaro et al. (2007) explored platelet 
glutamate uptake and release in 25 MO, 25 MA and 20 health controls. While MO subjects 
showed increased glutamate release from platelets into plasma, they also exhibited decreased 
platelet uptake relative to controls. There was also an increased plasma glutamate level in MO 
relative to controls. The authors refer to the role of SLC1A2 in this process, suggesting that 
transport of glutamate is altered in MO. The hypothesis is thus that defective cellular 
glutamate uptake is an aetiological mechanism in MO. 
There are, however, some research results that indicate that glutamate really plays a 
definitive role in chronification of MO (Sarchielli, Di Filippo, et al., 2007; Vargas, 2009). The 
discovery of the -181 A/C polymorphism of the SLC1A2 transporter promoter region has 
provided evidence of defective glutamate transport in chronic forms of migraine. The 
observation was made by Shin and colleagues (Shin, Han, Lee, & Park, 2011) that the A allele 
of this polymorphism is related to higher analgesic use (and therefore possibly transformation 
to medication over-use headache) amongst migraineurs is considered a vital clue to the 
potential mediating factors in migraine pain. The importance of examining temperament in 
migraine is also highlighted by Shin et al.’s research in which it is shown that  the occurrence 
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of the A allele (A/A and A/C) is associated with lower Reward Dependence (RD) scores than 
in C/C groups. This relationship is apparent in females, but not males (Matsumoto et al., 
2007).  
Genome-wide association studies (GWAS) have given rise to a more complex picture 
of glutamate’s role in migraine. In the discovery stage of Anttila et al.’s GWAS using seven 
European case collections (Anttila et al., 2010), 429 912 markers were successfully genotyped 
using Online Methods. When Cochran-Mantel-Haenszel (CMH) association analysis (P< 5x 
10-8) was conducted, only one significant marker was identified - the minor allele (A) of 
rs1835740 on chromosome 8q22.1 [p = 5.38x10-9; OR = 1.21 to 1.33 (95% CI 1.115 – 
1.528)]. Although replication was only successful in the larger groups, a stronger effect was 
noted amongst those with MA. Rs1835740 was found to lie between two candidate genes, 
metadherin (MTDH) and plasma glutamate carboxypeptidase (PGCP). The expression of 
quantitative trait locus (eQTL) conducted using fibroblasts, T cells and lymphoblast cell lines 
showed significant correlation with transcription levels of MTDH in the lymphoblasts. 
Rs1835740 is a cis regulator of MTDH expression in lymphoblasts. In astrocytes MTDH 
down-regulates SLC1A2 (aka EAAT-2 or GLT-1) and knock-out mice lacking SLC1A2 
suffer lethal spontaneous epileptic seizures. PGCP on the other hand is responsible for the 
hydrolysis of various substrates to form glutamate. The authors propose that down-regulation 
of SLC1A2 (the main glutamate transporter in the brain) or increase in PGCP activity causes 
an accumulation of glutamate in the synaptic cleft, which leads to the central sensitization and 
the CSD seen in migraine. They add that SLC1A2 transporter functional alteration is also 
linked to ataxia and epilepsy, two other episodic neurological disorders.  
On the other hand, Ligthart and colleagues (Ligthart et al., 2011) found less 
convincing results with respect to MTDH. They conducted a meta-analysis of GWAS in six 
European migraine cohorts obtained from Dutch and Icelandic databases. In total, the sample 
in the exploratory phase consisted of 2446 migraine cases and 8534 controls. The SNP, 
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rs9908234 emerged as a candidate for migraine (p= 8 x 10-8). This SNP is located in the 
Nerve Growth Factor (NGF) receptor gene. In silico methods did not replicate these results in 
any of the three additional cohorts from the Netherlands and Australia.  Comparison of the 
findings with other studies’ migraine gene and loci findings were not significant. In addition, 
only a modest association with MTDH was found.  
Some GWAS have focused specifically on MO. Christensen, Le, Kirchmann, and 
Olesen (2012) followed the GWAS by Anttila et al. (2010) with an investigation of the 
rs1835740 relationship to MO. They could find no statistically significant relationship 
between that allele and symptoms, comorbidity, provoking factors or the effect and use of 
different medical treatment in MO. A later GWAS by Freilinger, Anttila, Vries, and Malik 
(2013) identified six loci with genome-wide significance. Six SNP’s were identified on 1q22, 
all of which are located within the gene for the myocyte enhancer factor 2D (MEF2D). 
MEF2D supports newly formed neurons, but also regulates the formation of excitatory 
synapses. Aside from identifying four new associations with MO, Freilinger et al.'s (2013) 
study also confirmed the conclusions of an earlier study that implicated TRPM8 and LRP1 
(Chasman et al., 2011). 
Brief overview of glutamate in the human central nervous system. 
In-depth investigation of the biochemistry and neurophysiology related to glutamate is 
beyond the scope of this thesis, but some background is required to understand glutamate’s 
significance in MO. A brief overview of glutamate’s role in normal human central nervous 
system functioning and psychopathology is given. The reader is referred to more detailed 
accounts of some topics throughout the section. 
Glutamate is an anion of the amino acid, glutamic acid (Amiel & Mathew, 2007). As 
the main excitatory neurotransmitter in the human central nervous system glutamate has vital 
roles in higher cognitive functions, memory, learning and development (Cater, Vandenberg, 
& Ryan, 2014). Glutamate is distributed widely throughout the brain as it is required in 
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protein synthesis, intermediate metabolism, as a precursor for the human body’s main 
inhibitory neurotransmitter, Ɣ-amino butyric acid (GABA) and in ammonia detoxification 
(Behar & Rothman, 2001; Broman, Hassel, Rinvik, & Ottersen, 2000).  
Glutamate is found in various foods, but is also produced in the human body from 
gluatamine in the presence of glutaminase and from α-ketoglutarate via alanine 
aminotransferase (Behar & Rothman, 2001; Whillier, Garcia, Chapman, Kuchel, & Raftos, 
2011).  The dominant pathway for brain glutamate metabolism is the glutamine-glutamate 
cycle (also referred to as the glutamate/GABA-glutamine cycle) that occurs between 
astrocytes and neurons (Behar & Rothman, 2001).  
Depolarization of the presynaptic neuron leads to the release of glutamate  into the 
presynaptic cleft, where glutamate binds to receptors on the postsynaptic glutamatergic 
neuron, leading to the opening of the ion channels in the post-synaptic membrane (Behar & 
Rothman, 2001; Cull-Candy, 2002). Glutamate receptors are expressed in various 
permutations giving rise to a variety of glutamate effects (Cull-Candy, 2002). There are 
several ionotropic glutamate receptors, the most important of which are kainate, α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and N-methyl-D-aspartate (NMDA) as 
well as three metabotropic receptors (mGluR).  Full reviews of these receptors can be found 
in Cull-Candy (2002) and Ferraguti and Shigemoto (2006).  
The reuptake of glutamate from the synaptic cleft into astrocytes is accomplished 
through transporters. There are five high-affinity glutamate transporters that have been cloned 
in humans (named excitatory amino acid transporters or EAAT 1 to 5). SLC1A2 is the major 
transporter of glutamate in the human, being responsible for up to 90% of glutamate transport 
(Rainesalo, Keränen, Saransaari, & Honkaniemi, 2005; Shin et al., 2011).  Transport is Na+-
dependent and requires the co-transport of Na+ and H+ and counter-transport of K+ (Behar & 
Rothman, 2001).  
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Once in the astrocyte, glutamate is converted to glutamine through the uptake of an 
ammonia group in the presence of glutamine synthetase. This glycine is used by the 
presynaptic neuron to produce glutamate (mediated by phosphate-activated glutaminase). This 
is a rather simplistic representation of the fate of glutamate in the astrocyte, but it will suffice 
for this thesis. For more detailed accounts the reader is referred to Bak, Schousboe, and 
Waagepetersen (2006); Behar and Rothman (2001); Hertz (2013) and Petroff, Errante, 
Rothman, Kim, and Spencer (2002). 
Glutamate and pathology. 
Excess glutamate causes cytotoxicity and its concentration therefore needs to be 
carefully regulated. In healthy humans the serum levels of glutamate vary between 10 and 
100nmol/ml (Heresco-Levy et al., 2007). In toxic events (extracellular glutamate higher than 
100micromol/l, glutamate is oxidised in addition to undergoing conversion in the glutamate-
glutamine cycle (Behar & Rothman, 2001). 
Increased levels of glutamate have been documented in hypoxia and hypoglycaemia 
(Danbolt, 2001), stroke (Aliprandi et al., 2005; Mallolas et al., 2006) and epilepsy (Chapman, 
2000; Meldrum, 2000; Petroff et al., 2002). Furthermore, heightened glutamate levels have 
been associated with the C allele of the -181 A/C polymorphism of the SLC1A2 transporter 
promoter region in the poorer outcomes of at least two neurological disease states, namely 
stroke and multiple sclerosis (Mallolas et al., 2006; Pampliega, Domercq, Villoslada, & 
Sepulcre, 2008). Glutamate regulation is also an important aspect of pain hypersensitivity 
(Mathew, 2001; Sarchielli, et al., 2007) and glutamate receptors are now targets for drug 
treatments in chronic pain conditions (Bleakman, Alt, & Nisenbaum, 2006).  
The potential role of glutamate transporter disturbances in mood disorders has led to 
possible novel therapeutic agents (Hashimoto, Sawa, & Iyo, 2007; Krystal et al., 2002). 
Meanwhile, glutamatergic systems are also being scrutinised for their role in drug resistance 
in the treatment of schizophrenia (Hong, Yu, Lin, Cheng, & Tsai, 2001). 
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2.4.4 Psychosocial markers in migraine. 
The variable results even in GWAS suggest that genetic changes are not the only 
determinants of the occurrence of migraine. The emergence of epigenetic principles leads to 
questions regarding possible chromatin modifications in migraine. The pain experienced 
during MO attacks is variable (Diego, Vuillaume De Diego, & Lanteri-Minet, 2004) and has a 
significant impact on the patient, with some patients unable to sleep, eat or complete daily 
activities (de Velasco & Gonzalez, 2003). While the occurrence of migraine pain has been 
explained in some measure by sensitisation of meningeal nociceptors and sterile inflammation 
(Longoni & Ferrarese, 2006), there is support for the involvement of psychosocial  factors in 
the experience (Blomkvist, Hannerz, Katz, & Theorell, 2001; Fasmer, Akiskal, Kelsoe, & 
Oedegaard, 2009; Tietjen et al., 2010a, 2010b, 2010c; Tietjen & Peterlin, 2011). 
Temperament.  
Work on the processing of pain-related words has shown that there is enhanced 
sensitivity of the pain neural matrix in migraine patients over healthy subjects (Eck, Richter, 
Straube, Miltner, & Weiss, 2011). Moreover, personalities characterised by high emotionality 
are likely to experience high emotional burden related to their experience of pain (Mongini et 
al., 2009). The latter implies a relationship between the basis for personality (temperament) 
and pain regulation. For the purposes of this research, temperament is conceptualised using 
Cloninger’s Psychobiological Model of Personality, which takes into account state, trait and 
environmental aspects of personality. Cloninger’s theory describes four independent 
dimensions of temperament, namely Novelty Seeking (NS), Harm Avoidance (HA), Reward 
Dependence (RD) and Persistence (P). NS is related to the level of activation of exploratory 
activity, while HA indicates the efficiency of the behavioural inhibition system. RD is related 
to the maintenance of rewarded behaviour, whereas P indicates maintenance of behaviour as 
resistance to frustration (Hansenne et al., 1999). 
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These temperament traits are underpinned by different neurobiological systems: NS is 
related to the functioning of the dopaminergic system and high NS is characterized by low 
basal DA, whereas HA is regulated by the serotonergic system and high HA is related to high 
serotonin activity. RD appears to be related to the noradrenergic system and low basal NA. 
Meanwhile, P is regulated by the glutamate system (Conrad et al., 2007; Hansenne et al., 
1999; Mongini, Keller, Deregibus, Barbalonga, & Mongini, 2005). These assumptions 
underlie the core of this research question, which is whether the pain experienced in migraine 
is associated with temperament traits and regulated by neurotransmission.  
It was Wolf who, in 1937, termed the observed dominant personality traits and 
reactions in migraine sufferers “migraine personality”. However, research has not been 
conclusive in its definition of this psychological profile and Wolf’s description of resentment 
and neuroticism amongst migraine sufferers has been refuted in some instances. Likewise, 
findings around temperament in migraine have been variable (Abbate-Daga et al., 2007). 
Nylander et al. (1996), Di Piero et al. (2001) and Boz et al. (2004) could find no significant 
temperament trait differences between migraineurs and controls.  By contrast, Mongini (2005) 
found that migraine sufferers (n = 49) scored significantly higher than the controls in HA (p = 
.021) and P (p < .001). The significantly elevated HA scores have been confirmed in a later 
study of 142 migraine patients, 108 healthy controls and 30 patients with non-migrainous 
chronic pain (Sánchez-Román et al., 2007).  These findings indicate a possible temperament 
component in migraine. 
Parent-child relationships.  
A few studies conducted in the past decade have shed light on interesting dynamics 
that exist between parents of migraineurs and their children. For example, Esposito et al. 
(2013) studied 219 children referred for MO and 381 healthy controls. The Italian version of 
the Separation Anxiety Test was administered and daily headache diaries were kept to record 
information on headache frequency and duration. Whereas insecure/avoidant attachment 
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(Type A) was positively related with the intensity (r = .375, p = <.001), frequency (r = .392, 
p < .001) and duration (r = .184, p = .006) of MO attacks, insecure/ambivalent attachment 
(Type C) was negatively related with the frequency (r = −.348, p < 0.001) and intensity (r = 
−.305, p < .001) of the attacks. Secure attachment (Type B) was negatively related with the 
duration (r = −.229, p < .001) of the attack. These results indicate that avoidant attachment is 
a risk factor for more frequent and painful MO headaches, albeit that the relationship is not 
very strong. 
The article by Esposito, Roccella, Gallai, et al. (2013) explored the relationship 
between maternal personality (on the Minnesota Multiphasic Personality Inventory (MMPI-2) 
and frequency, intensity, and duration of migraine attacks in their children who suffer from 
MO (n = 422) and healthy children (n = 587). Results indicate that the mothers of the 
children with MO have a number of significantly higher indications of psychopathology (e.g. 
paranoia, social introversion and anxiety and low self-esteem) than the mothers of the healthy 
children (p < .05). The frequency with which MO attacks occurred in the children was 
significantly correlated with the mothers’ anxiety (r = .4903, p = .024) and maternal low self-
esteem (r = .5130; p = .017), while the duration of the attacks was significantly correlated 
with a number of the mothers’ psychological problems - especially hypochondriasis (r = 
.6155, p = 0.003), hysteria (r = .6235, p = .003) and health concerns (r = .7039, p = .001). 
The authors concluded that the mothers’ personalities affect the children’s experiences of 
their attacks. They posit that parental modelling is central to teaching children to cope with 
their own health problems and that this can have a significant impact on how often, how long 
and how intensely symptoms recur.  
Adverse early life events. 
Several studies indicate that traumatic life experiences are highly prevalent amongst 
those suffering from migraine. For example, Tietjen et al. (2010)  reported 21% physical 
abuse, 25% sexual abuse, 38% emotional abuse, 22% physical neglect and 38% emotional 
 43 
 
neglect amongst migraineurs (N = 1348). A prevalence study conducted amongst 13089 
Canadians showed that people with a history of childhood physical abuse were twice as likely 
to have a migraine diagnosis as those that had not been abused OR = 2.27 99% CI [ 1.80, 
2.86] (Fuller-Thomson, Baker, & Brennenstuhl, 2010).The relationship between migraine and 
childhood physical abuse was significant even when controlling for a number of confounders.  
These traumatic events moderate the relationship between migraine and headache 
disability and even chronicity. Epigenetics provides a clue to understanding the impact of 
these events (Rothrock, 2010). 
Stress.  
The physiology of stress is well documented and the details are not the focus of this 
study. The reader is therefore directed to the numerous resources dealing with the 
neurobiology of stress for further information (e.g. McEwen, Elland, Hunter, & Miller, 2012; 
McEwen, 2012; Tsigos & Chrousos, 2002).  
Borsook and colleagues (Borsook, Maleki, Becerra, & McEwen, 2012) reflect on this 
relationship between stress and migraine and conceptualise the effects of migraine on the 
brain in terms of allostatic load. Migraine sufferers report a high level of negative stressors 
and traumatic life events (Autret, Roux, Rimbaux-Lepage, Valade, & Debiais, 2010; Branch, 
2009; Tietjen et al., 2010b, 2010c) and the headache itself can serve as a stressor. When the 
attempts to maintain physiological stability (allostatic responses) become maladaptive, the 
stress response becomes dysfunctional. Such alteration to the stress response can alter brain 
structure and function through plasticity, which further augments the dysregulation. In 
migraine, this means that psychosocial stressors and the neurobiological response to these 
(and to the headache) all contribute to the subjective experience of the headache – and, by 
extension, a poor HRQOL. 
Stress is of particular importance in migraine for Martin (2007): In earlier work, 
Martin and Soon (1993) showed that perceived stress amongst migraine sufferers was higher 
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than amongst controls, while migraineurs were also much less satisfied with their social 
support than controls. Martin and Soon conclude this to mean that the psychosocial elements 
of migraine require further investigation.  
Sauro and Becker (2009) added to Martin and Soon's (1993) surmise about the role of 
stress in migraine by explaining that migraine onset appears to follow a stressful period 
(sometimes called the let-down period). This is known as the Stress-Relaxation Model 
(Robbins, Lipton, Laureta, & Grosberg, 2009). Lipton and his colleagues (Lipton et al., 2014) 
provided evidence to support this Stress-Relaxation Model in 17 migraineurs.  Hashizume et 
al. (2008), on the other hand, examined the perception of daily hassles in 16 migraine 
patients. The results indicate that sufferers perceive a higher burden of daily hassles in the 1-3 
days leading up to their migraine versus other days.  
Coping.  
The association between mood (depressed mood and irritability), cognitive symptoms 
(memory and attention deficits) and migraine was originally reported by Living in 1895 
(Pompili et al., 2010). Recent evidence correlates migraine with substance use and a number 
of psychiatric disorders: In a multicentre  study of 247 people suffering from medication 
overuse headache, Radat et al. (2008) found that a history of migraine was a risk factor for the 
development of dependence on acute migraine treatments. A further study by  Radat, Mekies, 
et al. (2008) amongst 5417 migraine patients showed how maladaptive coping combined with 
stress and impairment from migraine cause an escalation in psychopathology, with 
migraineurs progressing from no psychopathology to anxiety and finally concomitant anxiety 
and depression as the levels of the three mediators rise.  Autret, Roux, Rimbaux-Lepage, 
Valade, and Debiais (2010) and Singh, Shukla, Trivedi, and Singh (2013), have shown 
correlations between migraine and depression and anxiety.  
In order to investigate possible patterns in the psychological, behavioural and socio-
environmental factors associated with primary headaches, Kröner-Herwig and Gassmann, 
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(2012) compared 2132 children with primary headaches with 1267 healthy children in the 
Southern Lower Saxony region in Germany. Migraine sufferers made up 7.8% of the cohort 
(n = 314). Maladaptive psychological traits were particularly significant risk factors for 
migraine and both negative psychological variables and socio-environmental stressors were 
more strongly associated with migraine than tension type headache.  
Lake (2009) describes two forms of dysfunctional or maladaptive pain coping 
amongst headache sufferers, namely sensitising (hypervigilance and anticipating, 
catastrophising and hyperempathy) and minimising (alexithymia, stoicism, denial or anger 
suppression). Pain catastrophizing is a particularly prominent coping strategy amongst 
migraine sufferers (Abbate-Daga et al., 2007; Chiros & O’Brien, 2011; Thorn et al., 2007). 
Migraine sufferers also tend to suppress their anger, leading to internalised negative emotions 
(Abbate-Daga et al., 2007; Materazzo, Cathcart, & Pritchard, 2000). This catastrophizing and 
internalised anger may partly explain the occurrence of depression, substance abuse and 
anxiety in migraineurs. However, none of these studies claim to answer how these negative 
coping mechanisms evolved.  
2.5 Conclusion of Chapter 2 
When trying to understand the phenomenon of MO, it is not easy to avoid the political 
arguments that have arisen around its diagnosis. Most importantly for this study, one cannot 
ignore the challenges of using multiple laboratory tests to confirm and exclude symptoms in a 
large cohort. Though only reliant on self-report, the case definition for MO in this study 
requires that various other headache sub-forms are ruled out. However, migraine remains a 
complex disorder and unpacking its causes has not been easy for researchers, many of whom 
consider that both biological and psychosocial determinants are involved and urge a 
biopsychosocial approach to migraine research.  
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Chapter 3:  The Biopsychosocial Approach 
This chapter deals with the theoretical framework for the study, George Engel’s 
biopsychosocial approach. The aim of this discussion is to provide sufficient background on 
the biopsychosocial framework to help map the central outcome concept for the research 
(HRQOL in MO) within this frame. The chapter begins with the rationale for choosing a 
biopsychosocial frame. This is followed by a description of Engel’s main points on the 
framework and then critiques thereof. 
3.1 Rationale for choice of this framework 
The theoretical framework chosen to guide this journey is based on Engel’s 
Biopsychosocial Model. Though the biopsychosocial framework was originally proposed as a 
means of re-imagining psychiatric treatment, its use in this thesis is considered a pragmatic 
approach toward the integration of various forms of inquiry around HRQOL. This is because 
the biopsychosocial framework work has been adapted to inform a research framework that 
has been useful in guiding inquiry into multidisciplinary fields of health and disease - pain in 
particular (Andrasik, Flor, & Turk, 2005; Gatchel & Turk, 2008; Gatchel, 2004; Gatchel, 
Peng, Peters, Fuchs, & Turk, 2007; Lumley et al., 2011). This led to the starting point for this 
thesis - the assumption that HRQOL in MO may be better understood through a process of 
inquiry that examines various systems of a migraine patient's life and allows for the 
integration of biological and psychological methods in order to do so.  
The interdisciplinary nature of this study arose from curiosity around emotional, 
cognitive and behavioural aspects of migraine: Social scientist may be interested in how MO 
symptoms manifest in our society and how this impacts HRQOL (which relates to the first 
aim of this study). Physiologists want to know which neurobiological systems contribute to 
the subjective experience of HRQOL in pain (the second aim). Psychologists want to explore 
which factors of a MO’s sufferers life contribute to HRQOL, so that the best focus can be 
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found for interventions (this is linked to the third and final aim).These questions represent 
three facets of the attempt to build an integrated understanding of HRQOL in migraine as the 
researcher progress on a journey to becoming a neuroscientist.  
While the biopsychosocial approach was followed in this study as an approach to 
inquiry, biopsychosocial approaches have also been used in clinical practice. A clear 
formulation of the patient’s needs can lead to improved patient-clinician communication 
(Borrell-Carrió et al., 2004). There is evidence to suggest that a biopsychosocial treatment 
approach is at least moderately effective in treating pain (Vowles &McCracken, 2008). More 
recent models, such as the Functional Model of Headache, indicate that headache sufferers 
may benefit from treatments such as stress coping or couples therapy (Martin, 2008). Thus, a 
combination of biological and psychosocial approaches may be most beneficial to the patient.  
3.2 George Engel’s proposal 
In his model, Engel posited that biological activities, psychological events and social 
behaviours are interrelated in their involvement in health and illness (Suls & Rothman, 2004). 
In his paper titled: “The need for a new medical model: A challenge for biomedicine”, Engel 
(1977) criticised the adherence of psychiatry to what he viewed as a flawed model of disease, 
the dominant biomedical model. In the biomedical model's place, Engel put forward an 
understanding of disease, which embraced the social, behavioural and psychological, as well 
as the biochemical elements of the patient (Engel, 1977; Smith & Strain, 2002). He claimed 
that treatment could be improved by considering these four elements in combination, rather 
than simply isolating the physiochemical factors of disease (Smith & Strain, 2002).  
Essentially, Engel rejected the reductionist and dualistic nature of the biomedical 
model (McLaren, 1998); arguing that it had become dogma and propagated exclusionary 
sentiments that placed mental illness in the category of myth simply because its origin was 
not always clearly biochemical. Engel's main criticism of the biomedical model can be viewed 
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as two-fold (Borrell-Carrió, Suchman, & Epstein, 2004; Gatchel et al., 2007; Lumley et al., 
2011):  
1. The exclusion of subjectivity from study: Engel effectively took a systems 
perspective of disease and health, in which the view of the patient is incorporated 
into the understanding of the context (Borrell-Carrió et al., 2004). This conflicted 
with the biomedical model in which the health practitioner's view of the context 
was considered truth. Furthermore, Engel criticised the way in which practitioners 
ignored the influence of the observer on the observed. Borrowing again from 
systems theory, Engel encouraged practitioners to be mindful of how their 
behaviours contributed to the occurrence, worsening or improvement of symptoms 
(Engel, 1977). 
2. The blanket application of dualism and reductionism: The unyielding devotion to 
dualism in the biomedical model led to the reductionist belief that disease is either 
caused by the  physical or the psychological and that these two processes are 
discrete (Gatchel, 2004; Lumley et al., 2011). Sadly, this contributed to the 
reduction of all disease to a physiological explanation and the relegation of all 
psychological problems to a position of diminished usefulness. The perception 
then prevailed that, without a physiological cause, an illness was not real. In the 
case of pain that could not be conclusively linked to physiological change, the pain 
was seen as malingering or sustained through reinforcement (Andrasik, Flor, & 
Turk, 2005).  
In contrast, biopsychosocial perspective considers multidirectional relationships 
between physiological, behavioural and environmental factors (both physical and social) in 
disease (Nicholson, Houle, Rhudy, Norton, & Forest, 2007). This shifts the emphasis from the 
discussion of linear relationships to the use of linear approximations to understand circular 
causality in disease (Borrell-Carrió et al., 2004). Such reasoning marks a shift from the 
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"unidirectional, oversimplified" (Andrasik et al., 2005, p.s87) models of pain in general, and 
of headache in particular. 
Engel based his model on von Bertalanffy's general systems theory, believing that 
general systems theory would allow psychiatrists to examine various levels of the patient's life 
Therefore, central to Engel was the premise that “Nothing exists in isolation. Whether a cell 
or a person, every system is influenced by the configuration of the systems of which it is a 
part, that is by its environment” (Engel, 1980, p. 537). 
Engel (1980) arranged the human system into various levels, which he viewed as both 
hierarchical and continuous. These system levels are: molecule, cell, tissue, organ / organ 
system, nervous system, individual, dyad, family, community, culture -subculture, society-
nation, biosphere. Within a hierarchy, each level represents a distinct and complex integrated 
whole, requiring unique methods for being understood. As a continuum, each component of 
the system is also part of a higher level. In this way one can understand the individual as 
distinct from, and yet, part of a larger social system (Engel, 1980).  
Engel’s levels and how they link to this thesis are shown in Figure  3.1. In the current 
research, all levels in Engel’s work are used to examine HRQOL in MO, except the 
biosphere. The biosphere is omitted because there is little information on what this level 
entails practically in research. At the most fundamental level represented in the current thesis 
is the molecular wherein lies the examination of the serum concentration of glutamate and an 
examination of its transporter expression. This is followed by exploration of the individual’s 
behaviour with reference to his / her temperament and coping strategies. The subject’s 
interactions with those outside self (interpersonal relationships in terms of dyadic, family and 
community interactions) fit with the exploration of perceived social support. Although not 
prominently featured, the wider lifestyle behaviours (smoking and alcohol consumption) that 
are accepted in society are addressed in the analysis.  
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Figure  3-1: The levels of investigation for this study, in accordance with Engel’s 
Biopsychosocial Model 
  
At this point it may be useful to make explicit two points about the application of the 
Biopsychosocial Model in this thesis. The first being that there has been a transition from 
viewing the Biopsychosocial Model in the context of psychiatry to seeing the success and 
possibilities for the application of the approach in research. For some this is a natural and 
logical progression that hardly warrants mention. However, it is important to acknowledge 
that Engel’s work has a much wider application outside of psychiatric formulation. The 
second point relates to the use of the term “Biopsychosocial Model” versus “biopsychosocial 
approach”. The former refers to the original theory posited by Engel. The latter meanwhile, 
indicates the broader application of the theory and also acknowledges that there are multiple 
iterations of Engel’s work that have evolved into multiple branches of inquiry, such as 
psychoneuroimmunology (Irwin, 2008; Lutgendorf & Costanzo, 2003; Schleifer, Marbach, & 
Keller, 1990); mind-body medicine;  psychophysiology (Andrasik, 2006; Corr & Perkins, 
2006; Mangina, 2009; Ong, Gramling, Vrana, Nicholson, & Buenaver, 2006); behavioural, 
 51 
 
social and neurogenetics (Lee & Tracey, 2013; Slavich & Cole, 2013) and 
psychopharmacology (C. E. Dean, 2011; Nutt & Lingford-Hughes, 2004).  
3.2.1 Criticism of the Biopsychosocial Model. 
In the three decades since its inception, the Biopsychosocial Model has had its share 
of detractors alongside its supporters. The criticisms levelled at Engel’s work relate chiefly to 
its similarity to older models and whether or not it is actually useful.  
Blueprint or carbon copy?  
Engel described his work as a “blueprint for research, a framework for teaching, and a 
design for action in the real world of health care” (Engel, 1977, p.135). Critics have argued 
that Engel’s work is not original; for some, the Biopsychosocial Model bears too close a 
resemblance to Meyer’s Psychobiology (Ghaemi, 2009; McHugh, 1992; G. C. Smith & 
Strain, 2002). Ghaemi goes as far as to describe the Biopsychosocial Model as nothing more 
than eclecticism and attributed much of the theory (including the name) to Roy Grinker whose 
work appeared some 25 years before Engel’s.  
Schwartz (1982) lends some perspective to this criticism: Engel and many other 
theorists whose works have given rise to interdisciplinary behavioural medicine were 
products of a growing paradigm shift toward synthesis. Schwartz (1982) locates the origin of 
this zeitgeist in Canon’s work on stress, which implanted homeostasis as a consideration in 
psychology and sociology and not only medicine. Engel himself did acknowledge the 
influence of other theorists such as von Bertalanffy, Meyer and Mead on his work (Engel, 
1977), though Grinker’s name is notably absent.  
More or less useful? 
In examining the validity of the Biopsychosocial Model in modern psychiatry, Ghaemi 
(2009) argues strongly that Engel’s work has promoted the damaging effects of the 
eclecticism that ails the profession. He construes the Biopsychosocial Model as embodying 
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the unavoidable lack of boundaries inherent in eclectic thinking. Ghaemi predicts that 
“…eclectic views cannot survive careful theoretical or scientific analysis” (2009, p. 26) 
because they are too unfocused and eloquently argues that research success lies in the ability 
to focus. However, his argument fails to take into account that, while there is the potential for 
drowning in data by including too much in a biopsychosocial study, even the study with few 
variables runs this same risk if the researcher does not pay attention to the initial question(s).  
In response to the criticism that the Biopsychosocial Model attempts to incorporate too 
much information and thereby complicates questions, it is useful to note that, while Occam’s 
Razor may favour simplicity as the goal, it does not place simplicity as the paragon of 
accuracy (Domingos, 1999). Some questions have complicated answers. The exploration of 
the interconnectedness of systems of HRQOL in MO through a biopsychosocial approach 
might yield rich avenues for management of the disorder because the investigations of 
discrete areas of MO (genetic, physiological, pharmacological, etc) have brought us to a point 
of consolidation in the form of interdisciplinary research questions and approaches. In 
allowing for the possibility of multiple factors being involved in migraine, researchers now 
move to a time of trying to understand how these interplaying factors influence the system’s 
HRQOL. Earlier approaches to the study of migraine have already yielded numerous 
correlations between myriad variables. Continuing to study discrete parts of the migraineur’s 
subsystems is likely counterproductive, while testing the hypothesized relationships between 
these various factors and their (biological, psychological and social) domains may provide the 
metaperspective necessary to push migraine HRQOL research further forward. As Gatchel 
and Turk (2008, p.12) explain: “The fact that a Biopsychosocial Model requires a better 
understanding of the complex interaction of a number of factors does not make it untenable… 
We are still at the infancy stage in developing complex solutions for complex problems”.  
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Simply pragmatic? 
Engel insisted that the Biopsychosocial Model was a scientific model for achieving 
real world solutions in health care  (Engel, 1980; Engel, 1977). It is at this juncture that critics 
argue that Engel did not provide enough detail as to how the Biopsychosocial Model was to 
be applied. For McHugh, Engel’s descriptions are too non-specific to relate to any one 
particular disease. McHugh believes that the Biopsychosocial Model lacks the necessary 
structure and definitive rules to allow for disease categorisation (McHugh, 1992). One glaring 
deficiency is seen in Engel’s neglect of detail on the biosphere, which was mentioned earlier 
in this chapter. 
 Much of these arguments are communicated in McLaren's (1998) question: Is the 
Biopsychosocial Model in fact a model? McLaren is accurate in stating that the work does not 
meet the requirements of being called a scientific model, but it has enough to recommend it as 
a theoretical framework for guiding research - especially if one reads it as a pragmatic 
approach.  
Pragmatism in its early form is associated with the works of Charles Sanders Peirce, 
William James and John Dewey. James describes pragmatism as a method for clarifying 
concepts. For James (1981), pragmatism “…’unstiffens’ our theories… has no prejudices 
whatever, no obstructive dogmas, no rigid canons of what shall count as proof.” (p. 79). The 
essence of pragmatism is bound in the maxim that the value of a theory is derived from the 
fruits of its application (James, 1981; Liszka, 2012), or how useful it is within the context of 
the inquiry and taking into account the researcher’s goal (Long, 2013). Pragmatism 
acknowledges the fallibility of all methods, but  places empiricism at the centre of knowledge 
acquisition (Dewey, 1905; Long, 2013).  
Lewis (2008) reiterates both Engel’s desire for the Biopsychosocial Model to be a 
blueprint for research and McLaren’s view that the model never had the scientific 
underpinning required to reach this goal. Lewis then points out that the model has not 
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remained static since its inception and proposes a pragmatist re-interpretation of the 
Biopsychosocial Model as a logical step to allowing the integrated study of biology and 
psychology, without setting illogical limitations on what can and cannot be studied. 
Lewis (2008) counters the eclecticism arguments against the Biopsychosocial Model 
by pointing out that Dewey never advocated inquiry for inquiry’s sake. Engel’s work can then 
be seen as posited theory, as a point of departure (in this case a conceptual model) placed in 
public space for critique and improvement. This means that it is defensible to use various 
forms of the scientific method, with the understanding that each system may have a different 
language and warrant different methods of inquiry. 
Within the context of inquiry into a multifaceted concept such as HRQOL (or, indeed, 
MO), the strength of the biopsychosocial approach really lies in its appreciation of the 
complexity of human health and disease. Acknowledgement is given to the effects of the 
various systems of the individual - from the molecular to the societal (Borrell-Carrió et al., 
2004). This presents the researcher with the challenges of questioning reductionist approaches 
to disease and building dialogue between objective measures of illness and health and 
subjective experiences of the patient (Borrell-Carrió et al., 2004).   As Bourke (2013) states: 
"Pain does not emerge naturally from physiological processes, but in negotiation with social 
worlds" (p. 155) and understanding how patients make sense of their headache using the 
physiological and psychosocial can help advance us from a blaming position to respectful 
inquiry (Cecchin, 1987). This is not a new notion: In 1982 Loeser put forward a model of pain 
that included examination of the suffering (the emotional response) and the pain behaviour 
(overt communications of pain) of the patient. Waddell then underscored the importance of 
Loeser's inclusion of these two dimensions when, in 1987, he suggested that a full conception 
of pain requires comprehension of the person exposed to the pain (Gatchel et al., 2007).  
In Chapter 2 the major determinants of migraine put forward in the literature were 
already reviewed. Extensive research indicates that there are potential biological and 
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psychosocial determinants of the disorder: Temperament, coping, social support, adverse 
early life events, coping and stress are prominent psychological markers in migraine, while 
glutamate has emerged as a strong biomarker for the disorder. There is reasonable expectation 
that a  biopsychosocial approach may assist in our understanding of how these concepts fit 
together in MO as it has already been a useful approach in chronic pain assessment and 
intervention in osteoarthritis, fibromyalgia, rheumatoid arthritis, temporomandibular joint 
pain disorders, shoulder pain and even multiple sclerosis (George et al., 2008; Kerns, 
Kassirer, & Otis, 2002; Oliveira et al., 2009; Suvinen, Reade, Kemppainen, Könönen, & 
Dworkin, 2005). Biopsychosocial pain research has contributed to some of the most 
significant shifts in our conceptualisations of pain. Most notably, there has been movement 
from dualist and reductionist models towards more integrated theories through the acceptance 
that diversity in signs and symptoms of an illness can be the result of intricate 
interconnections of an individual's predispositions, biology, psychology, sociocultural 
environment; perception and response to illness and changes in these states (Andrasik et al., 
2005; Andrasik, Buse, & Grazzi, 2009; Van Eeghem, 2005).  
Martin (2007) reminds us that it is the vulnerability to migraine that is inherited and 
even with such a predisposition, some individuals will not suffer from the headache. In short: 
Biology cannot be viewed in isolation from the psychosocial aspects of an individual’s life. 
The implications of this assertion are far-reaching for MO research, as researchers are 
challenged to move away from the predominantly biomedical model of headaches and include 
psychosocial contexts in their investigations. Andrasik et al. (2005) argue that a 
biopsychosocial approach to understanding head pain acknowledges the complex interactions 
of biological, psychological and social factors in the diverse presentation of and the individual 
response to headaches. Including psychosocial alongside biological factors is necessary for 
accurate understanding that can lead to improved treatments for migraine (Andrasik et al., 
2005; Sieberg, Huguet, von Baeyer, & Seshia, 2012). The use of a biopsychosocial frame for 
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migraine studies has also been supported by Newton (2008). Meanwhile, Andrasik et al. 
(2009) have suggested that migraine be characterised as a biobehavioral disorder (a disorder 
constructed through links between biological, psychological and environmental aspects).   
Shifts toward a biopsychosocial frame of examining pain have already led to 
important discoveries regarding headache (Kröner-Herwig, Morris, & Heinrich, 2008; 
Nicholson, Hursey, & Nash, 2005). In particular, biopsychosocial research has shown the 
usefulness of biobehavioural interventions in migraine (Andrasik et al., 2009; Van Eeghem, 
2005); enhanced our understanding of how migraine is triggered (Hashizume et al., 2008) and 
sensitized the world about how severely migraine impacts HRQOL (Leonardi et al., 2010; 
Napolitano, 2008).  
3.3 Today’s challenge 
Reflecting on the history of migraine in research, the overall depiction is one of a 
fragmented approach in which no single theory has unlocked a comprehensive understanding 
of the headache. In addition, there has been a heavy emphasis on biomedical theories, with 
little or no reference to the role of the psychological and the social worlds in aetiology.  
The two dominant, divergent views of migraine as having either a neurological origin 
with vascular changes as secondary - the neural hypothesis (Blau, 1984) – or being the result 
of a primary neurovascular pathology, have persisted, and researchers have struggled to move 
into more integrated frameworks for explaining migraine. Some traction has been gained 
through the consideration that migraine may be a multifactorial disorder that is part of 
systemic rather than localised dysfunction (Loder et al., 2006). The challenge now appears to 
lie in conceding the involvement of psychosocial determinants (Andrasik, Flor, & Turk, 
2005). Arguments for a biopsychosocial approach to this research are examined in the 
following chapter. 
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3.4 Conclusion of Chapter 3 
This study is guided by the principles of Engel’s Biopsychosocial Model. Though 
criticized as not meeting the criteria for a model, the principles of the work are valuable as a 
guiding approach to research – in particular because they value the subjective view of the 
patient. In this thesis, the HRQOL of MO sufferers is examined from the molecular to the 
wider societal levels through investigations of glutamate, temperament, coping, social support 
and lifestyle.  
The call for biopsychosocial approaches to MO research has been influenced in part 
by the important contributions of similar studies in various pain disorders. Recent significant 
findings related to migraine using the biopsychosocial approach have highlighted its potential 
usefulness and promoted its application in this thesis.  
At this point it becomes necessary to start discussing how the biopsychosocial 
approach relates to the key concepts of this research. HRQOL has been chosen as the point of 
departure for this discussion as it is the main outcome variable measured in the study.  
 
  
 58 
 
Chapter 4:  Health-Related Quality of Life in a Biopsychosocial Framework 
Following the discussion of the biopsychosocial framework in the previous chapter, in 
this chapter how health-related quality of life (HRQOL) is constructed within a 
biopsychosocial framework is examined. The chapter then shifts focus to a discussion of the 
findings about the HRQOL of people suffering from migraine and which biological and 
psychosocial variables have been proposed as role-players in HRQOL in migraine. Drawing 
together this information, an argument is put forward for the inclusion of glutamate 
neurotransmission, temperament, pain coping and perceived social support in the examination 
of HRQOL in MO.  
4.1 Quality of Life and Health-Related Quality of Life 
Though the idea of “a life of quality” (Schalock, 1994, p. 266) is an ancient one, 
defining, conceptualising and operationalising quality of life (QOL)  is not easy. Debate 
persists amongst a number of researchers (Holm, Holst, & Perlt, 1994; Kuehn & McClainm, 
1994; Schalock, 1994; Wolfensberger, 1994), not least because QOL has been described 
using many terms, including well-being, life satisfaction, positive self-concept, personal 
meaning, enjoyment of life, improved social and environmental circumstances, the 
enhancement of  one’s various domains of life and the meeting of one’s needs (Brown & 
Brown, 2003; Goode, 1994; Holm et al., 1994; Kerce, 1992). While these are not necessarily 
disparate definitions of QOL, they are broad and perhaps more than just a little unwieldy. 
Moreover, these ideas are not easy to measure and research.  
The concept of HRQOL reflects a narrowing of the wider concept of QOL to focus on 
“the impact of disease and treatment on the lives of patients” (Wood-Dauphinee, 1999, p. 
356).  This was again widened a little to include the investigation of well-being and not only 
illness on the individual (Wood-Dauphinee, 1999). HRQOL is clearly defined by the Centers 
for Disease Control and Prevention (CDC) as those components of overall QOL that affect 
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mental or physical health (Centers for Disease Control and Prevention, 2011).  For the 
purpose of this study, the term HRQOL is used in keeping with the CDC definition. A very 
simple distinction between QOL and HRQOL is provided by Ferrans (2005) who states that 
HRQOL deals with the impact of disease and treatment and is distinct from those aspects of 
life that are outside of the scope of healthcare,  such as education and political freedom. This 
distinction may be a little simplistic though, and Ferrans does go on to acknowledge that some 
non-HRQOL factors can become health-related. For example, a lack of education can affect 
hygiene practices and lead to infection of a wound. The distinction is therefore not solid. 
An aspect of HRQOL research that the reader should take into account is that QOL 
and HRQOL are often used interchangeably, leading to confusion. Wolfensberger (1994) is 
highly critical of the way in which terminology is misused in QOL writings, but the practice 
continues and perpetuates the difficulty in clearly defining QOL. Some publications claiming 
to deal with QOL actually investigate HRQOL (e.g. Benedict et al., 2005; Ordu Gokkaya et 
al., 2012) or even perceived health status while claiming to investigate QOL (Moons, 2004). 
A concerted effort has been made to point out which concept is being discussed in the 
literature reviewed in this thesis and to keep the use of QOL and HRQOL separate to avoid 
confusion. 
4.1.1 Measuring health-related quality of life. 
In the 1970s practice began to shift from the exclusive use of clinical and laboratory 
measures to characterise disease to incorporating aspects of the patient’s subjective 
experience (Schalock et al., 2002; Wood-Dauphinee, 1999). This intensified the need for 
formal measures to examine changes in QOL. An important research milestone was reached 
in 1977, when QOL became a key word on the Medical Subject Headings of the United States 
National Library of Medicine MEDLINE Computer Search System and reference to QOL 
grew from 40 in the 1970’s to over ten thousand between 1986 and 1994 (Wood-Dauphinee, 
 60 
 
1999). This exponential rise in research on QOL also reflected a growth in the measures of 
both overall QOL and HRQOL – not all of which are of desired quality (Taillefer, Dupuis, 
Roberge, & Le May, 2003).  
 For Ferrans (2005) it is important to acknowledge that HRQOL, like QOL, is a 
multidimensional construct. The domains of HRQOL are usually noted as physical, mental 
and social, but also can include economic and spiritual domains (Ferrans, 2005; Wood-
Dauphinee, 1999). Many of the instruments used to measure HRQOL reflect these domain 
variations.   
There are a number of general HRQOL measures, such as the various Short Form (SF) 
formats. The SF-36 was developed as part of the Medical Outcomes Study (MOS). The MOS 
was a multi-year study of patients with chronic illnesses, which was designed to explore the 
differences in patient outcomes and to create tools for monitoring patients effectively (Tarlov 
et al., 1989; Ware, 2004). In designing the SF scale, the researchers used the following 
domains: Limitations in physical activities because of health problems; limitations in social 
activities because of physical or emotional problems; limitations in usual role activities 
because of physical health problems; bodily pain; general mental health (psychological 
distress and well-being); limitations in usual role activities because of emotional problems; 
vitality (energy and fatigue) and general health perceptions (Ware, 2004; Ware & Sherbourne, 
1992).  Progressively shorter versions of the SF have been released and  used in previous 
headache studies (Brna et al., 2006; Brna, Gordon, & Dooley, 2008; Fuh & Wang, 2006; 
Lipton, Hamelsky, Kolodner, Steiner, & Stewart, 2000; Rubino et al., 2013; Sharma, Singh, & 
Remanan, 2013; Wang, Fuh, Lu, & Juang, 2001). 
The measurement of HRQOL is as varied across studies as the illnesses investigated. 
Though some researchers rely on measures of symptoms (or their absence) or treatment 
recidivism, neither of these are extremely good markers of health (Becker, Diamond, & 
Sainfort, 2011) and illness-specific measures of HRQOL have therefore been developed. 
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Factors such as specificity (e.g., to a specific aspect of a disease), generalisability, culture, 
cost, accessibility and literacy levels have all added to the development of new measures or 
variations on previous measures. In her comprehensive review of scales to measure disease, 
Bowling (2001) lists no fewer than a dozen HRQOL scales specific to psychological health; 
she discusses numerous other HRQOL scales specific to cancer, respiratory, neurological, 
rheumatological, cardiovascular and other diseases.  Given that this is a comparative study, 
the choice was made to use a general HRQOL measure rather than a migraine-specific 
measure such as the Migraine-Specific Quality of Life Questionnaire (Martin et al., 2000). 
According to Higginson and Carr (2001), there are eight uses for HRQOL measures in 
practice, namely to: Rank problems, smooth communication, assess for possible 
complications, identify preferences, examine changes or treatment reactions and train new 
staff. The authors argue that the introduction of measures of the patients’ perspectives on their 
illness is justified as no illness is divorced from the individual’s social and individual context. 
Researchers clearly agree with the usefulness of HRQOL measurement and there is 
widespread use of HRQOL measures in examining inter alia the outcomes of people with 
mental illness (Becker, Diamond, & Sainfort, 2011), undergoing dialysis (Chan et al., 2012;  
Østhus et al., 2012), suffering from pain (Kolotylo & Broome, 2000; Nickel et al., 2008; 
Ostberg & Hall-Lord, 2011) and cancer (Hwang, Chang, & Kasimis, 2002; Stephens, 1998).  
Over the past four decades, a number of research consortiums have arisen to 
investigate QOL and HRQOL, many of which use different measures. These include the 
World Health Organisation’s working group, WHOQOL, the International Society for Quality 
of Life Research (ISOQOL) and the European Quality of Life group, EuroQoL and a number 
of disease-specific entities such as the European Organization for Research and Treatment of 
Cancer (EORTC).  
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4.2 Health-Related Quality of Life in Migraine 
Migraine is considered a significant burden on the sufferer’s HRQOL (Hazard, 
Munakata, Bigal, Rupnow, & Lipton, 2009; Raggi et al., 2012). The WHO has recognised this 
as a serious public health challenge (World Health Organization, 2012).  
HRQOL is fairly poor for migraine sufferers and falls below that of the general 
population and of people suffering from epilepsy and arthritis (Aydemir, Ozkara, et al., 2011; 
Brown et al., 2008). Significantly impaired HRQOL in migraine is a constant feature across a 
number of countries (Bera et al., 2014; Leonardi et al., 2010). One of the largest cross-country 
studies on migraine HRQOL is the International Burden of Migraine Study. This study made 
use of survey data from 10 countries (Australia, Brazil, Canada, France, Germany, Italy, 
Spain, Taiwan, the United Kingdom and the United States of America) and had a total sample 
of N = 23 312. The study made use of the Migraine-Specific Quality of Life Scale (MSQ), 
with results indicating that chronic migraine sufferers had a significantly lower HRQOL than 
episodic sufferers (p < .0001). Comparison with other illness populations shows that migraine 
has a considerable impact on daily living (Aydemir, Ozkara, et al., 2011; Brown et al., 2008; 
Dalhof & Dimenas, 1995). This is not surprising given the frequency with which attacks 
occur: A multi-site survey of 150 migraine patients in the United States, showed that the mean 
monthly frequency of attack was 4.4 + 3.6, with 20% of patients experiencing more than six 
attacks per month (Brown et al., 2008).  
4.2.1 Popular models of health-related quality of life and the biopsychosocial approach. 
A number of models of HRQOL have been proposed and many reflect similar 
components, domains and determinants. For Taillefer et al. (2003) there are concerns around 
the lack of sophistication and evaluation of these many models. A considerable number of 
models for HRQOL has been generated in the field of disabilities (Brown & Brown, 2005; 
Goode, 1994; Kuehn & McClainm, 1994; Parmenter, 1994; Prehn et al., 2007; Schalock et al., 
 63 
 
2002); and in the economics of healthcare (Broome, 1995; Torrance & Feeny, 1989). Models 
have been generated for various age groups (Brown, Bowling, & Flynn, 2004; Kelley-
Gillespie, 2009) and illnesses (Elliott & Richardson, 2014; Østhus et al., 2012; Parmenter, 
1992). 
Wilson and Cleary developed  the Conceptual Model of HRQOL (Wilson & Cleary, 
1995), in which they include four levels of variables that contribute to HRQOL. Wilson and 
Cleary posited that measures of health status could be conceptualised along a continuum that 
begins with simple biological and physiological factors, and moves through increasing 
complexity from symptoms to functioning to general health perception, and finally to 
HRQOL. These measures of health are influenced by individual and environmental 
characteristics and non-medical factors. Ferrans (2005) points out that the inclusion of values 
and symptoms in this model was a step forward in the inclusion of patient perceptions in 
HRQOL.  
A revision of this model was attempted using relevant literature from 1985-2005 
(Ferrans, Zerwic, Wilbur, & Larson, 2005). Figure 3.2 shows the original Conceptual Model 
(in blue) and the additions (in orange). The conceptual model was improved by the inclusion 
of more detailed explanations of the individual and environmental characteristics that 
influence HRQOL, based on McLeroy’s ecological model. Ferrans and her colleagues 
explained that individual characteristics are viewed as intrapersonal factors, while 
environmental characteristics are made up of interpersonal factors (social support), 
institutional factors, community factors and public policy.  
The Conceptual Model was arguably most thoroughly evaluated by Sousa and Kwok 
(2006). A sample of 917 HIV-positive patients drawn from the AIDS time-Oriented Health 
Outcomes Study (ATHOS) were evaluated for CD4 count, symptom status, functional status, 
general health perception and HRQOL. The measurement model fit the data adequately, while 
the structural model showed reasonable fit. 
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Figure  4-1 The revised conceptual model of health-related quality of life [adapted from Ferrans et al. (2005) and Wilson & Cleary (1995)] 
Public policy Community factors Institutional factors Interpersonal factors 
Non-medical factors removed by 
Ferrans et al. (2005) 
Environmental characteristics 
Biological and 
Physiological variables 
Symptom status Functional status 
Individual characteristics 
Intrapersonal factors 
General health 
perceptions 
Overall quality of 
life 
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A vast array of predictive models has also been generated in HRQOL (e.g. Ashing-
Giwa, Tejero, Kim, Padilla, & Hellemann, 2007; Herrera Ponce, Barros Lezaeta, & Fernández 
Lorca, 2011; Kolotylo & Broome, 2000). Each model appears to be informed by the type of 
illness and the theoretical approach of the researcher. For example, in their investigation of 
HRQOL of patients with prostate cancer and their spouses, Kershaw et al. (2008) made use of 
a stress-coping framework to develop a model that considered antecedent factors, appraisal 
variables and coping strategies as predictors of HRQOL. The biological factors investigated 
included symptoms and disease phase, while psychosocial factors included self-efficacy, 
social support, hopelessness and coping style. Kershaw et al. found that patient HRQOL was 
adequately predicted by a model that included more active coping strategies; lower avoidant 
coping, hopelessness and baseline symptoms; less negative views of the illness and being 
newly diagnosed. Kerhsaw et al.’s work shows a significant role for psychosocial factors in 
HRQOL.  
This is supported by the work by Ashing-Giwa, Tejero, Kim, Padilla, and Hellemann 
(2007). Ashing-Giwa and colleagues examined various predictive models of HRQOL in 703 
patients with breast cancer. Their final model consisted of medical factors (such as stage of 
cancer), general health status, emotional wellness, demographics, health care system 
characteristics (e.g. level of accessibility), socio-ecological factors and ethnicity (listed 
separately from demographics as a cultural factor). This model predicted 70% of the variance 
of HRQOL.  
Critique and the way forward for this research. 
In their review of English-language articles published in PubMed, MEDLINE, 
CINAHL, and PsychINFO between 1999 and 2010, Bakas et al. (2012) found that the original 
Conceptual Model to be the most widely used HRQOL model, with the revision by Ferrans 
and colleagues emerging as a guideline for comprehensive HRQOL research. Despite such 
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wide use, the authors note that there had only been a single randomized controlled trial that 
employed the Conceptual Model. In addition, the authors found that the many models 
generated in HRQOL have not been thoroughly assessed. They advocated for more 
experimental work to refine these models in order to develop consensus and advance the field. 
This sentiment is shared by Nuamah, Cooley, Fawcett, & McCorkle (1999). 
Essentially, there is no single HRQOL model to fit every person. The many predictive 
models – and even the conceptual ones - are based on the premise that understanding HRQOL 
requires a clear understanding of the individual’s systems (Kuehn & McClainm, 1994). Both 
psychosocial and biological factors are taken into account in this understanding of the 
individual’s systems, thus there is a strong case for viewing HRQOL within a biopsychosocial 
framework. Various predictive models in HRQOL also appear to include both biological and 
psychosocial elements to good effect. It was therefore considered justifiable to utilise a 
biopsychosocial approach to HRQOL in this research. 
An obvious dilemma in HRQOL research –even when guided by a model – is that 
researchers are left with a wide array of factors to consider and corresponding measurements 
from which to choose. Utilizing existing research to guide decisions, this research drew on 
findings from migraine and other illness HRQOL studies, as well as HRQOL studies of 
ageing populations to propose which factors to investigate in MO HRQOL. These are 
discussed in the following sections. 
4.2.2 Determinants / predictors of HRQOL.   
Various studies have investigated a broad range of biological and psychosocial 
determinants of HRQOL and the results are highly variable across age (Ordu Gokkaya et al., 
2012; Tajvar, Arab, & Montazeri, 2008) and the type of illness investigated. The latter 
includes studies of metabolic disorders (Vilhena et al., 2014), stroke (Carod-Artal, Stieven 
Trizotto, Ferreira Coral, & Menezes Moreira, 2009), cancer  (Kenzik, Huang, Rizzo, 
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Shenkman, & Wingard, 2015; Nuamah et al., 1999; Perlis et al., 2014), epilepsy (Au et al., 
2002; Aydemir, Özkara, et al., 2011; Elliott & Richardson, 2014; Luoni et al., 2011), renal 
disease (Chan et al., 2012;  Østhus et al., 2012), traumatic brain injury (Nestvold & Stavem, 
2009) and schizophrenia (Ho, Chiu, Lo, & Yiu, 2010; Ritsner, Gibel, & Ratner, 2006).  
In searching for literature reviews on predictors of HRQOL (no specified dates entered 
on PubMed with the search terms predictor HRQOL, predictor / determinant “migraine 
HRQOL”; predictor / determinant “migraine QOL”; determinant / predictor "migraine-
specific quality of life"), a few particularly informative reviews were located. These are 
summarised in Table 3.1. From these reviews a pattern emerges of the potential predictors of 
HRQOL. This pattern shows that both biological and psychological factors are potential 
determinants of HRQOL. Each determinant is discussed with reference to its review, followed 
by evidence from migraine studies. 
Interestingly, only two reviews were listed in the initial search pertaining specifically 
to migraine HRQOL (Lucas, Geraud, Valade, Chautad, & Lanteri-Minet, 2006; Santanello, 
Davies, Allen, Kramer, & Lipton, 2002) and another one relating to primary headaches (Abu 
Bakar et al., 2016). On further investigation it was noted that the work by Lucas et al. is 
actually an empirical study and not a review.  
Biological determinants. 
The biological predictors identified in the reviews are mainly disease-related 
biomarkers (Ross et al., 2003; Spiegel, Melmed, Robbins, & Esrailian, 2008), with some 
clinical markers also represented (Abu Bakar et al., 2016; Pragodpol & Ryan, 2013; Soh, 
Morris, & McGinley, 2011). Since not all biomarkers are pathognomonic, some biological 
and clinical predictors may overlap in various illnesses (markers of low-grade inflammation 
are possible candidates here) and may thus emerge as predictors of HRQOL across a few 
disorders.  
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In addition, not all disease-specific markers evaluated emerged as significant 
determinants. For Spiegel et al. (2008) it was surprising that mineral metabolism and 
inflammatory markers were not significant determinants of HRQOL in end-stage renal 
disease (ESRD). In reflecting on potential biomarkers for HRQOL in MO then, it does seem 
as though including a biomarker for the disorder is prudent. A full account of the role of 
glutamate as a biomarker for MO was presented in Chapter 2. Since glutamate is emerging as 
a promising role-player in MO pathophysiology (Andreou & Goadsby, 2011; Freilinger et al., 
2013; Lampl et al., 1999; Sarchielli, Di Filippo, et al., 2007; Vaccaro et al., 2007), it was 
hypothesised that investigating its role in MO HRQOL could provide important information. 
Comorbid mental illness / negative affect/affective distress. 
Psychiatric conditions were frequently found to be determinants of HRQOL across the 
reviews, with anxiety and depression being most frequently mentioned (e.g. Chang, 2004; 
Pragodpol & Ryan, 2013; Soh et al., 2011; Taylor et al., 2011). The relationship between 
mental illness and the HRQOL in migraine has been illustrated in various studies (Aydemir, 
Özkara, et al., 2011; Bera et al., 2014; Brna et al., 2006, 2008; Lantéri-Minet, Radat, 
Chautard, & Lucas, 2005; Mula et al., 2009; Raggi et al., 2012; Sharma et al., 2013). Though 
in their investigation of QOL of 40 patients with migraine and tension type headache, Bera, 
Goyal, Khandelwal, and Sood (2014) found that depression emerged as the most prevalent 
psychiatric problem amongst all headache sufferers, this prevalence was not significantly 
different from that of controls. This does not necessarily discount depression as a determinant 
in migraine HRQOL, but may indicate that depression is a general predictor across various 
illnesses.  
Stress. 
Another determinant identified in the reviews was stress - either daily stress or that 
resulting from early life adverse events (e.g. Chang, 2004; Cornish et al., 2009).  In an 
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investigation of perceived stress and coping in 20 migraine and 20 tension type headache 
patients in Pakistan, Najam and Aslam (2010) made use of the Perceived Stress Scale, the 
McGill Pain Questionnaire and the Brief Cope Scale. The authors found significant a negative 
relationship between perceived stress and avoidant coping (r = -.42, p < .001) and a 
significant positive relationship between perceived stress and active coping (r = .37, p < .001). 
Though both relationships are only moderately strong, this does show that less effective 
coping strategies and perceived stress go hand in hand for migraineurs. Furthermore, 
perceived stress had a significant correlation with the affective pain reported by the 
participants (r = .37, p < .001), while higher coping strategy scores were correlated with lower 
evaluative pain (r = -.27, p < .05). Therefore, the higher the perceived stress experienced by 
the migraineur, the more likely he or she is to be employing avoidant coping strategies and 
experiencing pain. 
Coping. 
Coping emerged as a predictor of HRQOL in the reviews by Abu Bakar et al. (2016); 
Chang (2004); Cornish et al. (2009); and Sales, Carvalho, McIntyre, Pavlidis, and Hypantis 
(2014). However, each study reflects a different form of coping: Pain coping and maladaptive 
or poor coping.  
Coping is defined as a person’s mutable changing efforts to manage internal and 
external stressors (Chiros & O’Brien, 2011; Downing, Williams, Leserman, & Paulsen, 
2013). Pain coping strategies include behaviours, cognitions and beliefs about pain; all of 
which have physiological consequences (Lake, 2009) and some of which are adaptive. 
Cognitions are self-statements about an event, while beliefs are pre-existing ideas about the 
nature of reality (Stroud, Thorn, Jensen, & Boothby, 2000).  Negative pain cognitions and 
beliefs are associated with increased disability and distress (Stroud et al., 2000).  
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Lake (2009) describes two forms of dysfunctional or maladaptive pain coping 
amongst headache sufferers, namely sensitising (hypervigilance and anticipating, 
catastrophising and hyperempathy) and minimising (alexithymia, stoicism, denial or anger 
suppression). Lake also describes adaptive coping, such as the balanced use of distraction and 
body awareness, proactive coping, balanced interpersonal discussion of pain and pain 
acceptance. 
There is evidence that various pain diagnostic groups are characterised by specific 
pain coping styles (Porter-Moffitt et al., 2006), with migraine being frequently associated 
with catastrophizing (Abbate-Daga et al., 2007; Chiros & O’Brien, 2011; Thorn et al., 2007). 
Catastrophizing is defined as a maladaptive strategy of coping in which an individual holds 
disproportionately negative cognitions about actual or expected pain (Lake, 2009). 
Catastrophizing usually presents with three features – rumination, magnification and 
helplessness (Lake, 2009; Sullivan et al., 2001). 
Catastrophizing is an important aspect of migraine management as it can influence the 
decision to continue healthcare consultation (Lantéri-Minet et al., 2007). Holroyd, Drew, 
Cottrell, Romanek, and Heh (2007) explored catastrophizing, comorbid anxiety and 
depression and migraine characteristics in relation to migraine HRQOL in 232 frequent 
migraine sufferers. Catastrophizing and severity of migraine symptoms predicted HRQOL 
across the Migraine-Specific Quality of Life, Headache Disability Inventory, SF-36 and the 
Migraine Disability Assessment (β weights 0.16– 0.50, all p < 0.01), indicating that these two 
variables play an important predictive role in HRQOL of migraine sufferers.  
Chiros and Brien (2011) examined catastrophizing alongside acceptance as forms of 
coping in migraine. They assessed 74 migraine patients on the Structured Diagnostic 
Interview for Headache, Chronic Pain Acceptance Questionnaire, Acceptance and Action 
Questionnaire, Pain Catastrophizing Scale and Chronic Pain Coping Inventory, while 60 
participants also kept a daily diary. The findings show that higher levels of catastrophizing 
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were related to higher levels of daily pain (t = 12.98, p < 0.001). The research also indicated a 
role for pain acceptance in decreasing the amount of catastrophizing. 
Pain / severity perception. 
The subjective experience of pain or symptom severity is a determinant of HRQOL in 
migraine (Abu Bakar et al., 2016), gastrointestinal disorders (Chang, 2004) and epilepsy 
(Taylor et al., 2011). In a study of 102 migraine patients, mild to moderate correlations were 
indicated between HRQOL on the SF-36 and increased migraine severity  (Leonardi, Raggi, 
Bussone, & D’Amico, 2010). Meanwhile, Kolotylo and Broome (2000) found that 65% of 
variance in HRQOL could be accounted for by depression, headache pain and chronic pain 
experience.  
Personality. 
The significance of personality in determining HRQOL was established in the study 
by Sales et al. (2014). In a selective overview of the psychiatric comorbidity in migraine and 
chronic daily headache sufferers,  Pompili et al. (2009) made the point that the presence of 
psychiatric disorders are generally associated with lower QOL, resulting in poorer prognosis 
and response treatment as well as chronicity of headaches. They found that there has been 
relatively little research into personality disorders and headache. In fact, much of this research 
is around temperament and migraine, which is discussed in Chapter 2.  
There are differences in temperament between migraine and other headache groups 
(Boz et al., 2004; Mazzone, Vitiello, Incorpora, & Mazzone, 2006) and particular 
temperament traits associated with migraine (Mazzone et al., 2006; Mongini, Fassino, et al., 
2005; Sánchez-Román et al., 2007). Furthermore, temperament is related to HRQOL in 
migraine (De Filippis et al., 2008). 
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Social support. 
The only social predictor to emerge from these reviews is social support (Cornish et 
al., 2009; Pragodpol & Ryan, 2013). Social support is essentially the resources provided by 
others (Swenson & Clinch, 2000), which can buffer against the impact of stress on 
psychological well-being (Skipstein, Janson, & Kjeldsen, 2012). According to  Kitamura and 
colleagues (Kitamura et al., 1999), Barrera divided social support into two types - enacted and 
perceived. Enacted social support is the actual support that individuals receive from those 
around them. On the other hand, perceived social support is the resources that individuals 
believe will be available to them when needed. The latter has been correlated with better 
mental health (Kitamura et al., 1999).  
Only one study could be identified that examines social support as a determinant of 
HRQOL in migraine. This study by Vos and Passchier (2003) showed that social support was 
an integral part of reducing the impact of migraine on daily life. However, this was a small 
study (N = 48) and limitations of sample size must be taken into account.  Social support is an 
important aspect of migraine management (Peters et al., 2005), yet female migraine patients 
are more inclined to engage internal defence mechanisms than seek social support when faced 
with a challenge (Stronks et al., 1999). Thus, seeking social support is considered to be a form 
of active coping (Rueda & Rothbart, 2009).  
In a study of 100 subjects, social support was one of the main factors associated with 
migraineurs consulting physicians about their headaches (Skomo, Desselle, & Berdine, 2006). 
Social support can therefore be an instrumental part of treatment amongst migraineurs. 
However, migraineurs tend to be less satisfied with the support they receive than non-
headache counterparts (Martin & Soon, 1993). 
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Sociodemographics. 
Sociodemographic and clinical factors that predict HRQOL are numerous and range 
from age, disease-specific risk factors and sex (e.g. Chang, 2004; Pragodpol & Ryan, 2013) to 
symptom severity (e.g. Abu Bakar et al., 2016) and the type of intervention employed 
(Santanello et al., 2002; Zainuldin, Mackey, & Alison, 2011). There do not appear to be clear 
indications of sociodemographic variables that predict HRQOL in migraine.  
Treatment. 
A study of the efficacy of homeopathic treatment of migraine in 53 patients indicated 
that such intervention significantly improves the HRQOL dimensions of bodily pain and 
vitality (p <.0001) after 4-6 months of treatment. The narrative review by D’Amico, Grazzi, 
Usai, Leonardi, and Raggi (2013) showed that migraine HRQOL is improved by various 
treatments, such as migraine symptomatic and prophylactic medication and surgery.  
There are also numerous studies dealing with the efficacy of various medicines, 
including sumatriptan (Colman et al., 2001; Wendt, Cady, Singer, Peters, et al., 2006), 
rizatriptan (Santanello et al., 2002) and topiramate (Silberstein, Neto, Schmitt, & Jacobs, 
2004). Santanello and colleagues reviewed the findings of two clinical trials on rizatriptan use 
in migraine (combined sample N = 1506).  Headache recurrence and relief from symptoms 
and restoration of function at two hours, two were found to be associated with better 
migraine-specific HRQOL, as was rizatriptan intervention. This indicates a role for the 
evaluation of biological factors in migraine HRQOL. 
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Table  4-1: Summary of determinants of health-related quality of life identified in review articles 
Citation Identified determinant(s) of HRQOL 
Quality of life in primary headache disorders : A review (Abu Bakar et al., 2016) Headache characteristics: Pain intensity and duration  
Migraine-specific characteristics: Presence of nausea  
Other health characteristics: Health-related disability, comorbid pain conditions 
Psychological characteristics: Psychological response to pain, pain coping and psychiatric 
comorbidity 
Determinants of migraine-specific quality of life (Santanello et al., 2002) Migraine therapy  
Critical review of factors predicting health-related quality of life in newly diagnosed 
coronary artery disease patients (Pragodpol & Ryan, 2013) 
Sociodemographic 
Positive predictors: Baseline HRQOL, education, marital status  
Negative predictors:  number of cardiovascular risks, female sex 
Inverse predictor: Age 
Clinical 
No positive or inverse predictors 
Negative predictors: Angina, physical functioning, fatigue 
Psychosocial  
Positive predictors: Social support, sense of coherence 
Negative predictors: Depression, anxiety and depression, overall psychosocial functioning 
or mood disturbance, anxiety, hostility 
Optimal intensity and type of leg exercise training for people with chronic 
obstructive pulmonary disease (Zainuldin et al., 2011) 
Exercise 
The course and predictors of health-related quality of life in living kidney donors: A 
systematic review and meta-analysis (Wirken et al., 2015) 
Low psychological functioning pre-donation 
Determinants of health-related quality of life in Parkinson's disease: A systematic 
review (Soh et al., 2011) 
Depression, motor symptoms, complications arising from treatment 
Predictors of health-related quality of life and costs in adults with epilepsy: A 
systematic review (Taylor et al., 2011) 
Clinical 
Seizure frequency, seizure severity 
Psychological 
Depression, anxiety 
Comorbidities 
Psychosocial predictors of health outcomes in colorectal cancer: A comprehensive 
review (Sales et al., 2014) 
Clinical 
Presence of a stoma 
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Psychological 
Type D personality, Sense of Coherence, ego-specific defence mechanisms 
Associations between social support and stroke survivors' health-related quality of 
life - a systematic review (Kruithof, van Mierlo, Visser-Meily, van Heugten, & Post, 
2013) 
Social support 
A systematic review evaluating health related quality of life, work impairment, and 
healthcare costs and utilization in bipolar disorder (B. Dean, Gerner, & Gerner, 
2004) 
Bipolar disorder 
The effect of anaemia treatment on selected health-related quality-of-life domains: a 
systematic review (Ross et al., 2003) 
Haematocrit (Hct) 
A systematic review of health-related quality of life in cutaneous melanoma 
(Cornish et al., 2009) 
Clinical 
Health status (probably related to insomnia and pain) 
Systemic therapy  
Psychosocial 
Non-cancer life stress, wishful thinking, maladaptive coping 
Social support 
Biomarkers and Health-Related Quality of Life in End-Stage Renal Disease: A 
Systematic Review (Spiegel et al., 2008) 
Hct, nutritional markers (e.g. albumin, body-mass index) 
Review article: epidemiology and quality of life in functional gastrointestinal 
disorders (Chang, 2004) 
Clinical 
Symptom severity, symptoms periodicity, pain 
Psychosocial 
Anxiety, stress, childhood adversity, poor sexual function because of irritable bowel 
syndrome (IBS), lack of social support, poor coping 
Sociodemographic 
Age 
Disability and quality of life in headache: where we are now and where we are 
heading? (D’Amico et al., 2013) 
Various treatments, such as migraine symptomatic and prophylactic medication and 
surgery 
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4.3 Proposed factors for inclusion in a biopsychosocial approach to HRQOL in MO 
While acknowledging the significant contribution of purely biological studies to our 
understanding of headache’s impact on daily life, Nicholson, Houle, Rhudy, Norton, and 
Forest (2007) explain that biology alone is not able “to account for all aspects of headache 
and disability” (p. 413) and that also investigating psychosocial factors could augment our 
research and therefore also improve patient treatment. The authors argue that a 
biopsychosocial approach to the study of headache would best serve such goals. They go on 
to explain that the central circuitry involved in cognition and affect overlap with mechanisms 
that modify pain. While Nicholson et al. use serotonin as their example, this study focuses on 
the glutamate as it plays roles in pain (Hashimoto et al., 2007; Mathew, 2001; Sarchielli, Di 
Filippo, et al., 2007) and has potential as a biomarker for MO (Anttila et al., 2010; Freilinger 
et al., 2013). Combined with the evidence that biomarkers do have a role to play in 
determining HRQOL, including glutamate in this research was seen as a justifiable step. 
In examining which psychosocial variables show promise for migraine HRQOL, 
temperament stood out as a variable of great interest. For Chess and Thomas (1996) 
temperament is “one of the basic aspects of the psychological mechanism of behavioural 
functioning” (p. 3). Temperament is frequently associated with the development of 
psychopathology (De Pauw & Mervielde, 2010; Nigg, 2006). Boz et al. (2004) point out that 
some studies have shown that migraine is related to HA and P temperaments (Mongini, 
Fassino, et al., 2005). In turn, temperament influences which coping strategies one uses (De 
Boo & Spiering, 2010; Rueda & Rothbart, 2009) and how one perceives and uses social 
support (Kitamura et al., 1999).  
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4.4 Conclusion of Chapter 4 
The HRQOL of migraine patients is generally poor.  Explaining or predicting this 
HRQOL has been a challenge. In order to understand HRQOL in MO, an examination of 
potential determinants is necessary, but which of the many possible determinants to examine 
is linked to how one conceptualises HRQOL. In biopsychosocial terms, this means that 
looking at the various spheres of a patient’s life can help us understand HRQOL. 
Temperament represents one’s automatic emotional response and has a strong 
biological basis at the neurotransmitter level. Temperament has been associated with coping, 
pain perception, lifestyle habits and perceived social support in various conditions. It is 
therefore posited that the impact of MO on HRQOL is influenced by types of coping 
mechanisms the individual employs as well as levels of perceived social support – 
underpinned by temperament, which in turn is linked to neurotransmission.  
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Chapter 5:  Methodology 
This chapter begins with a recap of the aims and research questions that were outlined 
in Chapter 1. The focus then moves to locating the research within its methodological 
framework, which includes a critical discussion of how the research questions informed the 
epistemological and ontological assumptions underpinning the study. The chapter ends with a 
description of the sampling and recruitment strategies for the research. 
5.1 The research aims and questions 
The purpose of this research was the exploration of HRQOL in MO. Exploratory 
research is mainly concerned with generating concepts and exposing patterns of relationships 
that can be tested further (Cargan, 2007; Louis Cohen, Manion, & Morrison, 2005; Stebbins, 
2001). 
The research began with three aims linked to specific research questions. Owing to the 
exploratory nature of the study, no hypotheses were posited. The first aim was to compare 
HRQOL amongst MO sufferers and non-migraineurs (NM). The research question formulated 
for this aim was: In what way does the HRQOL of MO sufferers differ from that of NM? The 
second aim of the research was to explore the association between temperament and pain 
coping in MO; the research question was posed as: What is the relationship between the harm 
avoidance (HA) temperament category and catastrophizing in MO? The third aim of the study 
was to examine how neurotransmission, temperament, pain coping, perceived social support 
and lifestyle factors contribute to the HRQOL experienced in MO. The research question was 
posed: To what extents do temperament, neurotransmission profile, coping strategy and 
perceived social support explain the variance in HRQOL in MO?  
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5.2Research paradigm 
Living systems are complex and they evolve. To believe this is perhaps also to believe 
that the quest to discover a single truth about such systems is too ambitious. Even within once 
strictly positivist fields such as neuroscience, shifts have occurred toward investigating 
subjective experience (Koyama, McHaffie, Laurienti, & Coghill, 2005; Solms & Turnbull, 
2002); opening dialogue with postmodernist theory (Cage, 2013); and acknowledging the role 
of power in what researchers choose to study, how our values and cultures impact how one 
interprets what is found and how this impacts on society (Farah, 2005; Roskies, 2002).  
All of this reflects the shift from staunch positivism to the postpositivism that guides 
this research. While a full discussion of postpositivism is beyond the scope of this chapter, 
three key points of postpositivism as they apply to this research require explication, namely: 
The question of realism; the objectivity of the researcher; and what constitutes knowledge / 
application of the scientific method. 
5.2.1 Epistemology. 
The study of pain processes is superficially divided into investigations of nociception 
(how pain is processed) and clinical pain (such as chronic or episodic pain). Whereas 
nociception research is largely conducted using objective measures such as quantification of 
autonomic and central responses (e.g. Gybels, Handwerker, & Van Hees, 1979; Hartley & 
Slater, 2014; Sikandar, Ronga, Iannetti, & Dickenson, 2013), the study of clinical pain relies 
heavily on subjective patient reporting (e.g. Hjermstad et al., 2011; Patel, Guralnik, Dansie, & 
Turk, 2013)  
For pure positivists, subjective reporting becomes a confounding variable (Hitt, 
McMillen, Thornton-Neaves, Koch, & Cosby, 2007; Lasch et al., 2002). Added to this 
research complexity are issues of the multi-dimensionality of pain and comorbidities with 
diseases such as depression (Mao, 2009). As a solution to some of these challenges, Mao 
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(cited in De Benedittis et al., 1990, p. 1002) suggests that pain research requires “coordinated 
bidirectional research approaches between bedside and bench in order to bridge the gap 
between pain research and clinical pain management”. This implies that the study of multi-
faceted concepts such as MO and HRQOL can benefit from a less reductionist approach than 
is supported by the boundaries of traditionally delineated academic disciplines. 
In keeping with Mao’s premise, this thesis combines genomic research with 
physiological and psychological measures to guide the exploration of HRQOL in MO. The 
combination of genotyping and phenotyping data was viewed as useful in bridging the gap 
between bench and bedside (Luciano et al., 2011). Working across the genetic, molecular and 
psychological levels is labour-intensive, but allowed a look beyond nociception mechanisms 
in order to include broader aspects of pain mediation such as subjective responses and 
psychological traits and relationships (Mao, 2009). 
The inter-disciplinary approach also allowed me to explore many possibly 
interconnected aspects at once (Dyer, 2003; Phoenix et al., 2013).  By drawing from the 
disciplines of psychology, physiology and genetics, the researcher was able to enter a 
respectful line of inquiry in which the subject is seen as a complex being and not solely a 
collection of symptoms. However, the researcher was aware that marrying the knowledge and 
methods from social and natural sciences is complicated by the seemingly irreconcilable 
paradigmatic approaches of the disciplines. Phoenix et al. (2013) caution against 
automatically framing inter-disciplinary research within a single paradigm for the sake of 
avoiding this problem of these clashing paradigms.  The authors go on to make a case for 
inter-paradigmatic research in which antitheses are crystallized to create approaches that 
traverse paradigms. 
For postpositivists, what constitutes knowledge depends on the purpose of the 
research, for example policy creation or social change (Phoenix et al., 2013; Ryan, 2006). In 
acknowledging this, postpositivists also accept that the researcher has an agenda that is used 
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to determine the type of data that would best fit and the way in which it should be gathered. 
Consequently, neither the choice of subject matter, nor the choice of method is objectively 
derived. It is important to point out that the pragmatism of the biopsychosocial approach 
(Lewis, 2008), which is discussed in Chapter 3 links well with the postpositivist principle of 
choosing the best fit between the desired data form and the means of gathering the data.  
The choice to study migraine grew from the observation of a lack of data in South 
Africa and the experience in practice that pain is sorely misunderstood by health care 
providers, families and sufferers and often misattributed to malingering or lack of 
commitment. Therefore, the study was undertaken in order to generate knowledge that will be 
useful in pain management programmes.  
The choice to explore migraine from biological and psychosocial perspectives is a 
product of the researcher’s belief about the reciprocity inherent in relationships between 
social milieu, psychological well-being and physiological functioning. The use of a 
biologically based concept (temperament) as a starting point in this study pushed a 
quantitative agenda. The quantitative method was therefore utilized, with cross-sectional 
research design and stages of descriptive and correlational process in an attempt to yield 
warranted assertions (Boyles, 2006; Floden, 2009; Wellman, n.d.). 
5.2.2 Ontology. 
The basis of postpositivism is critical realism, which combines a belief in the 
existence of some objective reality with a belief that any data is open to interpretation and 
therefore value-laden (Fischer, 1998; Ryan, 2006). As researchers, our presence shapes and 
colours the inquiry and we accept this ontological compromise (Fox, 2008).  
The researcher is clear that the biopsychosocial standpoint from which the researcher 
is punctuated allows for the theoretical representation of only a reality. The ontological 
assumption of postpositivism is that objective reality is a possibility, though not a foregone 
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conclusion in any study. The researcher therefore aimed to represent the complexity of the 
matter as best as she could, while acknowledging that her subjectivity or the context in which 
the investigation occurs has a profound impact on, for example, which concepts are included 
for investigation (McKelvey, 2001; Parry, Gnich, & Platt, 2001). In this study, the choice of 
temperament, neurotransmission profile, coping and social support as the key variables in 
determining HRQOL in MO can be seen as subjective, although the choice was based on 
evidence from literature.  
Ryan (2006) frames the postpositivist stance towards development vs. testing of 
theories as adopting a learning - rather than testing - role in research. The essence of a 
learning stance is in acknowledging that findings may lead to further questions. The 
researcher has proposed that HRQOL can be understood and predicted using a set of 
measurable biological, psychological and social parameters. Although the researcher tried to 
reflect some of the complexity of HRQOL in the model, she is not uncomfortable with the 
notion that there is no single theory that cannot be challenged with new data. For this reason 
the model is considered to be a reality and not the reality for MO sufferers.  
5.2.3 Design. 
This postpositivist paradigm together with the goal of quantifying various factors in 
this study led easily to a quantitative approach (Creswell, 2003).  The first phase of the study 
made use of a cross-sectional survey design. In line with the general purpose of surveys, this 
survey was designed to gain information from a large sample of the population (Fowler, 
2009). Some of this information was then used to select cases and NM participants for the 
second phase of the study. The second phase made use of retrospective, cross sectional 
design. No interventions were implemented.  
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This study began with a survey of the occurrence of migraine (MO and MA) in 
Gauteng, South Africa (phase 1). This phase was quantitative and descriptive. The data from 
this phase was used to answer the first two research questions.  
From the initial sample (N = 341), 43 MO and 23 NM participants were chosen (Phase 
2). This phase was comparative and correlational. Data from these 66 participants was used to 
examine the third research question. The NM and MO participants were compared in terms of 
glutamate levels, clinical laboratory results, transporter expression, demographic and 
psychosocial variables. Correlations were investigated between key variables before 
regression analysis. 
5.2.4 Sampling and recruitment. 
Phase 1 made use of convenience sampling. The choice of the Gauteng province was 
based on the fact that it is the most densely populated province in South Africa. Nearly a 
quarter of the country (12.9 million people or 24%) reside in this province (Statistics South 
Africa, 2014). Questionnaires were distributed electronically throughout the province. The 
planning of the sampling for this phase of the research was based on the original plan to 
conduct structural equation modelling. The recommended minimum number for such analysis 
is 200 (Kline, 2011).   
For Phase 2, a sub-sample of the participants in Phase 1 was selected. MO and NM 
that had indicated willingness to donate blood for analysis were invited to participate. These 
participants were requested to supply blood samples for genetic and clinical laboratory 
testing.  
Participants were recruited using a mixture of media and field work approaches 
between 2014 and 2015. The research was advertised in a local health magazine (Melomend 
Health); on the free international research advertising site, Call for Participants; using Google 
Adwords over 30 days (March / April 2015). The study was also profiled on the UNISA 
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campus radio show, UNISA Radio, for four weeks (October / November 2014) as part of a 
broader conversation on migraine. Four postgraduate students were recruited to assist with 
marketing the study. One was involved in researching a different aspect of MO at Master’s 
level and the other three were students at another South African university. The latter were 
required to become involved in an aspect of research as part of a credit-bearing course at their 
institution. These students found the researcher via the study’s Facebook page and contacted 
the researcher for an opportunity to work on the advertising. These students handed out 
pamphlets and collected e-mail addresses of people that wanted to have the study link sent to 
them.  
 In addition, two high schools, three higher education institutions, five allied medical 
societies and two corporates agreed to disseminate the survey link to their members or 
employees. No permission was granted to name these sites. 
Furthermore, the study link and approximately 6 000 flyers were distributed through 
restaurants, cafés and social networks in Pretoria. A Twitter campaign ran for four months 
(December 2014 to March 2015) and a Facebook page was created to market the study and 
inform the public about migraine symptoms, advances in management and means of 
managing the impact of the headaches on daily life (May 2014 to May 2015).  
5.2.5 Self-report data. 
As mentioned in Chapter 2, there are some debates around the diagnosis of migraine 
cases using self-reporting. The ideal would be that such data is screened by a specialist 
physician and that laboratory investigations are included to rule out confounding variables.  
Nevertheless, self-reporting of signs and symptoms remains an acceptable and widely-used – 
not to mention practical - means of collecting headache data (Schürks et al., 2009). 
The use of psychometric scales that rely on self-reporting has been criticised because 
the method relies on the assumption that participants have the necessary insight into their 
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psychological processes to answer reliably (Malt & Ursin, 2003). It does become more 
difficult to embrace such an assumption when seeing the pattern of, inter alia, catastrophizing 
and depression in migraine patients (Boz et al., 2004; Mongini et al., 2003; Mongini, Fassino, 
et al., 2005). Despite this, self-reporting does remain an acceptable form of data collection. 
5.2.6 Ethical considerations. 
The ethical considerations for this research were myriad. Not only did the researcher 
have to consider the questions of best practice in relation to the collection of psychological 
data, but it was also necessary to engage with questions about how best to anonymize data 
without losing the ability to link psychological and laboratory results, how best to explain the 
laboratory procedures to participants, the reporting of incidental findings and the storage / 
destruction of genetic material.  
The relevant guidelines were considered to be: Unisa’s Research Policy (University of 
South Africa, 2006), the National Institutes for Health (NIH, 2012) and the 1000 Genomes 
Project (1000 Genomes, 2012) and H3 Africa (H3Africa Working Group, 2013) guidelines on 
genomic research. The researcher followed the requirements of Unisa for ethics clearance. A 
copy of the informed consent brochure can be found in Appendix A. 
Using these guidelines, the researcher built in three levels of consent for participants. 
The first level pertained to consent to participate in the survey and the second to be contacted 
to potentially supply blood samples. The third level was consent to supply blood specimens. 
The principles of the phlebotomy and the laboratory methods were included in the informed 
consent along with the guarantee that all unused specimens would be destroyed post-research. 
All participants were informed of the potential benefits of having their routine laboratory 
results shared with their healthcare practitioners and were encouraged to supply contact 
details for these practitioners. All results were then sent in a standardised report format to 
these practitioners. 
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5.3 Conclusion of Chapter 5 
There are three research questions posed in this thesis: (i) In what way does the 
HRQOL of MO sufferers differ from HRQOL of those without MO? (ii) What is the 
relationship between the harm avoidance (HA) temperament category and catastrophizing in 
MO? And (iii) To what extents do temperament, neurotransmission profile, coping strategy 
and perceived social support explain the variance in HRQOL in MO? As this was an 
exploratory study, no hypotheses were associated with the questions.  
These research questions were investigated from a postpositivist perspective, which 
acknowledges the links between neurotransmission, temperament, coping and social support 
determined within a biopsychosocial framework are only one version of reality for MO 
sufferers.  
The pragmatism of the biopsychosocial approach and the postpositivist assertion that 
the nature of the data and its measurement have a good fit to one another and allowed the 
thesis to be conducted as interdisciplinary research that drew on the disciplines of psychology, 
physiology and genetics. Data were collected from adult residents of the Gauteng Province in 
South Africa. Participants were recruited using a number of social media and platforms and 
word of mouth. The data were analysed used quantitative methods to describe HRQOL and 
compare outcomes between MO sufferers and NM and explore the relationships between 
glutamate levels, clinical laboratory results, transporter expression, demographic and 
psychosocial variables 
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Chapter 6:  Materials and Methods 
This chapter describes the methods and materials for each of the two phases of the 
research. The measures are discussed in terms of what they are employed to determine, their 
scoring and reliability. The laboratory measures are described and, where relevant, their 
validation explained. Thereafter follow descriptions of the data analysis, a discussion of the 
ethical considerations in the research and the steps taken to ensure reliability and validity. 
Finally, the funding source and role players are described. 
6.1 Materials and methods: Phase 1 
Phase 1 consisted of a series of questionnaires that were administered via an online 
survey tool, Qualtrics. All participants were required to complete a biographical questionnaire 
that consisted of nine items about sociodemographic information, such as age, sex, highest 
level of education and ethnic origin. A further four questions were posed on personal health 
history, alcohol consumption and smoking.  
All participants were also requested to complete the Short-Form 6 (SF-6D), 
Tridimensional Personality Questionnaire (TPQ), and Social Support Questionnaire (SSQ6). 
The question “How often do you experience headaches in a month?” was employed to screen 
out participants that do not suffer from any headaches: Individuals that answered “Never” 
were not required to complete any further headache questions. Participants that chose any 
other option (“Less than once a month”, “Once a month”, “2-3 times a month”, “Once a 
week”, “2-3 times a week”, 4-6 times a week”, “Daily” or “More than once a day, every day”)  
were required to complete the Pain Catastrophizing Scale (PCS) and items to provide more 
information on the characteristics of the headaches suffered (the duration of the headache, 
severity of the pain, its location, triggers and treatments). The headache items were derived 
using information in the literature and various headache reporting questionnaires used in 
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clinical settings (Breslau & Davis, 1993a; Headache Classification Committee of the 
International Headache Society, 2005b; Sabo & Maddox, 2009).  
In order to understand the medication use pattern in headache sufferers, three items 
about medication (over-)use (“Do you find yourself thinking about when next you will be able 
to take some headache medication, even if you do not have a headache?”, “Do you feel that 
the need for taking the medication is too strong to control even when you do not have a 
headache?” and “Do you find it difficult to cope without the medication, even if you are not 
having a headache?”) were included. These items were adapted from the Leeds Dependence 
Questionnaire and scored on a four-point Likert-type scale (0 = Never, 3 = Nearly always). 
The Leeds Dependence Questionnaire is a 10-item self-report questionnaire developed as part 
of a treatment evaluation package for substance dependence (Raistrick et al., 1994).  
6.1.1 Short Form 6 (SF-6D). 
The SF-6D is a 10-item measure of general HRQOL.  The scale is a significantly 
shortened version of the SF-36, which contained 36 items (Brazier, Roberts, & Deverill, 
2002).  
The SF-36 has been used in a number of headache studies (Aydemir, et al., 2011; 
Brown et al., 2008; Wang et al., 2001). The SF-36 measure is composed of eight subscales, 
namely: physical functioning, role limitations due to physical problems, bodily pain, general 
health perceptions, vitality, social functioning, role limitations due to emotional problems and 
mental health (MH). These eight subscales yield a physical and a mental health component 
score (Montazeri et al., 2011).  
The SF-6D, on the other hand, has only six dimensions: physical functioning, role 
participation, social functioning, bodily pain, mental health and vitality (Optum, n.d.). An 
index rating was generated to illustrate the individual’s health state from 0.0 (worst health 
state ) to 1.0 (best health state) (Hanmer, 2006; Optum, n.d.). This index and the scores for the 
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six dimensions were calculated using an algorithm developed by  the University of Sheffield 
(University of Sheffield, n.d.).  
The SF-6D has been used across a number of studies (Bozzani, Alavi, Jofre-Bonet, & 
Kuper, 2012; Keating, Peeters, Swinburn, Magliano, & Moodie, 2012; Shiroiwa et al., 2015). 
However, the measure does not yet appear to have been used in migraine studies. A number 
of population norms have also been developed for a number of countries, including Australia, 
Brazil and Japan (Shiroiwa et al., 2015; University of Sheffield, n.d.), but not for South 
Africa. 
SF-6D performance in this thesis 
Although the SF-6D provides a number of scores, the index score that is relatable to 
the SF-12 is referred to as the SF-12 index score or the SF-6D preference-based measure of 
health. In this thesis it is referred to either as the HRQOL or as the SF-12 index score, which 
gives the overall health-related quality of life index score from 0 to 1.  
The central tendencies and distributions for the SF-6D index in this study are shown in 
Table 6.1. The data are non-normally distributed, with skewness of ranging from -.59 to .34 
(SE = .13) and kurtosis varying from an insignificant -.01 to -.69 (SE = .26).  
 
Table  6-1: Central tendency and distribution for the SF-6D-4 in the current study (N = 341) 
 
 
SF12index 
(represents 
HRQOL) 
Minimum Maximum Mean SD Skewness Kurtosis 
Statistic SE Statistic SE 
.39 1.00 .73 .13 -.179 .132 -.83 .26 
 
SF-6D has been found to be reliable in estimating HRQOL in systemic sclerosis 
(Khanna et al., 2007) with good test-retest reliability (ICC = 0.82 [95% CI: 0.76, 0.87]), 
though some floor effects are noted for the poorest health states (Brazier et al., 2002) The 
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Cronbach α score was calculated using the transformed and not the raw scores for the SF-6D. 
The score was .78, which is higher than the .7 limit for acceptability (Lowenthal, 2001). It is 
therefore adequate. 
6.1.2 Tridimensional Personality Questionnaire (TPQ). 
The TPQ is based on Cloninger’s Psychobiological Theory of Personality and consists 
of 98 items rated as either true or false by the respondent (Stewart, Ebmeier, & Deary, 2004). 
The TPQ originally distinguished three temperament dimensions – Harm Avoidance (HA), 
Novelty Seeking (NS) and Reward Dependence (RD). Later, it was found that some items did 
not measure RD, but rather a fourth dimension called persistence (P) (Verweij et al., 2010).  
The TPQ cannot be marked by the researcher and has to be scored through 
Anthropedia, an organisation that markets and sells the test. The algorithm for scoring the test 
is not publicly available. The results returned indicated the totals for the three original 
dimensions. Each scale has four subscales labelled 1 to 4. However, the subscale RD2 is now 
regarded as the measure of P. The scales and subscales as well as their descriptions are shown 
in Table  6-2 (adapted from Celikel et al., 2009; Hansenne et al., 1999; Mardaga & Hansenne, 
2007; Sovio et al., 2007; Verweij et al., 2010). 
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Table  6-2: Scales, subscales and descriptions of the Tridimensional Personality 
Questionnaire (TPQ) 
Scale and description Subscale and description 
Novelty Seeking (NS): Level of activation of exploratory activity (33 
items) 
NS1: Exploratory excitability 
NS2: Impulsiveness 
NS3: Extravagance 
NS4: Disorderliness 
Harm Avoidance (HA): The efficiency of the behavioural inhibition 
system (34 items) 
HA1: Anticipatory worry 
HA2: Fear of uncertainty 
HA3: Shyness with strangers  
HA4: Fatigability 
Reward Dependence (RD): Maintenance of rewarded behaviour (22 
items) 
RD1: Sentimentality 
RD3: Attachment 
RD4: Dependence 
Persistence (P): Maintenance of behaviour as resistance to frustration 
(9 items) 
RD2: Persistence 
 
TPQ performance in this thesis 
The central tendencies and distributions for the TPQ dimensions in this study are 
shown in Table 6.3. The data are non-normally distributed, with skewness of ranging from -
.59 to .34 (SE = .13) and kurtosis varying from an insignificant -.01 to -.69 (SE = .26).  
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Table  6-3: Central tendency and distribution for the TPQ in the current study   
TPQ 
dimension 
  
Minimum 
  
Maximum 
  
M 
  
SD 
  
Skewness Kurtosis 
Statistic SE Statistic SE 
NS 2.00 30.00 14.56 5.54 0.25 0.13 -0.30 0.26 
HA 0.00 34.00 14.82 7.60 0.34 0.13 -0.69 0.26 
P (RD2) 0.00 9.00 5.82 1.91 -0.59 0.13 -0.01 0.26 
RD 2.00 28.00 17.43 4.64 -0.19 0.13 -0.39 0.26 
 
The test has generally demonstrated adequate psychometric properties, such as 
internal consistency levels that range from 0.55 to 0.89 (Sher, Wood, Crews, & Vandiver, 
1995). The test and Cloninger’s theory continue to enjoy wide use in both clinical and non-
clinical populations. The Cronbach α scores for the scales of the TPQ were calculated by 
Anthropedia as: NS α = .78; HA α = .90; RD α =.72 and P α = .56. All the scales are 
adequately reliable, except for P. 
6.1.3 Social Support Questionnaire 6 (SSQ6). 
The SSQ6 is a six-item questionnaire measuring perceived social support (Sarason, 
Sarason, Shearin, & Pierce, 1987). Each item has two parts: The first part asks the subject to 
list the people that can be relied on for support in a specific situation; the second part asks the 
subject to rate his / her satisfaction with the perceived support on a scale of one to six (1 = 
Very satisfied, 6 = Very dissatisfied). Each item is scored according to the number of people 
listed as sources of support. Two scores are computed, the first by dividing the sum of people 
named (a maximum of nine people may be listed per item) by the number of items and the 
second by dividing the sum of satisfaction scores by the number of items (Callaghan, 1998; 
Monteiro, 2011). The focus of this study rested on the amount of perceived support, so only 
the first score was computed.  
SSQ performance in this thesis 
The objective of this study was to study social support only in terms of the perception 
of how many people are available to lend support. In order to obtain a score for this aspect of 
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social support the formula from the SSQ6 scoring instructions was utilised: SSQTotalNumber 
= Σ (Items 1a, 2a, 3a, 4a, 5a, 6a) / 6. The maximum possible score on this index is six and the 
minimum is zero. The distribution and central tendency for the number of supporters subscale 
is shown in Table 6.4. The data are non-normally distributed, with skewness of .43 (SE = .13) 
and kurtosis of -.60 (SE = .26).  
 
Table  6-4 :Central tendency and distribution for the SSQ6 items related to the amount 
of social support in the current study (N = 340) 
  SSQ6 Minimum 
  
Maximum 
  
M 
  
SD 
  
Skewness Kurtosis 
 Statistic SE  Statistic SE 
 0.50 7.83 4.03 1.75 0.43 0.13 -0.60 0.26 
  
The instrument has shown high reliability coefficients for both subscales  at 0.97 and 
0.94, respectively (Callaghan, 1998). The Cronbach α for the six items was .83, which 
indicates good internal consistency. 
6.1.4 Pain Catastrophizing Scale (PCS). 
The PCS consists of 13 items that evaluate the negative cognitions and emotions 
related to pain (Sullivan, Rouse, & Bishop, 1997). Items are scored on a 5-point scale (0 = 
Not at all, 4 = All the time). The global score indicates the level of catastrophizing, while the 
three subscales measure rumination, magnification and helplessness (Sullivan, 2009) The total 
PCS score is derived by summing the responses to all 13 items. Scores range from 0 to 52, 
with higher scores indicating greater use of catastrophizing for coping with pain. The subscale 
scores are derived as follows:  
(i) Rumination = Σ (Items 8, 9, 10, 11) 
(ii) Magnification = Σ (Items 6, 7, 13) 
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(iii) Helplessness =  Σ (Items 1, 2, 3, 4, 5, 12) 
A shorter version of the PCS was developed by Bot et al. (2014). The revised scale 
makes use of items 3, 6, 9 and 11 to yield an overall catastrophizing score. It has been found 
to have good internal consistency (α = .86) and correlated strongly with the 13-item PCS (r = 
.96). Further evaluation of this four-item PCS (referred to as the PCS-4) was conducted in a 
group of chronic musculoskeletal pain patients (N = 280). Again, the PCS-4 showed 
significantly strong correlation with the original (r = .93) and high internal consistency (α = 
.81). This shorter version was employed in the current study. 
PCS-4 performance in this thesis 
The central tendency and distribution for the PCS-4 in this study is shown in Table 
6.1. The data are non-normally distributed, with skewness of .99 (SE = .14) slight kurtosis of 
.09 (SE = .28).  
 
Table  6-5: Central tendency and distribution for the PCS-4 in the current study (N= 
311) 
PCS-4 Minimum 
  
Maximum 
  
M 
  
SD 
  
Skewness Kurtosis 
Statistic SE Statistic SE 
0 16.00 4.26 4.27 0.99 0.14 0.09 0.28 
 
The test has been used extensively in pain studies and translated into various 
languages (Cho, Kim, & Lee, 2012; Fernandes, Storheim, Lochting, & Grotle, 2012; Morris, 
Grimmer-Somers, Louw, & Sullivan, 2012). The test has shown acceptable reliability for use 
in clinical and non-clinical populations (Osman et al., 1997). The PCS has acceptable internal 
consistency: total PCS α = .87, Rumination α = .87, Magnification α = .66, and Helplessness α 
= .78 (Sullivan, 2009).The Cronbach α for the four items was .89.This indicates good internal 
consistency. 
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6.2 Data analysis plan for Phase 1 
Questionnaires were completed on Qualtrics, which is an electronic survey site 
(www.qualtrics.com). Each participant was randomly assigned a unique participant 
identification number by the Qualtrics software. All data were downloaded in .csv format, 
cleaned and then exported to SPSS. 
The TPQ copyrighted limits scoring to the sole distributor, Anthropedia. All 
information was removed from the data set, except the unique identifier and the TPQ items. 
The file was sent to Anthropedia. The scored data were then returned via e-mail. 
The SF-6D data were scored on the software provided by the University of Sheffield. 
The algorithm provided could be directly applied to the SPSS data. 
The attrition rate was calculated using the number of incomplete questionnaires as a 
percentage of all questionnaires started. Diagnosis of MO was established using the ICHD-II 
criteria. Interval data were described using the mean or median and standard deviation, while 
categorical variables were described in frequencies and percentages.  
During analysis of the phase 1 data, four groups emerged from preliminary analysis: 
Those that had never experienced a headache (Group 1); participants that have experienced 
headaches, but not MO (Group 2); those with possible MO (Group 3) and those with MO 
(Group 4).Between-group differences for ordinal and continuous data were calculated using 
the Kruskal-Wallis Test. Although analysis of variance (ANOVA) is popularly used for such 
comparison, the sample did not meet the assumption of normality required (Field, 2013). In 
addition, the group sizes differed considerably and this can have a significant effect on 
ANOVA calculation (Bliese & Halverson, 1998). Between-group differences for categorical 
data were calculated using Chi-square or Fisher’s Exact Test. 
Correlations were calculated using Spearman’s rho. The correlations were also 
executed controlling for variables that showed significant differences in the group 
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comparisons. Effect sizes for correlations were classified as trivial (<.1), small to medium (.1-
.3), medium to large (.5-.8) and large to very large (<.8) (Cohen, 1992).   
The data were then explored for suitability to conduct regression analyses. The 
specific criteria and steps for suitability are discussed in detail in Chapter 7. These criteria 
were met, allowing for the use of hierarchical regression. Mediator and moderator effects 
were investigated using the PROCESS method (Hayes, 2013).  
6.3 Materials and methods: Phase 2 
Participants consenting to providing blood for Phase 2 underwent a set of laboratory 
tests. These laboratory tests were used to help understand the pattern of dysfunction that may 
occur in MO and to guide the sample selection. Participants were requested to be headache-
free for seven days before providing samples.  
Samples were collected by registered phlebotomists at the Ampath Laboratory of the 
subject’s choice (after 10-hour fast). The fasting glucose, clotting and lipid profile tests were 
carried out by Ampath Laboratories. These three sets of results were used to describe the 
overall health profiles of the participants in Phase 2. The researcher conducted the glutamate 
ELISA and qPCR determinations at the University of Pretoria. 
6.3.1 Fasting glucose.  
This test is used to detect abnormal blood sugar levels such as those seen in diabetes. 
Blood (3ml) was collected in a heparinised tube, then centrifuged and separated within 45 
minutes of collection. The glucose concentration was quantified using a hexokinase-mediated 
reaction via the Roche/Hitachi Modular P Chemistry analyzer (University of Minnesota 
Medical Center, Fairview Collaborative Studies Clinical Laboratory Minneapolis, n.d.). The 
reference range used by Ampath for fasting glucose is 3.9–6.0 mmol/l. 
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6.3.2 Clotting.  
The measure of the efficiency of the intrinsic clotting pathway is called activated 
partial prothrombin time ratio (aPTT ratio). Ampath phlebotomists collected 3.5ml of blood in 
a citrate tube and an activator was added before starting the clotting process (Practical 
Haemostasis.com, 2016). The ratio is calculated using the absolute aPTT by the midpoint of 
the reference range (University College London Hospitals, 2012) and should ideally be 
between 0.8 and 1.2. 
6.3.3 Lipid profile. 
Total cholesterol and triglyceride levels were measured by Ampath. Blood (4ml) was 
collected in Vacutainer blood collection tubes and left to stand for 45 minutes to allow 
complete clotting of the sample. The sample was then centrifuged at 1,500 x g for 30 minutes 
at 4°C. Cholesterol and Triglycerides/GPO reagents were used to digest the cholesterol for 
analysis on a Hitachi 704 Analyzer (Lipid Laboratory Johns Hopkins, 2003).  
The reference range utilised by the Ampath Laboratory are as follows:  
(i) Total cholesterol: 2.8-4.9 mmol/l 
(ii) Triglycerides: 0.4-1.6 mmol/l 
(iii) High density lipoporoteins (HDL):  
(iv) Low density lipoproteins (LDL): 1.2-1.9 mmol/l 
(v) Non-HDL Cholesterol: 0.9-3.7 mmol/l 
6.3.4 Enzyme-linked Immunosorbent Assay. 
Enzyme-linked Immunosorbent Assay (ELISA) is an umbrella term for a number of 
immunoassays that involve the use of a reagent immobilised on a solid phase together with an 
enzyme that acts as a signal generator  (Butler, 2008). The ELISA technique was developed 
by Engvall and Perlman in 1971 (Charan & Gautam, 1984; Engvall & Perlmann, 1971). 
ELISA is a widely used laboratory technique for quantifying the concentration of an analyte 
(AbDSerotec, 2015; Lequin, 2005), based on the principles of antibody immunological 
reactions. There are a number of types of ELISA depending on, for example, whether the 
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antibody or the antigen is immobilized, whether the assay is competitive or not and whether 
the immune response to the analyte is measured directly or indirectly. The technique is 
distinguished from other assays by its use of antibody-antigen binding in detecting the analyte 
(SeraCare Life Sciences, 2013). The enzyme acts to report that the specific antibody-antigen 
reaction has occurred and can also be used to quantify the extent of the reaction (Butler, 
2008). 
6.3.5 Glutamate ELISA.  
Glutamate concentration was quantified in this research using Abnova’s glutamate 
ELISA kit (catalogue number KA1909). The kit is used for quantifying L-glutamate in urine, 
plasma and serum. This is a competitive assay, meaning that the reference and sample 
analytes compete for binding to a limited number of antibody binding sites. Antigen is bound 
to a solid phase of the plate. Free antigen and antigen-antibody complexes are washed away 
after the reaction has reached equilibrium (Abnova, n.d.; SeraCare Life Sciences, 2013).  
Blood (5mL) was collected in an EDTA tube, centrifuged at 3000rpm and transferred 
to 1.5ml Eppendorf tubes before storage at -20°C. Samples were stored for six months and 
were defrosted for an hour before use. Each subject’s sample was tested at least in duplicate, 
although 19 were conducted in quadruplicate (for quality assurance). Statistical analysis was 
conducted using the mean concentrations of the replicates. 
ELISA performance in this thesis. 
The central tendency and distribution for the ELISA in this study is shown in Table 
6.6. The data are non-normally distributed, with skewness of .1.557 (SE = .295) and kurtosis 
of 2.454 (SE = .582).  
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Table  6-6: Central tendency and distribution for the ELISA glutamate results in the 
current study (n = 66) 
Glutamate 
serum 
ELISA 
(µg/ml) 
Minimum Maximum M SD Skewness Kurtosis 
Statistic SE Statistic SE 
4.9 84.830 24.718 17.007 1.557 
  
.295 
  
2.454 
  
.582 
  
 
 Abnova’s glutamate ELISA kit is reported to have less than .1% cross-reactivity with 
aspartate, glutamine, glycine, alanine and 5-aminovaleric acid.  
Precision was investigated through calculating the intraplate coefficients of variation 
(%CV), which indicate how much the duplicates vary from one another. The samples were 
split over two plates. The %CV of each plate was calculated using equation SD of optical 
density / mean optical density x 100 (Crowther, 2002). 
The intraplate %CVs were 10% for both the first and second plates. This indicated that 
duplicate concentrations of glutamate for the same sample varied by 10% on this kit. Such 
variations mainly arise because of inadequate mixing of reagents or pipetting errors 
(Crowther, 2002). To improve the precision of the technique, all samples that exhibited more 
than 15% variance (n = 19) were re-run. The 15% cut-off is the recommended %CV for 
ELISA (Crowther, 2002). A pipetting error saw a single row receive twice the required Q-
Buffer. The optical densities for those eight samples were excluded and the concentration was 
calculated only on the one reading. The CV for the third kit was improved at 7%. This was 
considered to be within normal experimental error limits for this type of assay. The 
concentration for a sample was calculated using the duplicate optical densities from the plate 
where the readings had the lowest %CV. 
6.3.6 Transporter investigations. 
EAAT2 expression was quantified via real time reverse transcription (RT2) / 
quantitative polymerase chain reaction (qPCR) using Qiagen’s qPCR Primer Assay. qPCR is 
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the process of amplifying DNA sequences exponentially and measuring the quantity of 
amplified product (Nolan, Hands, & Bustin, 2006; Pestana, Belak, Diallo, Crowther, & 
Viljoen, 2010). In traditional PCR amplification products are measured post-reaction using 
gel electrophoresis (Fraga, Meulia, & Fenster, 2008; Pestana, Belak, Diallo, Crowther, & 
Viljoen, 2010). However, qPCR involves continuous measurement of product throughout the 
reaction.  
The qPCR has a number of steps and the work flow for this thesis is illustrated in 
Figure 6-1. qPCR involves the extraction of RNA, reverse transcription (RT) of RNA to 
cDNA and amplification of the cDNA (Nolan et al., 2006; Tichopad, Kitchen, Riedmaier, 
Becker, & Ståhlberg, 2009). The task is labour intensive and time consuming and has a 
number of check and balances at various stages.  
 
 
 
Figure  6-1: Steps in the qPCR workflow for this thesis 
Specimen collection. 
Samples of blood (2.5mL) were drawn by Ampath phlebotomists into Qiagen’s 
Preanalytix PAXgene Blood RNA Tubes. These tubes contain a patented agent for RNA 
 101 
 
stabilization, which prevents RNase action and limits gene induction (Magee, 2011). Samples 
can remain stable for 3 days at 18 – 25˚C, 5 days at 2 – 8˚C and at least 50 months at -20˚C. 
Samples were stored for six months at -20˚C before use. 
Isolation of RNA. 
Qiagen’s PAXgene Blood RNA Kit was used to prepare total RNA from the whole 
blood. The process for manual isolation of RNA was followed in this thesis (Preanalytix, 
2015).  
This process is column based. It involves the digestion of proteins by proteinase K 
before removal of cell debris on the shredder column. This is followed by several wash steps, 
before the elution of the RNA (Preanalytix, 2015).  
Quality assurance. 
The extracted total RNA was analysed using spectrophotometry on the NanoDrop 
ND-1000. Samples were evaluated on three criteria: (i) RNA concentration (determined by 
A260) had to be > 200ng/µl, (ii) A260:A280 values had to be > 1.5 and (iii) A260:A230 had 
to be > 1.  
Although these criteria are less stringent than those suggested by the manufacturer 
(Qiagen, 2015), the adjustments were a practical necessity because of low yield. The low 
yield is caused by challenges or errors in any stage of the extraction, storage challenges and 
protein contamination – it can be difficult to pinpoint (Kennedy, 2014). An additional step 
was undertaken to minimise the effect of low yield: The elution of RNA was conducted with 
40uL or supplied eluent, rather than 80uL, in order to increase concentration. Of the 66 
original samples, 26 (40%) met the criteria. 
qPCR Assay.  
Quantification of levels of EAAT2 expression was attempted in the remaining 26 
samples. The cDNA synthesis was carried out using Qiagen’s First Strand Kit and 200ng of 
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RNA extracted from the sample using dual hybridisation probes - Qiagen’s SYBR Green - on 
Roche’s LightCycler Nano. Qiagen’s SYBR Green Mastermix is fluorescence based binding 
dye technology. The dye binds double-stranded DNA and the amount of cDNA is detected by 
the increase in fluorescence through the reaction.  
Each reaction was performed in a final volume of 25μL (1μL cDNA diluted with 
10.5μL of RNAse-free water, 1μL Qiagen RT2 qPCR primer assay and 12.5μL of Qiagen’s 
RT2 SYBR Green Master Mix). The amplification process was started with 10 minutes of 
activation at 95˚C. This was followed by 55 cycles of 95°C for 15s and 60°C for 1 minute. All 
samples were run in duplicate and mean values were calculated. The efficiency of the process 
is reportedly greater than 90% (Qiagen, 2012). The quantification cycle, also sometimes 
known as the threshold cycle (Ct) was determined for the reference genes and the gene of 
interest (GOI) in each sample. The Livak method was utilized for data analysis. All non-
detected Ct values were imputed using the model described by Mccall, McMurray, Land, and 
Almudevar (2014). The mean Ct was calculated for the genes. Livak’s Method (Livak & 
Schmittgen, 2001) was used to calculate fold change: Mean values were calculated for the Ct 
values of gene of interest (SLC1A2) for the two groups. A mean Ct was calculated for the two 
reference genes together for the two groups. The first step was normalisation: The differences 
Ct in between the gene of interest and the reference genes (ΔCt) was calculated as ΔCt = 
Mean(CtGOI) – Mean(CtReference genes). The differences in Ct between MO and NM was 
calculated as ΔΔCt = Mean ΔCt(MO) - Mean ΔCt(NM). Finally, the fold change was 
calculated as 2(-ΔΔCt). The central tendency analysis (Table 6-6) shows that the qPCR data is 
non-normally distributed. 
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Table  6-6: Central tendency and distribution for the qPCR normalized SCL1A2 and 
fold-change data in the current study (n = 20) 
 Minimum Maximum Mean SD Skewness Kurtosis 
Statistic SE Statistic SE 
Normalized 
SCL1A2 
0.015 5345.095 321.688 1194.132 4.339 0.512 19.091 0.992 
Fold-change -3.625 11.975 5.992 4.381 -0.703 0.512 0.341 0.992 
 
Quality assurance. 
There are a number of qPCR products available and, according to Nolan et al. (2006), 
no two methods produce the same results. The reasons for variation are myriad and some of 
these are described by Tichopad et al. (2009).  
In an effort to diminish the effects of some errors sources across all these methods, 
standardised guidelines have been produced. The most notable guidelines are the Minimum 
Information for Publication of Quantitative Real-Time PCR Experiments or MiQE Guidelines 
(Bustin et al., 2009). The MiQE guidelines were followed in this thesis with regard to testing 
for genomic DNA (gDNA) contamination, biological replicates and the inclusion of 
endogenous controls or reference genes (sometimes called housekeeping genes) (Bustin et al., 
2009).  
GDNA contamination was evaluated using Qiagen’s gDNA Control primer assay 
Each sample (n = 26) was run with Qiagen’s gDNA SYBR Green Mastermix and reverse 
transcriptase (+RT) and a no-reverse transcriptase no template control  
(-RT/NTC). A Ct value between 30 and 35 indicates that caution must be exercised when 
interpreting the results as gDNA contamination may have influenced the expression profiling. 
However, a Ct value above 35 suggests gDNA contamination that is too low to interfere with 
the reactions. All samples showed Ct values above 30. Any gDNA present is therefore 
unlikely to have affected the analysis. 
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Four reference genes were noted in the literature for SLC1A2. These were GAPDH 
(Miguel-Hidalgo et al., 2010), B2M (Vallejo-Illarramendi, Domercq, Pérez-Cerdá, Ravid, & 
Matute, 2006), RPL13A (Jacob et al., 2007) and ACTB (Martisova et al., 2012). The best 
performing reference genes were determined on nine samples. Ideally, the expression of 
reference genes should remain invariable (Qiagen, 2011b). The stability of a gene in 
expression is calculated using the log-transformed Ct (Spiegelaere et al., 2015). The worst 
performing reference gene was identified using the Microsoft Excel add-in, NormFinder 
(Molecular Diagnostic Laboratory, 2010). NormFinder is a free software tool that analysis 
gene expression stability, which is considered acceptable when <1.5 (Ling & Salvaterra, 
2011). The most stable gene was RPL13A (M = 1.042) and the best combination of reference 
genes was RPL13A with GAPDH (combined M = 1.395). Subsequent runs were conducted 
only using these two reference genes. NormFinder has been used in numerous studies and has 
been found to be sufficiently reliable with small samples (Spiegelaere et al., 2015). 
Normalization of the data was therefore conducted with two reference genes. Table 6.7 shows 
the details of the genes used as the target and references. 
A further check for gDNA was introduced during the reactions. A –RT control was 
run for every +RT reaction. A difference of six or more in the Ct value of the two (-RT - +RT) 
indicated that gDNA contamination did not affect the reaction (Qiagen, 2015). Reactions that 
showed differences less than six were excluded from analysis. Thus, the final sample was 20 
for the qPCR analysis. 
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Table  6-7: Primers used for the qPCR 
Gene name Primer assay 
catalogue 
number 
Accession 
number 
Length 
(bp) 
Reference 
position (in 
RefSeq) 
Solute carrier family 1 (glial high affinity 
glutamate transporter), member 2 or 
excitatory amino acid transporter 2 
PPH01440F NM_004171.3 70 2213 
Ribosomal protein L13a PPH01020B NM_012423.3 90 994 
Glyceraldehyde-3-phosphate 
dehydrogenase (spermatogenic) 
PPH14985F NM_014364.4 100 686 
6.4 Data analysis for Phase 2 
Interval data were described using the mean, median and standard deviation, while 
categorical variables were described in frequencies and percentages. Between-group 
differences were calculated using the Mann-Whitney U Test or Student’s t-test for interval 
variables, whereas χ2 or Fischer’s Exact Test was used for categorical variables. Given that the 
data are mainly non-normally distributed, Spearman’s correlation coefficient was used instead 
of Pearson for interval variables as it is considered a more robust test for small samples 
(Field, 2000). 
6.5 Ethical considerations 
The guidelines supplied by the National Institutes for Health (NIH, 2012), the 1000 
Genomes Project (1000 Genomes, 2012) and H3 Africa (H3Africa Working Group, 2013) 
were followed with regard to privacy, storage and analysis of genetic material. The Patient 
information and Informed consent leaflet reflects these guidelines. Participants were given the 
choice of providing their health practitioners’ details for the routine blood test results.  
The use of an online platform for the administration of tests posed potential challenges 
for maintaining confidentiality. For this reason, a platform with data security options was 
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used. The Qualtrics platform has various levels of data protection, including password 
protection and anonymizing of surveys. Only the primary researcher and the database 
administrator had access to this password. The database administrator signed a confidentiality 
agreement for the study. 
The study was reviewed by the ethics committee of the Department of Psychology at 
Unisa. Clearance was granted for the study by that committee in 2013 (see Appendix B). The 
researcher was also granted permission to recruit staff and students at Unisa for the study. The 
latter required review by a separate committee and clearance was granted for this in 2014 (see 
Appendix B). 
6.6 Reliability and validity 
Several steps were taken to increase the reliability and validity of the process. The first 
step was to calculate power for the study in order to approximate the ideal sample size. 
Funding was secured to approach the ideal sample size. However, this sample size was not 
realised within the timeframe. Power calculations were carried out to determine effect sizes 
and these are reported in the results.  
The second step was to ensure the reliability of the questionnaires chosen. For this 
reason questionnaires with a reported reliability close to 0.9 were chosen. Thirdly, the validity 
of the questionnaires was tested using the internal consistency method. These results are 
reported earlier in this chapter. 
With regard to the blood tests, Ampath Laboratories is an accredited diagnostic 
laboratory. This laboratory conducted the cholesterol, glucose and clotting profiles. Although 
the ELISA and qPCR testing did not take place in an accredited laboratory, the measures were 
conducted under supervision and were conducted in duplicate. qPCR included reference 
genes. 
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6.7 Funding and roles 
Funding for this research was provided by the National Research Foundation. Funding 
was approved through the Thuthuka PhD Track grant. UNISA waived all tuition fees, except 
registration fees as it does for all employees. 
The collection of bloods and the standard laboratory assessments (fasting glucose, 
aPTT and lipid profile) were carried out by Ampath Laboratories, Pretoria, South Africa. The 
ELISA measures were carried out by the candidate at the Department of Physiology at the 
University of Pretoria under the guidance of Dr Alida Koorts and with assistance from Ms 
Jaqueline Harvey. Ms Harvey was a Master’s student in the Department of Psychology, 
UNISA (under the researcher’s supervision) at the time that the work was conducted. 
The qPCR determinations were completed at the Department of Physiology at the 
University of Pretoria with training and support from Dr André Stander. Assistance was 
provided again by Ms Harvey and technical support by Ms Ting Hua Chang. Further 
theoretical training was provided by Dr Charles Wairuri from Whitehead Scientific, South 
Africa. The researcher conducted the statistical analyses in SPSS, with statistical support 
provided by Dr Mardé Booyse of the ARC. 
6.8 Conclusion of Chapter 6 
This thesis consisted of two data gathering phases. In phase 1 a survey was conducted 
to gather data on sociodemographics, migraine symptoms, temperament, social support and 
coping. Participants who indicated a willingness to donate blood specimens for analysis were 
invited to participate in phase 2. Ampath Laboratories collected the blood specimens and 
provided fasting glucose, total cholesterol and clotting analyses. The researcher conducted 
glutamate serum ELISA, qPCR and statistical analyses with the support of members of the 
Department of Physiology at the University of Pretoria, the ARC and Ms Jaqueline Harvey. 
The National Research Foundation provided the project funds.  
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Chapter 7:  Results of phase 1 
The data from phase 1 of the study are presented in this chapter. The phase 1 data is 
used to describe the occurrence of MO in Gauteng. HRQOL was examined and compared for 
NM and MO sufferers. This was followed by an examination of how the psychological data 
can help predict HRQOL.   
7.1 Data collection and attrition for Phase 1 
Survey data collection took place between May 2014 and July 2015. All adults living 
in the Gauteng province of South Africa were eligible to participate. Participants were 
recruited through various media and this process is discussed in detail in the methodology 
chapter.  
Of the 723 people that started the questionnaire, 341 (47%) completed it. The 
questionnaire used piping to direct those that have experienced a headache to answer 
questions about their symptoms, while participants that stated that they had never experienced 
a headache (n = 30; 9%) did not have to answer these questions.  
7.2 Exclusion from migraine without aura diagnosis and emergence of groups 
Two participants reported that they had been diagnosed with a terminal illness. Six 
more reported having a degenerative nervous disorder. These eight participants were excluded 
from any migraine diagnosis. One participant reported weakness and 72 reported possible 
scintilla. All 73 participants described these as symptoms that occurred during headache and 
not as prodromal symptoms and therefore they were not classified as experiencing aura. No 
other possible signs of aura were reported.  
As mentioned in the materials and methods (Chapter 6), four groups emerged during 
data analysis. These groups are: Those that had never experienced a headache (Group 1); 
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participants that have experienced headaches, but not MO (Group 2); those with possible MO 
(Group 3) and those with MO (Group 4). These groups were used in further analysis. 
7.3 Headache characteristics 
In order to gain insight into the headache characteristics for the sample, the occurrence 
of MO symptoms is described. Each criterion is described separately before the rates of MO 
and possible MO are presented. Table  7-1 shows the frequency with which the four migraine 
symptoms (ICHD-II criteria A to D) appears in the sample.  
More than two-thirds of the sample experience headache on a monthly basis or more 
frequently (n = 232; 68%), with the rest (n = 109; 32%) never or seldom (less than once a 
month) experiencing a headache. More than a third of participants (n = 128; 38%) 
experienced headaches of more than 4 hours.  
The mean severity of the pain associated with headaches in this sample (n = 311; 
91%) was 46.72, SD = 27.79 on a 100-point scale. The moderate to severe classification is 
based on the VAS norms (45-100) (Jensen, Chen, & Brugger, 2003). There were 167 (49%) 
participants that described their average headache pain as moderate to severe.  
It is worth noting that more than half of the sample experienced headaches of a 
pulsating nature (n = 193; 57%) or with nausea and / or vomiting or photophobia and 
phonophobia (n = 176; 52%). Few experienced aggravation of headache by or resulting in 
avoidance of routine physical activities (n = 10; 3%), unilateral location (n = 29; 9%). 
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Table  7-1:  Frequencies (n, %) of migraine without aura symptoms (N = 341) 
Criteria  Frequency (n; %) 
A: At least five attacks 232; 68 
B: Headache attacks lasting 4-72 hours 128; 38 
C:       Unilateral location 
 
29; 9 
          Pulsating quality 
 
193; 57 
          Moderate or severe pain intensity  
 
167; 49 
           Aggravation by or causing avoidance of routine physical activity  
           (e.g. walking or climbing stairs) 
10; 3 
D: nausea and / or vomiting or  photophobia and / or phonophobia 176; 52 
7.4 Migraine occurrence 
MO and possible MO frequencies were calculated by identifying participants that met 
all four MO criteria (criteria A to D) or any combination of three of the criteria (ABC, ABD, 
ACD or ABD). All four criteria were met by 94 participants. The criteria for possible MO 
were met by an additional 62 participants, but two were excluded from diagnosis because they 
suffered from a degenerative nervous disorder. The occurrence of MO is therefore 28% and 
18% for possible MO in this sample. Only three of the 94 participants meeting all four criteria 
for migraine reported having been diagnosed with a headache disorder.  
7.5 Group comparisons 
The four headache groups were compared on a number of variables. For ordinal or 
continuous variables such as age, medication overuse, frequency of alcohol intake or number 
of cigarettes smoked, groups were compared using the Kruskal-Wallis test. Chi-square tests 
were utilised when comparing categorical data. However, Fisher’s Exact test was used to 
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investigate the difference between groups where an excessive number of cells had counts less 
than five and therefore a Chi-square was not suitable (Howel, 2013).  
7.5.1 Demographics. 
The mean age was calculated without missing values (n = 323) and was 36.64, SD = 
11.74 years. The groups did not differ significantly regarding age distribution (p = .748).  
The frequency distributions for a number of demographic variables are shown in 
Table  7-2. Only the highest frequencies of each category are shown. The results of the 
between-group comparisons are shown under p-values.  
The majority of participants were female (n = 268; 79%), spoke English at home (n = 
177; 52%), were employed (n = 283; 83%) and educated to the tertiary level (n = 309; 91%). 
The question on ancestry allowed for multiple responses for each individual. Most 
participants identified themselves as having European heritage (n = 251; 62%), while 98 
(29%) identified with African heritage and 33 (10%) with Asian heritage.  
There were no significant differences between groups [never experienced a headache 
(Group 1); participants that have experienced headaches, but not MO (Group 2); those with 
possible MO (Group 3) and those with MO (Group 4) ] on highest level of education attained, 
employment category or ancestry. However, the groups differed significantly regarding the 
distribution of home language (p = .035) and sex (p = .001).  
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Table  7-2: Frequencies (n, % of group) of demographic information and comparisons 
across groups 
Variable Total sample  
(N = 341) 
Group 1  
(n = 44) 
Never 
experienced 
headache 
 
Group 2  
(n  =  143) 
Have 
experienced 
headaches, 
but not MO 
Group 3  
(n = 60) 
Possible 
MO 
Group 4  
(n = 94) 
MO 
p 
n % n % n % n % n % 
Ancestry 
(multiple 
responses 
permitted) 
European 251 74 27 6 112 78 43 72 69 73 .162 
African 98 29 14 32 39 27 18 30 27 29 .939 
Asian 33 10 6 14 13 9 6 10 8 9 .794 
Employment Employed 283 83 33 75 124 87 50 83 76 81 .300 
Students 84 25 10 227 33 23 19 32 22 23 .583 
Highest level 
of education 
Tertiary 32 9 42 95 132 92 54 90 81 86 .273 
 Secondary 309 79 2 5 11 8 6 10 13 14 
Home 
language 
English 177 52 25 57 71 50 30 50 51 54 .035 
Afrikaans 126 37 8 18 58 41 25 5 35 37 
Sex Female 268 79 28 64 104 73 51 85 85 90 .001 
Male 72 21 16 36 38 27 9 15 9 10 
7.5.2 Health. 
There were no significant differences between the four groups for medication overuse 
or number of cigarettes smoked. However, the groups did differ on the frequency of alcohol 
intake. Post-hoc analysis with Dunn-Bonferroni testing indicated that Groups 2 and 4 differed 
significantly (p = .016). Table  7-3 shows a summary of the health data and the p-values for 
between-group comparisons. Here the groups did differ significantly on the number of 
members that reported head or neck injuries 
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Table  7-3 
Frequencies (n, % of group) of health information and comparisons across groups 
Variable Total 
sample   
(N = 341) 
Group 1  
(n = 44) 
Group 2  
(n  =  143) 
Group 3  
(n = 60) 
Group 4  
(n = 94) 
p 
n % n % n % n % n % 
Bleeding disorders 15 4 3 7 4 3 1 2 7 7 .185 
Brain infection 13 4 0 0 4 3 3 1 6 6 .065 
Cancer 14 4 1 2 5 4 4 7 4 4 .895 
Degenerative disorders 6 2 1 2 5 4 0 0 0 0 .342 
Head or neck injury 18 2 6 14 9 6 10 17 36 38 <.001 
Psychiatric disorders 56 16 7 16 20 14 9 15 20 21 .316 
Seizures 6 2 0 0 3 2 1 2 2 2 .884 
Stroke 5 2 2 5 1 1 0 0 2 2 .176 
Terminal illness 2 1 1 2 1 .1 0 0 0 0 .211 
7.5.3 Health-related quality of life, temperament, coping and social support. 
The central tendencies and comparisons across the groups for the psychological data 
are shown in Table  7.4.  These results are discussed under the separate headings that follow. 
Scores of the TPQ are shown for the four separate categories. The maladaptive coping 
strategy of catastrophizing is not prominent, with the mean score for the PCS at 4.264 SD = 
4.269 for the full sample. The highest score possible here is 20. The index for amount of 
social support in the full sample is 4.029 SD = 1.753. The highest possible score for this index 
is 9. Though the amount of social support perceived by the groups does not differ 
significantly, there are significant differences in terms of HRQOL, HA and the PCS 4 Item 
score. 
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Table  7-4: Means, standard deviations and comparisons across groups of psychological data 
Variable Total sample   
(N = 341) 
Group 1  
(n = 44) 
Group 2  
(n  =  143) 
Group 3  
(n = 60) 
Group 4  
(n = 94) 
p 
M SD M SD  M SD M SD M SD 
SF-12 Index .731 .126 .743 .149 .763 .112 .718 .132 .687 .117 < .001 
NS 14.557 5.541 14.023 4.901 14.126 5.721 15.7 5.646 14.734 5.444 .121 
HA 14.815 7.599 12.25 6.613 13.511 7.163 16.45 7.425 16.957 8.091 < .001 
RD 17.434 4.644 17.523 5.781 17.161 4.442 17.583 4.077 17.713 4.747 .802 
P 5.821 1.908 5.728 2.336 5.664 1.8 5.75 1.772 6.149 1.923 .117 
Pain coping Scale 4.264 4.269 6.429 6.272 2.210 2.868 5 4.17 6.596 4.316 < .001 
Amount of social support (index) 4.029 1.753 3.957 2.054 4.288 1.810 3.886 1.826 3.761 1.408 .187 
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7.5.4 Health-related quality of life. 
The group with the lowest HRQOL was the MO group (M =.687, SD = .117), 
followed by the possible MO group, then the group that had never experienced a headache. 
The non-MO headache group experienced the highest HRQOL of the four groups (M =.763, 
SD = .112).  
Significant differences were found between the four groups on HRQOL (p < .001). 
Post-hoc Dunn’s testing with Bonferroni correction showed significant differences between 
Group 1 (never experienced a headache) and Group 4 (those with MO) (p = .035) and 
between Group 2 (non-MO headache sufferers) and Group 4 (p < .001).  Thus, the MO group 
had significantly poorer HRQOL than both non-migraine groups, but not significantly 
different HRQOL from the possible MO group. 
7.5.5 Temperament and coping. 
Significant differences were found between the four groups on HA and PCS (p < 
.001). Post-hoc Dunn’s testing with Bonferroni correction was conducted. This showed the 
significant differences on HA to be between Group 1 (never experienced a headache) and 
Group 3 (possible MO) (p = .022); between Group 1 and 4 (those with MO) (p = .003); and 
between Group 2 (non-migraineurs) and 4 (p = .007). HA is highest amongst those with MO 
(M = 16.957, SD = 8.091) and was closely followed by HA amongst possible MO sufferers 
(M = 16.45, SD = 7.425), without significant difference between the two groups. Pain coping 
scores differed significantly between Group 1 and 2 (p = .034), Group 2 and 3 (p < .001) and 
between Group 2 and 4 (p < .001). The migraineurs thus employ the maladaptive coping 
strategy of catastrophizing significantly more than those not suffering from MO. 
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7.6 Correlations 
Correlations were calculated using Spearman’s rho and controlling for language, sex, 
frequency of alcohol intake and head or neck injury (see Figure  7-1). Significant correlations 
with small effect sizes (Cohen, Manion, & Morrison, 2011) were found between HA and 
Catastrophizing (rs = .222, p < .001) and the Amount of social support and Catastrophizing (rs 
= -.176, p < .001). A significant correlation with moderate effect size is seen between HA and 
the Amount of social support (rs = -.307, p < .001). 
A small effect size is also seen in the significant correlation between the Amount of 
social support and HRQOL (rs = .210, p < .001). This shows that more perceived social 
support increases HRQOL. HA is also significantly correlated with HRQOL (rs = -.390, p < 
.001), indicating that the higher the HA, the lower HRQOL. The effect size is moderate. The 
significant correlation between HRQOL and maladaptive pain coping (Catastrophizing) 
approaches a large effect size (rs = -.414, p < .001). This shows that lower use of 
catastrophizing is related to better HRQOL.  
    
 
 
 
 
 
 
 
 
Figure  7-1: Correlations between psychological variables (N = 341) 
*All correlations controlled for sex, language, frequency of alcohol intake and head or neck injury; all significant 
at p < .001 
rs = .210 
rs = -.414 
rs = -.176 
rs = -.390 
HA 
Catastrophizing 
Amount of social support 
HRQOL 
rs = .222 
rs = -.307 
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7.7 Predicting health-related quality of life  
The potential relationship between temperament, neurotransmission profile, coping strategy 
and perceived social support was explored. The analysis was directed at understanding which 
variables could significantly account for variance in HRQOL. Neurotransmission is only 
examined in the next chapter. 
7.7.1 Linear regression. 
In order to determine whether HRQOL could be predicted using the psychological 
data, regression analysis was conducted. Before conducting the regressions, the following 
assumptions were checked: (i) Linearity, (ii) normal distribution of the residuals, (iii) 
homoscedasticity (Field, 2013).  As indicated in Table  7-5, the correlations between HRQOL 
and the three potential predictors are significant even when not correcting for those variables 
presented in in section 7.8.3. The correlations between Catastrophizing and HRQOL and HA 
and HRQOL are moderate, while the correlation between HRQOL and the amount of social 
support is weak. Nevertheless, the correlations do indicate a linear relationship between the 
variables, which satisfies the first assumption.  
Table  7-5: Correlations between HRQOL, pain coping, social support and temperament  
 SF-12 Index Statistic Catastrophizing Amount of Social support HA 
r -.436 .171 -.412 
p .000 .002 .000 
N 311 340 341 
 
Q-Q plots were generated for HRQOL, Catastrophizing, Amount of social support and 
HA. Visual inspection of the graphs showed good fit. The non-parametric Levene’s test for 
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non-normal distribution was used to determine homoscedasticity. The result was significant (p 
< .001), indicating that the third assumption was met for this data.  
Power was explored using the G*Power software 
(http://www.gpower.hhu.de/en.html). For medium effect size, a sample of 77 would have 
been required, thus the sample is sufficient for this regression. 
The 30 participants that never experienced a headache were excluded from analysis. 
Outliers were identified using cut-off scores for Mahalanobis, Cook’s and Leverage. Two 
cases were outliers for two of the three calculations and were excluded from mediator and 
moderator analysis.  
Aside from the several assumptions examined before linear regression was used, there 
are a few more assumptions to be tested in order to decide if a model can be generalised 
beyond this sample. These are (iv) Errors must be independent, (v) There should be no perfect 
multicollinearity (vi) Variables must be quantitative and the outcome variable must be 
continuous (Field, 2013). Independence of errors was investigated using the Durbin-Watson 
test. The Durbin-Watson statistic was 1.746, which indicates that error terms are independent. 
Tests of multicollinearity were below 2, indicating that multicollinearity is not a problem. The 
variables used in the regression are all quantitative and HRQOL as measure on the SF-12 
Index is a continuous variable. Therefore the regression model is potentially generalizable 
outside of this sample.  
Hierarchical regression was utilised to control for the effect of sex, language, 
frequency of alcohol intake and head or neck injury.  Regressions were run with HRQOL (SF-
12 index) as the dependent variable (Models 1 and 2). The results are shown in Table  7-6.  
The model explained 29% of the variance in HRQOL scores,  R2 = .292, F(3, 301) = 
37.130, p < .001. Although HA and Catastrophizing both contributed significantly to the 
model (p < .001), social support did not (p = .232). 
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Table  7-6: Summary of the hierarchical regression analysis for variables predicting 
health-related quality of life with regression coefficients (beta weights), proportions of 
variance accounted for (adjusted R2) and changes in R2 (Δ R2 ) with SF-12 Index scores 
as dependent variable (n = 308) 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t p 
β Std. 
Error 
β 
1  HRQOL as dependent variable            
Sex -.048 .018 -.154 -2.751 .006 
Language -.004 .003 -.073 -1.301 .194 
Head injury .041 .017 .136 2.422 .016 
R2 .039 
Δ R2  .048 
2 HRQOL as dependent variable             
Sex -.022 .016 -.069 -1.390 .166 
Language -.003 .003 -.042 -.871 .385 
Head injury .028 .015 .090 1.860 .064 
Catastrophizing -.010 .002 -.337 -6.685 .000 
Amount of 
Social support 
.004 .004 .061 1.197 .232 
Harm avoidance -.005 .001 -.293 -5.607 .000 
R2 .292 
Δ R2  .257 
 
7.7.2 Mediation and moderation effects. 
Mediation and moderation were investigated using the Hayes’ Process Model (Hayes, 
2013). The tool provided by Hayes was downloaded and used in SPSS. Sex, frequency of 
alcohol intake, head and neck injury and home language were used as covariates in all 
calculations to control for possible effects. 
Moderation effects (Process Model 1) were investigated using catastrophizing as the 
outcome, with HA as the predictor and average headache pain severity, amount of social 
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support, headache frequency and medication overuse as potential moderators. No significant 
moderation effects were found. 
Mediation effects (Process Model 4) were investigated for the relationship between 
HA and Catastrophizing, testing average headache pain severity, amount of social support, 
headache frequency, frequency of alcohol intake and medication overuse as possible 
mediators. Only partial mediation effects were noted. A summary of the mediation effects is 
shown in Table  7-7. 
 
Table  7-7: Summary of results for the mediation analyses for the prediction of 
Catastrophizing by Harm avoidance 
Mediator Partially standardized 
indirect effect 
Completely standardized 
indirect effect 
z p 
β Standard error β Standard error 
Headache pain intensity .006 .003 .046 .020 2.019 .043 
Headache frequency .008 .003 .062 .022 2.799 .005 
Amount of social support .009 .004 .066 .031 2.281 .023 
 
 Average headache pain severity. 
In the first step of the mediation model, HA significantly predicted average headache 
pain severity, b = .396, t(300) = 2.051, p = .041. The average headache pain severity 
significantly predicted Catastrophizing, b = .092, t(299) = 12.661, p < .001. The third step of 
the mediation was the regression of HA on Catastrophizing, controlling for average headache 
pain severity, and this was also significant b = .071, t(299) = 2.679, p = .008. The regression 
of HA on Catastrophizing was however still significant when not controlling for the mediator, 
b = .108, t(300) = 3.347, p = .001. The Sobel test did confirm a partial mediation effect, 
though (z = 2.019, p = .043). 
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 Headache frequency. 
HA significantly predicted headache frequency, b = .046, t(300) = 3.412, p = .001. 
Headache frequency significantly predicts Catastrophizing, b = .794, t(299) = 5.099, p < .001. 
The third step of the mediation was the regression of HA on Catastrophizing, controlling for 
headache frequency, and this was also significant b = .073, t(299) = 2.353, p = .019. As 
previously reported, this relationship remained significant when not controlling for the 
mediator, though. The Sobel test again indicates a partial mediation effect for headache 
frequency (z = 2.799, p = .005). 
 Amount of social support. 
HA significantly predicted the Amount of social support, b = -.073, t(300) = -6.147, p 
< .001. Amount of social support significantly predicted Catastrophizing, b = -.346, t(299) = -
2.488, p = .013. The third step of the mediation was the regression of HA on Catastrophizing, 
controlling for headache frequency, and this was also significant b = .082, t(299) = 2.417, p = 
.016. Once again, this relationship remained significant when not controlling for the mediator, 
though. The Sobel test again indicates a partial mediation effect for headache frequency (z = 
2.281, p = .023). 
The results of the hierarchical regressions and mediation analyses were combined to 
form a single figure. The resulting model is depicted in Figure  7-2. Though the figure 
represents a potential path diagram for HRQOL in MO, path analysis was not conducted as 
there were insufficient MO cases to justify such analysis (Kline, 2011).
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Figure  7-2: Model summary for regression analysis predicting HRQOL when controlling for sex, head and neck injury and language.  Red 
indicates the outcome variable, yellow the original predictors and blue the emergent partial mediators. Numbers are standardized beta coefficients, 
significant at p < .05. I represents the indirect effect. 
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7.8 Conclusion of Chapter 7  
Over a year, 341 adult residents of Gauteng Province, South Africa completed the 
survey of headache symptoms, temperament, pain coping and social support. A total of 154 
(46%) met the criteria for MO or possible MO. Home language and sex emerged as 
significantly different between those with MO or possible MO and those without. HA and the 
pain coping strategy of catastrophizing were significant predictors of HRQOL, even when 
controlling for sex, language, frequency of alcohol intake and head or neck injury. 
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Chapter 8:  Results of Phase 2 
The data from phase 2 of the study are presented in this chapter. This begins with 
attrition rate, which is followed by the comparisons between the migraine without aura (MO) 
and non-migraine participants (NM) groups. The comparisons of the two groups (on 
demographic and health variables) were conducted for two reasons: To establish whether or 
not the subsets differed significantly from the larger sample (N = 341) and to determine if the 
serum glutamate subset (n = 66) differed significantly from the transporter expression subset 
(n =20). This was necessary for determining if the results from the studies of the two subsets 
were generalizable to the larger study. The phase 2 data were then used to determine the 
contribution of biological predictors to health-related quality of life (HRQOL) in MO.   
8.1 Data collection for Phase 2 
Of the 341 participants that completed the survey, 164 granted permission to be 
contacted for the collection of blood. Invitations were sent via e-mail to these participants to 
inform them of the details of specimen collection. Follow ups were made via e-mail, SMS and 
telephone between October 2015 and February 2016. Of these 164 participants, eight 
withdrew because of poor health and two had relocated to other countries.   
Participants reported once-off for blood collection over a period of five months. 
Participants could choose to visit one of four Ampath depots for collection or to have the 
phlebotomist come to place of employment. A total of 66 participants (19%) donated blood. 
The high attrition could not be accurately accounted for as 10% of the missing 98 participants 
did not reply to any form of contact. A detailed discussion of the possible reasons for this 
outcome is undertaken under the section on methodological limitations in Chapter 9.  
The 66 participants were divided into two groups: NM (n = 23) are those participants 
that do not meet the criteria for MO (people that have never experienced a headache and those 
whose headaches do not meet at least three of the ICHD-II criteria for MO, as explained in 
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chapter 7) and the MO group (made up of participants that met either the criteria for MO or 
possible MO, according to the ICHD-II criteria, n = 43). Concentration of serum glutamate 
was examined in all 66 participants’ samples. All 66 samples underwent the RNA extraction. 
However, only 26 samples yielded results from the SLC1A2 expression analysis (this attrition 
was due to quality control steps and is explained in Chapter 6 under the section on transporter 
analysis). Six of the 26 SLC1A2 samples yielded differences in Ct values for the reference 
and target genes less than six, which suggested a problem with contamination (Qiagen, 
2011a) and these were therefore omitted. Given that the psychological, ELISA and qPCR data 
were gathered on different sized groups, it was important to examine the demographic, health 
and psychological data for varying patterns at each stage.  
8.2 Demographic differences between the migraine without aura and non-migraine 
participants groups  
The NM and MO groups were compared for significant differences on age, home 
language, sex, heredity, employment and frequency of alcohol intake.  No significant 
differences were noted in either the ELISA (n = 66) or the qPCR study (n = 20). It can be 
inferred therefore that the sub-samples are similar to one another. However, the significant 
differences between MO and NM groups that were seen in the larger sample (n = 341) are not 
reflected in these sub-samples: The larger sample (n = 341) showed significant differences 
regarding the distribution of home language (p = .035) and sex (p = .001). This does suggest 
that the results of the smaller sample studies should be interpreted cautiously when making 
inferences about the larger sample. 
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8.3 Health differences between the migraine without aura and non-migraine 
participants groups 
The two groups were compared against one another for differences in their physical 
and psychological health histories. They were also compared on the health indicators of 
fasting glucose, total cholesterol and intrinsic clotting efficiency.  
The only significant difference on medical / psychological history was noted with the 
previous diagnosis of headache disorders (p = .025), in which the MO group had 18 previous 
diagnoses and the NM group only four (n = 66). This differs from the results of the group 
comparisons of the larger sample (n = 341) in which a significant difference was only seen 
with respect to head and neck injuries (p < .001). Once again, this indicates that some caution 
should be exercised when trying to generalise the smaller sample results to the larger sample.  
Table  8-1 shows the medical screening data for the two groups. The groups did not 
differ significantly on fasting glucose, total cholesterol or clotting indicators. 
 
Table  8-1: Fasting glucose, total cholesterol, intrinsic clotting and serum glutamate 
levels of the migraine without aura (n = 43) and non-migraine participants groups (n = 
23) 
 MO (n = 43) NM (n = 23) P 
M SD Mdn M SD Mdn 
Fasting glucose (mmol/l) 5.291 
 
.798 
 
5.1 5.33 .773 5.2 .762 
Total cholesterol (mmol/l) 5.023 0.974 4.900 5.048 0.896 5.100 
 
.666 
Clotting (aPTT ratio) 0.958 
 
0.103 
 
1.000 
 
0.952 
 
0.090 
 
1.000 
 
.762 
Serum glutamate (µg/ml) 23.719 17.649 18.440 26.582 15.948 21.935 .933 
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8.4 Biological variables selected for predicting HRQOL 
The two biological variables selected as potential predictors of HRQOL in this study 
were serum concentration of glutamate and the level of expression of glutamate’s main 
transporter, SLC1A2. The study of serum glutamate concentration was conducted on 23 
controls and 43 MO participants. The SLC1A2 qPCR yielded data for five NM and 15 MO 
participants.  
8.4.1 Glutamate concentration. 
Glutamate concentration for the sample (n = 66) was within the normal range for 
healthy people (Abnova, n.d.) at 24.718 µg/ml (Mdn = 18.755, SD = 17.007 µg/ml). Table  8-2 
shows the central tendency data for the two groups. The NM have higher glutamate levels 
than the MO group. However, there was no significant difference between the two groups on 
glutamate concentration (p = .933).  
8.4.2 SLC1A2 expression. 
Figure 8-1 shows the median Ct values for normalized SLC1A2 expression for the two 
groups. The expression of SLC1A2 is higher amongst the NM. However, the difference in the 
Ct values between the two groups is not statistically significant (p = .168).  
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Figure 8-1: Relative expression of SLC1A2 of the migraine without aura (n = 15) and NM 
groups (n = 5) 
 
8.5 Correlation analysis 
Table  8-2 shows the correlations for the smaller study. Only the relationships to 
HRQOL were examined: The correlations remain significant (as they were for the larger 
sample, N = 341) and in the same directions for HA and HRQOL (r = -.414, p = .001), 
Catastrophizing on the Pain Coping Scale and HRQOL (r = -.380, p = .002) and the amount 
of social support and HRQOL (r = .290, p = .018).  No significant correlations were seen with 
the glutamate ELISA and qPCR data and any of the psychosocial variables. There were also 
no significant correlations seen between the ELISA and qPCR data.  
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Table  8-2: Correlation matrix for psychosocial and biological variables (n = 66 except 
for SCL1A2 where n = 23) 
    NS HA P RD SF-12 Index 
Pain 
coping 
Scale 
Amount 
of social 
support 
(index) 
Serum 
glutamate 
concentration 
SLC1A2 
(fold 
change) 
NS 
r 1 -.101 -.16 .149 -.037 .223 .069 .003 .159 
p   .418 .2 .233 .766 .081 .579 .982 .503 
HA 
r -.101 1 -0.014 .084 -.414** .229 -.325** .101 -.003 
p .418   0.913 .503 .001 .073 .008 .421 .99 
P 
r   -.014 1 .529** -.012 .007 .014 -.143 -.032 
p   .913   0 .925 .959 .913 .251 0.895 
RD 
r     .529** 1 -.114 .106 .098 -.053 -.391 
p     0   .36 .411 .433 .67 .89 
SF-12 Index 
r       -0.114 1 -.380** .290* -.016 .142 
p       0.36   .002 .018 .896 .055 
Pain coping 
Scale 
r         -.380** 1 -.301* .164 -.026 
p         .002   .017 .203 0918 
Amount of 
social support 
(index) 
r           -.301* 1 .025 -.276 
p           .017   .843 .238 
Serum 
glutamate 
concentration 
r             .025 1 .144 
p             .843   .544 
SLC1A2 (fold 
change) 
r               .144 1 
p               .544   
 
8.6 Regression analysis  
Power was explored using the G*Power software. Unfortunately, the small sample (n 
= 66) is not sufficient to detect an effect size at anything above power of .14 for regression. 
No regression analysis was therefore conducted. 
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8.7 Conclusion of Chapter 8 
A set of participants (n = 66) chose to supply blood specimens for analysis for phase 2 
of this study. Examination of serum glutamate concentration via ELISA showed that there is 
no significant difference between MO and NM participants in the amount of glutamate 
detectable in their serum. In addition, the qPCR analysis of 26 of the participants also did not 
yield significant group differences. The psychological data did not correlate significantly with 
either of these biological data points.  
 
 131 
 
Chapter 9:  Conclusion  
This chapter provides a final, integrated discussion of the most important results of the 
research, as they pertain to the aims and research questions. Briefly, the study aimed to compare 
the health-related quality of life (HRQOL) of migraine without aura (MO) sufferers and NM; to 
explore the association between temperament and pain coping in MO and to examine how 
neurotransmission, temperament, pain coping, perceived social support (with consideration of 
lifestyle factors) contribute to the HRQOL experienced in MO. The three research questions 
addressed were: (i) In what way does the HRQOL of MO sufferers differ from the HRQOL of 
those without MO? (ii) What is the relationship between the harm avoidance (HA) temperament 
category and catastrophizing in MO? (iii) To what extents do temperament, neurotransmission 
profile, coping strategy and perceived social support explain the variance in HRQOL in MO? 
Following the discussion of the main findings, the limitations of the thesis are described in order 
to provide suggestions for future research. The chapter concludes with the contributions of the 
work to research, public health and clinical practice. 
9.1 Comparing health-related quality of life 
From the literature it is clear that answers to the first research question have been pursued 
extensively in Europe, North America and Asia, where migraine is acknowledged as a highly 
incapacitating primary headache disorder (Leonardi et al., 2005; Steiner, Stovner, & Birbeck, 
2013). Sufferers experience intense pain with variable response to medication (Chia, Lim, & 
Wang, 2003). Aside from the pain of the attack, migraineurs also have to cope with the high cost 
of treatment, stigma, absenteeism and the many knock-on effects of these consequences of their 
disorder (Aydemir, Özkara, et al., 2011; Breslau & Davis, 1993b; Katsarava & Andre, 2011). For 
many migraine sufferers there is a significant effect on health-related quality of life (HRQOL) 
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(D’Amico et al., 2015; Dalhof & Dimenas, 1995; Hazard et al., 2009; Hung, Wang, Yang, & 
Liu, 2008; Kolotylo & Broome, 2000).  
HRQOL is recognised as a vital aspect of patient care as the understanding grows that the 
impact of both the illness and the intervention on the individual extends beyond the body to all 
aspects of wellbeing (Addington-Hall & Kalra, 2001). The results indicate significant differences 
between MO participants and NM (p < .001). People that had never experienced a headache and 
those without MO headaches had higher HRQOL on the SF-6 than those with MO or possible 
MO. The MO group thus had significantly poorer HRQOL than non-MO sufferers. These results 
confirm those found in previous studies on migraine and control groups (Aydemir, Özkara, et al., 
2011; Kolotylo & Broome, 2000).  
To further contextualise this lower HRQOL, consider the following: The HRQOL for the 
MO participants in this thesis (indicated by the SF-12 Index score of the SF-6) was M = .687 SD 
= .117. The mean score for a non-institutionalised adults living in the United States of America  
(N = 54 995) ranges from .857, 95% CI  [.851-.862] for those in their 20s to .742, 95% CI [.723 -
.761] for octogenarians (Janel Hanmer, Lawrence, Anderson, Kaplan, & Fryback, 2006). In a 
general population study in Greece (N = 1005), the mean SF-6 score was .759, 95% CI [.750 - 
.768]. Meanwhile, a Brazilian study (N = 5000) showed that the mean SF-6 score was .82 SD = 
.15. The MO score in this thesis was well below the American, Greek and Brazilian data, which 
is not unexpected for a disorder that is known to impact so many aspects of well-being 
(Aydemir, Ozkara, et al., 2011; Dalhof & Dimenas, 1995; Leonardi et al., 2010; Martin et al., 
2000). 
However, what was not expected was the severity of the impact of MO. The HRQOL for 
people with MO is more comparable with the data from British liver transplant patients 12 
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months post-transplant M = .615, 95% CI [.570 - .652] (Longworth & Bryan, 2003); Dutch post-
coronary artery bypass graft (CABG) patients M = .62 (SD not reported) (Stel & Buskens, 2006); 
or even Japanese people (N = 1143) older than 70 years M = .674 SD = 0.137 (Shiroiwa et al., 
2015).  
There are a number of implications of these findings. First and foremost, they raise 
concern about the amount of suffering Gauteng MO patients are subjected to in their daily lives. 
When exploring the components of HRQOL one is reminded that poor HRQOL translates into 
difficulties negotiating many aspects life, including physical and social activities, emotional 
regulation, pain and mental health (Ware, 2004; Ware & Sherbourne, 1992).   
If MO has such a profound and pervasive effect on an individual’s daily life, the effects 
on the individual’s other related systems are likely to be significant as well. The effects of 
migraine on family, work and socio-economic spheres were highlighted in Chapter 1: Migraine 
causes great strain on the spousal and parental subunits and can disrupt daily family life very 
severely, even contributing to divorce or separation (Lipton et al., 2003; Smith, 1998). Migraine 
sufferers are less productive at work and are frequently absent form their jobs because of 
migraine symptoms (Gerth et al., 2001; Lantéri-Minet et al., 2003; Lipton & Bigal, 2005; 
Osterhaus et al., 1992; Rasmussen et al., 1995; Rasmussen, 1995; Unger, 2006; Shuu-jiun Wang, 
2003). Furthermore, the monetary costs of migraine runs into billions of dollars in the United 
States and billions of Euros in Europe (Linde, 2006; Norton et al., 1999).  
All clinicians would do well to assess each patient’s perception of their HRQOL and to 
examine which aspects of the MO sufferer’s life would benefit from intervention.  The level of 
intervention for migraine therefore needs to be extended beyond medical treatment to include 
family therapy (Payne & Norfleet, 1986; Rosenstock & Cambor, 1979) and more practically-
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focused psychoeducation and occupational therapy interventions - none of which appear to be a 
frequently offered option for MO patients, judging from the lack of peer-reviewed publications 
on such interventions.  
9.2 Predictors of health-related quality of life in migraine without aura 
For migraine researchers such as Kröner-Herwig, Morris, and Heinrich (2008), Martin 
(2007) and Newton (2008) there is particular usefulness in approaching migraine questions from 
a biopsychosocial perspective. The biopsychosocial approach allows the integration of a number 
of potential HRQOL determinants into a single project within a coherent framework. Thus, the 
biopsychosocial approach was considered a pragmatic approach to attempting to answer the 
questions about predictors of HRQOL in migraine and this thesis was framed in this 
biopsychosocial approach. 
In examining the role(s) of temperament, perceived social support, pain coping and 
glutamate in MO HRQOL, the researcher tried to discern the pattern of how the genomic, 
molecular, cognitive, emotional and behavioural may interact to allow one individual suffering 
immense pain to enjoy a high HRQOL, while another might not. 
As discussed in Chapter 2, one of the challenges of this biopsychosocial study of 
migraine was that there are neither psychological, nor biological markers for migraine. However, 
neither biomarker , nor psychological candidates are in short supply (Abbate-Daga et al., 2007; 
Loder et al., 2006; Mongini, Fassino, et al., 2005; Sánchez-Román et al., 2007; Tietjen et al., 
2010b), which complicated the choice of factors to investigate in this study. In the biological 
study of migraine, glutamate is purported to be a major player in migraine pathogenesis, though 
the mechanism is still under investigation (Anttila et al., 2010; Cananzi, D’Andrea, Perini, 
Zamerlan, & Welch, 1995;  Ferrari, Spaccapelo, Pinetti, Tacchi, & Bertolini, 2009; Párdutz et al., 
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2012; Schürks, 2012). Five major themes emerged from the psychologically-directed research 
into migraine: Temperament, parent-child relationships, adverse early life events, stress and 
coping. The connection between glutamate and psychological aspects of behaviour, cognition 
and emotion became evident through Cloninger’s Psychobiological Model of Personality. As 
explained in Chapter 2, the temperament dimensions proposed by Cloninger are underpinned by 
four neurotransmitter systems - one of which is glutamate (Conrad et al., 2007; Hansenne et al., 
1999; Mongini, Keller, Deregibus, Barbalonga, & Mongini, 2005).  
As discussed in Chapter 4, there are numerous factors that can contribute to and detract 
from HRQOL in any disorder (Carod-Artal et al., 2009; Ho et al., 2010; Nestvold & Stavem, 
2009; Ordu Gokkaya et al., 2012; Ritsner et al., 2006; Tajvar et al., 2008; Vilhena et al., 2014). 
Various predictors of HRQOL in MO (Lucas et al., 2006; Santanello et al., 2002) have also been 
proposed, including glutamate (Andreou & Goadsby, 2011; Freilinger, Anttila, Vries, & Malik, 
2013), temperament (De Filippis et al., 2008), pain coping (Abbate-Daga et al., 2007; Chiros & 
O’Brien, 2011; Thorn et al., 2007) and social support (Cornish et al., 2009; Pragodpol & Ryan, 
2013), which were examined in this thesis.  
Thus, the literature on predictors of HRQOL across various disorders and then in 
migraine specifically revealed some overlap with psychological aspects of migraine research. In 
particular, temperament and coping (including social support) were foregrounded (Abu Bakar et 
al., 2016; Chang, 2004; Cornish et al., 2009; Pragodpol & Ryan, 2013; Sales et al., 2014). This is 
discussed in detail in Chapter 4. Thus, the focus of the thesis settled on how HRQOL in MO 
might be affected by glutamate, temperament, coping and social support.  
HRQOL was significantly correlated with all three psychological variables (p < .05), but 
with neither of the biological variables. The correlations between HRQOL and Catastrophizing 
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(r = -.436, p < 0) and HRQOL and HA (r = -.412, p < 0) are both moderately strong. This 
suggested that HRQOL would be decreased significantly if the MO sufferer has high HA or high 
catastrophizing tendencies. The weaker correlation between HRQOL and social support (r = -
.171, p = 0.002) suggested that HRQOL could be increased if a MO sufferer has the perception 
of having more social support. Essentially, the perception of a higher level of social support may 
improve the outlook for a MO patient.  
Significant predictors were found for HRQOL when controlling for sex, head and neck 
injury, frequency of alcohol intake and language. These two predictors are HA and 
Catastrophizing. The results of the regression analyses (mediation and hierarchical regressions) 
are depicted in Figure  7-2. The hierarchical regression model only accounts for 29% of the 
variance in HRQOL. In their study of 247 American women with migraine, Kolotylo and 
Broome (2000) showed that the chronicity of the pain, presence of depressive symptoms and the 
intensity of the headache pain accounted for 63% of the variance in HRQOL of the participants. 
Other researchers have also reported a central role for psychiatric disorders (Breslau & Davis, 
1993b; Finocchi, Villani, & Casucci, 2010; Napolitano, 2008) in the HRQOL of migraine 
sufferers. This suggests that the addition of one or more psychiatric symptoms to the regression 
may be worthwhile.  
9.2.1 The migraine personality revisited. 
As discussed in Chapter 2, the maladaptive coping strategy of Catastrophizing is a 
prominent feature of the psychological functioning of people suffering from migraine (Abbate-
Daga et al., 2007). Though it is difficult to infer causality from the available literature, it is 
possible to deduce at the very least that temperament has a role to play in how people with MO 
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develop Catastrophizing as a pain coping strategy (Compas, Connor-Smith, & Jaser, 2004; 
Hachaturova, 2010; Rueda & Rothbart, 2009).  
Previous studies have highlighted the association between harm avoidance (HA) and 
migraine (Mongini, Fassino, et al., 2005; Sánchez-román, Téllez-Zenteno, Zermeño-phols, 
García-Ramos, & Guevara-López, 2007). This thesis confirms that HA is a feature of the MO 
sufferer’s psychological makeup. In Chapter 7 the MO group not only displayed significantly 
higher HA scores than non-MO participants, but HA was significantly correlated with 
Catastrophizing  (rs = .222, p < .001). These results are interpreted with some caution as the 
effect size is small (Cohen, Manion, & Morrison, 2011).  
HA is associated with traits such as worry, social shyness, pessimism and fatigability 
(Richman & Frueh, 1997). According to Conrad et al. (2007), HA in pain can be explained by 
the Fear-Avoidance model, which posits that individuals that are highly fear-avoidant will 
interpret pain in a catastrophic manner. This leads the individual to try and behave in ways that 
will result in circumvention of the pain. Unfortunately, these actions are ineffective and 
ultimately only worsen the pain. Moreover, pain sufferers that are highly harm avoidant also 
exhibit decreased pain thresholds and tend to rate their pain more intensely than those with lower 
HA (Park, Han, & Yang, 2006). When an individual has a heightened perception of pain as a 
threat to well-being, then she is more likely to evaluate the pain more negatively and to employ 
more passive coping strategies (Jackson, Wang, & Fan, 2014). Passive coping strategies are 
defined as maladaptive strategies, in which persons experiencing the pain allows the pain to 
affect their lives adversely or permit someone else to take over their roles and functions in 
response to pain (Jackson et al., 2014). This can include catastrophizing about pain.  
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Catastrophizing is seen as an exaggerated negative cognitive set toward pain in which a 
person will ruminate about the pain, magnify its significance and believe that he or she is 
helpless in relation to the pain (Lake, 2009). Thus, despite efforts to avoid pain, the highly HA 
individual has an exaggerated sense that any pain experience will be overwhelming (Sullivan et 
al., 2001). According to Sullivan et al. (2001) pain catastrophizing is consistently also  associated 
with increased pain experience. This interaction represents a reciprocal relationship between HA 
and Catastrophizing.  
Harm avoidance and Catastrophizing. 
The preceding discussion answers the third research question about the variables 
involved in predicting HRQOL, but what about the specific relationship between HA and 
Catastrophizing that formed the second research question? When exploring this HA and 
Catastrophizing relationship in more detail, it was noted that, though the two were significantly 
correlated in this study when controlling for language, sex , frequency of alcohol intake and head 
or neck injury the relationship was weak (rs = .222, p < .001). This relationship is partially 
mediated by how subjectively intense the headache pain is, how frequently the MO occurs and to 
how much social support the MO sufferer believes he or she has access. MO sufferers receiving 
adequate social support and experiencing fewer and less painful headaches are less likely to 
catastrophize their pain even if they have a high HA.  
In Chapter 2 social support in migraine was discussed, while the potential role of social 
support in HRQOL was discussed in Chapter 4.  Literature shows lower levels of satisfaction 
with perceived social support in migraineurs versus controls  (Martin & Soon, 1993) and the 
importance of social support for mitigating the negative effects of migraine on HRQOL (Vos & 
Passchier, 2003). The effects of social support on migraine are sparsely documented, but studies 
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into chronic pain strongly suggest that social support can help decrease the psychological 
implications of the headaches, such as stigma and embarrassment (Davison, Pennebaker, & 
Dickerson, 2000), while also decreasing the level of acute pain experienced (Montoya, Larbig, 
Braun, Preissl, & Birbaumer, 2004; Montoya, Pauli, Batra, & Wiedemann, 2005) 
 Although social support did not emerge as a predictor HRQOL, it emerged as a partial 
mediator in the relationship between HA and Catastrophizing. These results suggest that the 
relationship between HRQOL and social support may be more indirect than previously thought. 
Martin and Soon (1993) suggest that more psychosocial elements of migraine require 
investigation. These could include aspects of religion, spirituality, sense of community or 
workplace satisfaction (Ben-Arye, Bar-Sela, Frenkel, Kuten, & Hermoni, 2006; Cohen & 
Koenig, 2003; Marks, 2010; Truchon & Fillion, 2000). The use of only one aspect (number of 
people available for supplying social support) of the Social Support Questionnaire (SSQ6) may 
have contributed to a limited exploration of social support and future studies should rather 
investigate both density of (number) and satisfaction with social support. Given the results of this 
thesis, more aspects of social support should be investigated not only for their direct effects on 
HRQOL in MO, but also for potential mediation and moderation of variables. 
It is also noted that the pain experienced by the individual with MO and frequency of 
these headaches may play key roles in the relationship between HA and Catastrophizing in MO 
alongside social support. One interpretation of this finding is that limiting pain will limit the 
tendency to catastrophize – even if one has a high level of HA. Once again, patients may benefit 
from assessment of these constructs by their clinicians. While pain frequency and intensity are 
likely to be assessed at most visits to a medical practitioner, assessment of social support, 
temperament and coping mechanisms are not standard. While a review of the instruments 
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available for such assessments are beyond the scope of this study, there are short questionnaires 
available to measure temperament, social support and coping, including those utilised in this 
study. 
 
9.3 What about glutamate and SLC1A2? 
Perhaps the most surprising results for this thesis materialised from the biological data: 
Neither serum glutamate concentrations, nor relative expression of SLC1A2 differed 
significantly between MO and NM. The increasing amount of literature implicating glutamate in 
pain and in MO, which was reviewed in Chapter 2 (Alam et al., 1998; Andreou & Goadsby, 
2011; Cananzi, D’Andrea, Perini, Zamberlan, et al., 1995; Ferrari et al., 1990; Lampl et al., 
1999; Ramadan, 2003; Vikelis, 2007) could not be substantiated in this thesis. 
 These results are contrary to the expectation that MO sufferers would have higher 
glutamate levels than NM, contradicting the previous findings of differences in glutamate 
concentrations between migraine and control participants in plasma or CSF (D’Andrea & Leon, 
2010; Vaccaro et al., 2007). Though the differences were not significant, the serum glutamate 
concentrations were actually higher amongst the NM (n = 23) than amongst the MO (n = 43) 
participants.  
The differences across groups may simply not have been detected because of the small 
sample for the biological variable measures. On the other hand, the results may be another 
indication that glutamate is a more prominent feature of MA than MO (Pietrobon, 2005). 
However, this research made use of serum for the ELISA, whereas other researchers have found 
differences in plasma and CSF (D’Andrea & Leon, 2010; Ferrari, Spaccapelo, Pinetti, Tacchi, & 
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Bertolini, 2009; Mallolas et al., 2006), which  could account for the differences in these 
observations. 
The differences in glutamate concentration between the various sample sources could be 
due to a variety of factors and there are numerous considerations for choosing serum or plasma 
in analyses (Lundblad, 2008). The difference in results between this thesis and other publications 
indicates that further understanding is required of the release of glutamate in the clotting process.  
It may be more efficient to avoid serum glutamate analysis in future studies in favour of plasma, 
platelet or CSF. Serum glutamate levels may not be a suitable target for biomarker studies for the 
same reason. The plasma concentration of amino acids is well-correlated with, for example, 
nutritional status (Fadel et al., 2014) and is probably a more sensitive peripheral indicator of 
amino acid neurotransmitter concentration. 
Though SLC1A2 expression was also not significantly different between the MO and 
NM, the transporter is more highly expressed in NM than in MO participants (p = .168).  This is 
an interesting finding that should be explored further in a larger sample. Upregulation of 
SLC1A2 has been purported to play a protective role in glutamate excitotoxicity (Kanai & 
Hediger, 2003), indicating its potential value in therapeutic intervention in ischeamia.  The 
implication of this finding is that it may be the efficiency of the glutamate cycle that determines 
allodynia and hyperalgaesia in MO. The understanding of the mechanisms behind allodynia and 
hyperalgaesia is constantly evolving and further work in this field is warranted with respect to 
migraine and the role of SLC1A2 in these processes.  
9.4 Occurrence of migraine without aura  
Although establishing the MO occurrence for Gauteng was not an aim of the thesis, it 
was an important by-product of the research. In Chapter 1 it was emphasized that prevalence data 
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is lacking for South Africa and so, the occurrence findings of this thesis were considered 
important enough to discuss in the conclusion. 
In Chapter 7, occurrence was calculated by identifying participants that met all four MO 
criteria (criteria A-D) or any combination of three of the criteria (ABC, ABD, ACD or ABD). 
The occurrence of MO was 28% and 18% for possible MO. This is in stark contrast to the 
estimated 10% put forward for South Africa (Green, 2015) and  the 10% reported in another 
African country, Ethiopia (Mengistu & Alemayehu, 2013).  
9.4.1 A word of caution. 
The first point to consider is that the sample is not random and one plausible explanation 
for this high occurrence is interest bias. Generalising of epidemiological findings should 
therefore be done cautiously.  
Though one could speculate that the occurrence is elevated due to the absence of specific 
medical screening for comorbid disorders, self-reporting is an acceptable and widely used 
practice for population-based studies – as discussed in Chapter 2. Examination of participant 
blood tests (in the smaller study) for elevated cholesterol or fasting glucose and abnormal 
clotting profiles, revealed no significant differences between controls and MO participants in 
Chapter 8. This indicates that the MO sufferers were relatively healthy and medical screening 
may not have decreased the MO diagnoses significantly.  
However, the high number of reported previous head injuries is difficult to ignore (46 of 
the 154 MO or possible MO participants). In the case definition put forward for this study in 
Chapter 2, it was explained that the relationship of the head injuries to MO could not be 
established through self-reporting for this research. There is literature to suggest that even mild 
head trauma should be investigated as a possible cause for headaches (Haas, 1996; Theeler & 
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Erickson, 2009). Most importantly for this thesis, the question of post-traumatic headaches has 
implications for the prevalence estimates.  
9.5 Limitations of the study and suggestions for future research 
The limitations of the research are discussed in terms of methodological shortcomings 
and the challenges presented by the processes involved in biopsychosocial research. Proposals 
are put forward for improved studies of this nature. 
9.5.1 Methodological limitations. 
The methodological limitations of this thesis are summarised with respect to its power, 
selection criteria, selection of participants and the choice of measures. These are discussed in the 
following sections and suggestions are put forwarded for future studies. 
Statistical power. 
The limited power of the thesis clear. The ideal would have been a large cohort study in 
which the initial survey sample number could have been sustained to the qPCR analysis stage, 
which would ideally have been substituted for a full gene expression analysis.  
Future studies that do realise a larger sample and that undertake full gene expression 
analysis would require stricter application of the migraine criteria (Wang, Chen, & Fuh, 2010) 
and additionally stringent exclusion criteria.  The aim of such exclusion criteria would be to 
assist in gathering information from a homogeneous sample. Suggested exclusions for future 
research are available in various migraine studies and summarised here: (i) Pregnant and 
lactating women and subjects with bleeding, clotting, terminal or degenerative diseases -  based 
on good practice guidelines for protecting vulnerable subjects (Schwenzer, 2008). (ii) There is 
considerable controversy around the disorder migralepsy and how it is to be diagnosed and 
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classified (Verrotti, Coppola, Fonzo, & Tozzi, 2011). The inclusion of this migraine-triggered 
form of epilepsy would present unnecessary added complexity to data analysis.  (iii) In addition, 
seizure events, whether provoked or spontaneous, can be of numerous origins, some of which 
overlap with other factors being related to the study of migraine study, such as abnormal blood 
sugar levels (Shneker & Fountain, 2003). Seizures may also be related to a history of acute 
neurological insult, which may include head trauma, infections such as meningitis and stroke 
(Shneker & Fountain, 2003). (iv) The relationship between stroke and migraine, although not 
clearly understood, is another potential confounding variable in migraine studies as it represents 
underlying vascular conditions such as vasospasm and arterial stiffness (Viola, Viola, Litterio, 
Buongarzone, & Fiorelli, 2012). (v) It may also be prudent to exclude subjects with 
hypertension: Both paroxysmal and malignant hypertension have been identified as causes of 
migraine (Agostini & Aliprandi, 2008). Although these data remain controversial, there is 
sufficient evidence that hypertension-migraine (Sarchielli, Mancini, & Floridi, 2007) could 
represent a peculiar subtype of the headache disorder. (vi) It should also be a consideration to 
exclude post-menopausal women from such a study as hormonal changes that occur during 
menopause have been implicated in the decreased frequency of migraine in women after the age 
of 50 years (Aegidius, Zwart, Hagen, Schei, & Stovner, 2007), yet the introduction of hormone 
replacement therapies into the life of a postmenopausal woman may have side effects, which 
include the worsening of migraine symptoms (Facchinetti, Nappi, Tirelli, Polatti, & Nappi, 
2002).  
Selection bias. 
Selection bias is a factor limiting this research as the sample was mainly derived from 
Gauteng residents that were educated to tertiary level and had access to the internet. Future 
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studies should include participants further away from the two main cities of Gauteng (Pretoria 
and Johannesburg).  
The selection bias was possibly increased by the decision of many participants not to give 
blood for laboratory assessment.  More time may need to be spent on explaining this aspect of 
the research (Abu-Saad Huijer & Abboud, 2013). It may be particularly useful to improve the 
discussion on the use of genomic data and the collection of blood for participants (Butali et al., 
2015). In this thesis 98 participants stated that they were of African ancestry; only 11 of these 
participants volunteered to donate blood for analysis, which did raise a question about the role of 
history and cultural beliefs in volunteering for research in South Africa. In their research into 
perceptions of voluntariness in medical  research, Barsdorf and Wassenaar (2005) interviewed 
111 members of the South African public. They found that Black participants perceived medical 
research to be a less voluntary process that Indian and White South Africans (p < 0.001). This 
difference was independent of level of education, knowledge of medical research procedures and 
experience of medical research. Barsdorf and Wassenaar point out that it is important for South 
African researchers to bear in mind the historical context of apartheid, the legacy of racial 
mistrust and how this manifests in perceptions of personal agency, alongside factors such as lack 
of values clarification; general public perceptions about medical research and the treatment of 
subjects in developing countries. Though alluded to in Barsdorf and Wassenaar's (2005) 
investigation, the question of cultural beliefs is not explored here. It may be useful for future 
studies to focus on questions of how beliefs can influence participation. Cultural and religious 
beliefs can shape health beliefs, which can influence how people access or approach health 
services – including health-related research (Shavers-Hornaday, Lynch, Burmeister, & Torner, 
1997). Decisions to donate organs (Randhawa, 1998), blood for transfusion (Copeman, 2009; 
 146 
 
Zaller et al., 2005) or relatively small specimens for genetic testing (Wong, Chia, Yam, Teodoro, 
& Lau, 2004) are highly influenced by culture.  
Choice of measures. 
Undoubtedly there is a limitation in the choice of neurotransmitter investigated. 
Cloninger’s theory implicates four major neurotransmitters (Cloninger, Zohar, Hirschmann, & 
Dahan, 2012; Gillespie et al., 2003; Verweij et al., 2010), but this study only examined one 
neurotransmitter. An extension of this research would be to examine the pattern of 
neurotransmission for the other three neurotransmitters (dopamine, noradrenalin and serotonin) 
(Matsumoto et al., 2007; Verweij et al., 2010).  
A further logical extension of the work would be to triangulate data from various 
techniques.  For example, temperament questionnaires other than the Tridimensional Personality 
Questionnaire (TPQ) could be used. Alternatively, normative data for the South African 
population could be established for the TPQ. Such data is already available for a number of other 
countries (Gana & Trouillet, 2003; Hansenne et al., 1999).  
The serum ELISA could be replaced with gold standard quantification techniques such as 
amino acid analysis or LC-MS, while the single gene qPCR investigation could be optimised 
through the use of targeted array analyses (Vallejo-Illarramendi et al., 2006) , or investigations of 
the glutamate-glutamine cycle (Hertz, 2013). 
9.6 Contribution of this study  
Despite its limitations, the thesis does make a valuable contribution to our understanding 
of migraine. As both a clinical and public health concern migraine has to be regarded from both 
epidemiological and clinical practice perspectives if society is to understand sufferers’ needs and 
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plan and evaluate intervention  (D’Amico et al., 2015) and this thesis starts addressing the 
fundamental need for epidemiological data in South Africa, while also exploring some of the 
factors that need to be taken into account for successful treatment. The key contributions of the 
thesis are discussed in terms of the biopsychosocial approach, intervention strategies for 
sufferers and the contributions the work makes to headache research and public health 
knowledge. 
9.6.1 The usefulness of the biopsychosocial approach. 
This thesis makes an important contribution to HRQOL literature through the use of a 
biopsychosocial approach. The work also makes an important contribution to growing literature 
on the integration of biological and psychosocial approaches in the exploration of pain, which 
has been on the increase for two decades  (Norton, Asmundson, Norton, & Craig, 1999; Racine 
et al., 2012). 
Given the relatively new emphasis on biopsychosocial studies of migraine (Kröner-
Herwig et al., 2008; Martin, 2007), this research is an important addition to a growing field. 
Though emphasis on HRQOL is not new in migraine research (Caproni et al., 2015; D’Amico et 
al., 2015; de Velasco & Gonzalez, 2003; Freitag, 2007; Kolotylo & Broome, 2000), the 
biopsychosocial approach is novel. The biopsychosocial approach is considered a useful means 
of making sense of the volume of data already available on MO as it offers researchers the 
chance to put together various iterations of the existing information without necessarily reducing 
the complexity of emerging answers. To paraphrase Gatchel and Turk (2008), this is an example 
of using more complex means to improve understanding of the complex answers that have 
already been gathered. 
 148 
 
Aside from contributing to an improved understanding of MO HRQOL, the use of a 
biopsychosocial approach in this thesis also integrates the research on a number of different 
levels as patient, scientist, molecular and social data are combined to offer various perspectives. 
While more information is not necessarily better, this approach does allow researchers, patients 
and health care providers to triangulate data. Triangulation still remains a powerful means of 
strengthening the reliability and validity of research. 
This research data may be useful to clinicians as it indicates the potential usefulness of 
investigating both biological and psychological aspects of the MO patient’s experience. MO 
sufferers are usually subjected to comprehensive medical examinations that emphasize the 
biological component of the disorder and medical treatments are then suggested accordingly. By 
introducing psychological assessment or even a brief psychological screening, the psychological 
burden of the disorder may be dealt with as well. Clinicians could offer such brief screenings in 
their own practices or refer the patient to a psychologist that works with pain-related disorders. 
Evidence to support the use of psychological assessment to plan treatment is found in the works 
of Martin (2008) and Turner and Houle (2013). The latter provide a useful review of the 
psychological constructs most often associated with headaches, which can help clinicians to 
understand the relationship between biological and psychological aspects of such pain.  
9.6.2 Directions for possible interventions. 
This thesis indicates a clear contribution of pain coping and temperament to MO 
HRQOL. If one turns this information to application in interventions, the results emphasize the 
importance of psychological involvement in managing migraine. A few peer reviewed 
publications have dealt with psychological interventions such as behavioural interventions and 
stress management techniques (Andrasik et al., 2009; Sieberg et al., 2012; Van Eeghem, 2005),  
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but much more work is required for strategies to be more widely accessible for patients and their 
health-care providers.  
Facilitating change in the fearful and avoidant approach to pain that a MO patient may 
employ needs to become a central focus for interventions.  Although temperament is considered 
stable over the lifespan (Calati et al., 2008), researchers acknowledge the potential impact of 
socio-cultural learning on temperaments. It is difficult to recommend specific intervention 
strategies for adjusting temperament, just as it is for changing personality structure. However, 
such interventions are documented (Chanen et al., 2008; Smith Benjamin, 1996). 
This thesis shows that specific interventions for shifting catastrophizing coping 
tendencies are also likely to improve a sufferer’s HRQOL. There is a large body of literature on 
the efficacy of interventions for adults in altering negative cognitive sets, with much of this 
literature focused on behavioural interventions of varying degrees of success (Kjøgx et al., 2016; 
Vranceanu, Hageman, Strooker, Vrahas, & Ring, 2015). However, it has been suggested that 
coping interventions would be more effective if pain acceptance is the focus, rather than 
instructing the patient in various coping strategies (McCracken, 1998; Rodero et al., 2011). Pain 
acceptance has been associated with decreased preoccupation with the pain and improved sense 
of competence as the pain sufferer becomes more motivated to participate in  daily tasks (Lake, 
2009). 
9.6.3 Contribution to headache research. 
The WHO has joined hands with three international non-governmental headache 
organizations to start a charity called Lifting the Burden: The global campaign to reduce the 
burden of headache worldwide (l-t-b.org, 2009). One of the concerns of the charity is that 
headache prevalence data is only partially detailed worldwide (Stovner et al., 2007). As 
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discussed in Chapter 1, peer-reviewed epidemiological data for South Africa is not available. 
One surmise is that prevalence in the country is similar to the estimated world prevalence of 10% 
(Green, 2015). This thesis therefore makes a key contribution to the campaign to decrease 
headache burden by providing epidemiological data that has been gathered in a systematic 
fashion.   
 The exclusive focus on MO in this thesis makes a very particular contribution to 
migraine research. In their systematic review of psychosocial challenges faced by migraineurs, 
Raggi et al. (2012) show that there is relatively little focus on MO versus MA. They also indicate 
that a number of studies investigate both MA and MO as a single entity and do not distinguish 
between them when reporting on HRQOL. This means that some of the nuances of MO are 
underexplored.  
9.6.4 The significance for public health knowledge. 
MO was shown to be a significant health concern for Gauteng residents in this thesis. The 
lack of research into the disorder will need to change if local public health systems are to adapt 
to public need. For example, only three (3%) of the participants meeting all four criteria for 
migraine (n = 94) reported having been diagnosed with a headache disorder. The occurrence data 
and the data on previous diagnosis raise questions about the lack of awareness of headache 
disorders in the Gauteng community.  
The under-diagnosis of MO is perhaps not surprising given that headaches are 
underdiagnosed  the world over  (Lucas, Géraud, Valade, Chautard, & Lantéri-Minet, 2006; 
World Health Organization, 2012) and that South Africa has a number of more prominent health 
concerns with which it contends (Mayosi et al., 2009). The pattern of under-diagnosis was also 
previously well-illustrated in the FRAMIG 3 French population-based study (Christian Lucas et 
 151 
 
al., 2006): A mere 40% of the 2 245 migraine sufferers were actually aware of their disorder. 
Lack of awareness translates into lack of effective treatment and untold suffering for 97% of the 
MO suffers in this study.  
Such under-diagnosis also perpetuates the misperception that migraine has little impact 
on the individual or on society (Hazard et al., 2009). From the already-widespread literature 
(Hazard et al., 2009; Katsarava & Andre, 2011; Payne et al., 2011; Stokes et al., 2011) it is clear, 
though, that society cannot afford to ignore the individual,  occupational and social impact of 
migraine. 
9.7 Conclusion of thesis 
This thesis proposed the involvement of two biological (glutamate and SLC1A2) and 
three psychosocial (temperament, pain coping and social support) variables in determining the 
HRQOL of people with MO. MO sufferers exhibited higher levels of the temperament dimension 
HA and the pain coping strategy catastrophizing than those without migraine. HA and 
Catastrophizing are significant predictors of HRQOL in MO. There were no significant 
associations detected for the two biological predictors.  
These findings imply that there are specific psychological markers in MO. Migraine 
sufferers have been described as choleric in ancient times, and later, as neurotic. Most recently 
migraine sufferers have been shown to have high levels of harm avoidance tendencies and this 
was confirmed in this thesis. MO sufferers fear pain and believe that they will not be able to cope 
with their pain.  
The roles of HA and Catastrophizing in predicting HRQOL for MO sufferers holds very 
important significance for MO interventions: The medical interventions for MO would be more 
beneficial for patient HRQOL if they were combined with interventions aimed at augmenting 
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coping and dealing with fears around pain. It is important to bear in mind that neither HRQOL 
nor headache pain are simple concepts to define, measure or explain.  Their presentation and the 
experiences of them are subjective and vary from one person to the next. Improving the 
management of MO will require that this complexity be acknowledged and allowed to guide us 
through more interdisciplinary inquiry if there are to be more effective solutions for people 
suffering from MO. 
Finally, this thesis shows how considerably MO diminishes HRQOL. Gauteng residents 
suffering from MO are potentially unaware of their diagnosis and therefore of potential 
management for their disorder. Awareness around MO needs to be the first step in limiting this 
disorder’s devastating impact on individuals, their relationships and their potential to contribute 
meaningfully to society. 
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PARTICIPANT INFORMATION LEAFLET AND INFORMED CONSENT 
Migraine in South Africa 
 
You are invited to participate in our research project about migraine in South Africa.  
There is very little published information about the subject in this country and we would like to 
increase the knowledge in this field. We hope that this research will help health professionals 
that deal with patients with migraine to understand the disease better and to develop more 
effective treatments. The aim of this information leaflet is to help you to decide if you would like 
to participate in the study. Please read and understand this document before the start of the study. 
Before you agree to take part in this study you should fully understand what is involved.  You 
should not agree to take part unless you are completely happy about what is expected of you. If 
you have any questions, do not hesitate to ask us.  If at any time you may be suffering from any 
of the symptoms mentioned or if you have any medical questions, you are advised to consult 
your doctor. This is a research project and does not offer any medical care and it is best that you 
see your health care provider if you have a health problem or medical question.  
  
What is the purpose of this research? 
Migraine has been estimated to occur in 15–17% of women and 5% of men. The aim of 
this research is to describe the prevalence of migraine headaches in South Africa and to 
understand the psychological and genetic make-up of the South Africans suffering from the 
disorder.  
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WHAT WILL YOU BE ASKED TO DO IF YOU DECIDE TO PARTICIPATE? 
The study is made up of two parts. In the first part you are asked to fill out a 
questionnaire. The completion of the questionnaire may take about 40 minutes.  The 
questionnaire begins with a few questions about you (such as your name and age). Although 
these questions are personal, please be assured that we will not use this information to judge you. 
You can therefore feel free to be honest. The next part of the questionnaire focuses on headache 
symptoms you may experience. These are followed by some questions about the pain you 
experience from your migraine. Finally, there is a list of questions about how you react in 
situations. 
 
The questionnaire must be handed to the researcher along with this signed consent form 
once you have completed it.  Please remember that you do have to put your name on the 
questionnaire. The only people that have access to the questionnaires are the principal researcher 
and the database administrator, who has signed a confidentiality agreement. Once you have 
completed the form, the principal researcher (Ms Catherine Govender) will assign a unique code 
to your questionnaire. Your name and unique code will be recorded in a list to which only Ms 
Govender will have access. We will handle your information in the strictest confidence and will 
make sure that the information is kept safe.  
 
Once you have handed in your paperwork, we will take a few months to analyse the 
information from all the people that are participating in the study. Ms Govender will then contact 
some participants (and you may be one of them) to supply some blood. If you are contacted to 
donate blood and you are willing to assist, you will need to do the following: 
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Ms Govender will advise you of the nearest Ampath Pathologist practice in your area. 
You will choose a day that is most convenient for your testing. It is important that you 
have your tests done only if you have been without a headache for seven consecutive days. If you 
are taking any medication (chronic or acute) in the week leading up to your tests, you will need 
to provide Ms Govender with a list of these.  
You will need to fast for eight to ten hours before your blood is drawn (some people find 
it best not to eat or drink after 22:00 and then to go to Ampath early the next day. If you choose 
to do this, please make sure of the opening time of the Ampath in your area) 
At Ampath you will be asked to complete some paperwork. The laboratory will know 
that this is for a research project, but if they ask, just remind them.  
The qualified staff will draw your blood. Remember that we are running six tests and 
collecting an extra vial for genetic testing. Please read further for a description of the aim of the 
tests. In total we will be drawing 55ml of blood. Just to put this into perspective, when you 
donate blood, 500ml is taken.  
Please remember that the investigator retains the right to withdraw you from the study if 
it is considered to be in your best interest.  Please also remember that it is very important to be 
honest and follow the guidelines and the regulations of the research. If, for any reason, you are 
unable to follow the instructions, please let us know.  
 
WHY DO THE RESEARCHERS WANT TO KNOW PERSONAL THINGS ABOUT YOU? 
We would like to try and understand which groups of people (according to different 
criteria such as age, ethnicity and medical history) suffer from migraine. By considering all these 
factors, we may be able to understand how migraines affect people.  
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WHAT WILL HAPPEN TO THE BLOOD THAT YOU GIVE US? 
We will send the blood to a laboratory to be processed and stored. When the sample is 
sent to the laboratory it will be labelled with your unique code, the location you were in when it 
was collected and the date of collection.  
We will run the following tests: 
• Complete blood count: This is a group of tests in which the number of various 
blood cells are counted. This can tell us if you have certain diseases such as 
anaemia (a lack of red blood cells).  
• Fasting glucose: A test such as this is able to detect abnormal blood sugar levels 
such as those seen in diabetes 
• Lipid profile: We will be able to tell how much cholesterol you have.  
• Prothrombin time and International Normalized Ration: (PT and INR) and Partial 
thrombin time (PTT): These two tests will tell us if you have any clotting 
problems 
• Neurotransmitter ELISA: these tests are done to measure how much of the 
neurotransmitters are in your blood. Some of your blood will be used for genetic 
testing. Over the next 1-5 years we will do the following with your blood sample: 
• Use a technique to measure the expression of a neurotransmitter transporter 
• Put all the data in a confidential scientific database;  
• Study the genetic variation data from all the samples; and  
• Compare individual samples and samples from different ethnic or geographic 
groups.  
 
We may not use all of your blood in this study. Any blood that is not used will be 
destroyed once the results have been satisfactorily achieved. 
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WHAT ARE THE COSTS INVOLVED? 
Neither you, nor your medical aid will be required to pay for the assessments carried out. 
You will also not receive any gifts or payment for participating in this study. Some of the 
research done with your samples or the information in the scientific databases may eventually 
lead to the development of new predictive or diagnostic tests, medicines, or other commercial 
products. If this happens, there is no plan to provide you with any of the profits from those 
products, or any discounts on or special access to the products.  
  
ARE THERE RISKS INVOLVED IN THIS RESEARCH? 
Some people may be uncomfortable about the types of questions asked. Please remember 
that we are not here to judge you and we request only that you be honest in your answers. You 
are welcome to let the researcher know about your discomfort with certain questions and may 
decline to answer, but please remember that this will influence the accuracy of our results.   
 
Drawing blood can be uncomfortable and may cause bruising. Some people become 
dizzy or faint from the process. However, the people that will draw your blood are trained to do 
so and will take the necessary precautions to cause you as little discomfort as possible and to 
comply with best practice standards. If you have any kind of bleeding problems, we ask that you 
rather not participate. Your health and safety are very important to us.  
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WHO WILL HAVE ACCESS TO MY INFORMATION? 
As mentioned, once you have filled in the questionnaire, you will be allocated a unique 
code. Only the principal researcher will have access to the master list that shows your name and 
code. Any processing of your information (e.g. recording your answers) will be done using this 
code and not your real name. This is to protect your privacy and ensure your anonymity.  
 
All identifying information obtained during the study will be treated as strictly 
confidential. Any data that we share with our colleagues in the scientific world will not contain 
your identifying details. Data that may be reported in scientific forums (such as journals) will not 
include any information that identifies you as a participant in this study. We will not sell/give 
your information to a third party.  We may use your test results for future studies. 
 
All information obtained during the course of this research is strictly confidential.  
Data that may be reported in, for instance, scientific journals will not include any 
information which identifies you as a participant in this research.  In connection with this 
research, it might be important for domestic and foreign regulatory health authorities and 
the College of Agricultural and Environmental Sciences Ethics Committee, University of 
South Africa, as well as your personal health care providers, to be able to review your 
records pertaining to this research. Any information uncovered regarding your test results 
or state of health as a result of your participation in this research will be held in strict 
confidence.  You will be informed of any finding of importance to your health or continued 
participation in this research via your doctor, but this information will not be disclosed to 
any other party - in addition to the ones mentioned above - without your written 
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permission.  The only exception to this rule will be cases in which a law exists compelling us 
to report individuals infected with communicable diseases.  In this case, you will be 
informed of our intent to disclose such information to the authorized state agency.          
 
WHAT ARE MY RIGHTS AS A PARTICIPANT IN THIS RESEARCH? 
Your participation in this research is entirely voluntary and you can refuse to participate 
or stop at any time without stating any reason.  Your withdrawal will not affect your access to 
health care.  Should you wish to stop participating, please make contact with the research team 
and ask for a ‘Withdrawal of Consent’ form. You will have to fill the form in and send it back to 
us.   
 
HAS THE RESEARCH RECEIVED ETHICAL APPROVAL? 
This protocol was submitted to the Department of Psychology Ethics Committee, 
University of South Africa and written approval has been granted by that committee.  The study 
has been structured in accordance with the Declaration of Helsinki (last update: 2008), which 
guides biomedical research involving human/subjects.  A copy of the Declaration may be 
obtained from the investigator should you wish to review it.  
 
WHY MUST I GIVE MY DOCTOR’S NAME? 
We feel that it is our duty to report potentially serious problems picked up in your 
laboratory tests. By law, this information may not be communicated directly to you by the 
laboratory. The information therefore must be sent to your doctor. Your doctor will then 
communicate this information to you.  
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PLEASE REMEMBER THAT IF YOU SIGN BELOW, YOU ARE AGREEING TO: 
Give blood 
Have your DNA sequenced 
Complete the necessary questionnaires 
 
If you have any queries, please contact our principal researcher: 
Name Telephone Postal address Fax E-mail 
Catherine 
Govender 
+27 12 
4296189 
Department of 
Psychology, PO Box 
392, Unisa, 0003 
 
+27 12 429 
3414 
govenco@unisa.ac.za 
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INFORMED CONSENT FOR THE PROJECT ENTITLED: MIGRAINE IN SOUTH AFRICA 
PLEASE COMPLETE THIS IF YOU CONSENT TO PARTICIPATE Please note that this information 
will not be used by the investigator to break confidentiality. Should the investigator need to contact you, 
however, these details will be necessary. Please inform the investigator of any changes to these 
contact details. 
Full name:            
Telephone number (work):           
Cellular phone number or after hours contact number:        
E-mail address:             
Your doctor’s name:      Your doctor’s telephone number:   
Your doctor’s address:            
I hereby confirm that I have been informed about the nature, conduct, benefits and risks of the 
study.  I have also received, read and understood the above written information (Participant Information 
Leaflet and Informed Consent) regarding the investigation. I am aware that the results of the research, 
including personal details regarding my sex, age, date of birth, initials and diagnosis will be 
anonymously processed into a research report. I may, at any stage, without prejudice, withdraw my 
consent and participation in the research.  I have had sufficient opportunity to ask questions and (of my 
own free will) declare myself prepared to participate in the research. 
Participant's name        Participant's signature     Date    
                               (Please print) 
Witness's name                    Witness's signature                  Date    
                             (Please print)  
                                       
VERBAL PARTICIPANT INFORMED CONSENT   (APPLICABLE WHEN PARTICIPANT 
CANNOT READ OR WRITE) 
 234 
 
The undersigned investigator has read and explained fully to the participant and/or his/her 
relative, the participant information leaflet, which has indicated the nature and purpose of the 
research in which I have asked the participant to participate.  The explanation I have given has 
mentioned both the possible risks and benefits of the research and the alternative treatments 
available for his/her illness.  The participant indicated that he/she understands that he/she will be 
free to withdraw from the research at any time for any reason and without jeopardizing his/her 
subsequent injury attributable to the drug(s) used in the research, to which he/she agrees. I hereby 
certify that the participant has agreed to participate in this research.                           
Participant's Name          
           (Please print) 
Investigator's Name     Investigator's Signature    Date    
             (Please print) 
Witness's Name       Witness's Signature           Date                      
(Please print) 
Please return this signed consent form and your answer 
sheet to the investigator. Thank you for your time! 
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The items for this thesis are not available because of copyright requirements. For more information, please 
consult the sections on the relevant questionnaires. 
